

Powering Implantable and Ingestible Electronics

So-Yoon Yang, Vitor Sencadas, Siheng Sean You, Neil Zi-Xun Jia, Shriya Sruthi Srinivasan, Hen-Wei Huang, Abdelsalam Elrefaey Ahmed, Jia Ying Liang, and Giovanni Traverso*

Implantable and ingestible biomedical electronic devices can be useful tools for detecting physiological and pathophysiological signals, and providing treatments that cannot be done externally. However, one major challenge in the development of these devices is the limited lifetime of their power sources. The state-of-the-art of powering technologies for implantable and ingestible electronics is reviewed here. The structure and power requirements of implantable and ingestible biomedical electronics are described to guide the development of powering technologies. These powering technologies include novel batteries that can be used as both power sources and for energy storage, devices that can harvest energy from the human body, and devices that can receive and operate with energy transferred from exogenous sources. Furthermore, potential sources of mechanical, chemical, and electromagnetic energy present around common target locations of implantable and ingestible electronics are thoroughly analyzed; energy harvesting and transfer methods befitting each energy source are also discussed. Developing power sources that are safe, compact, and have high volumetric energy densities is essential for realizing long-term in-body biomedical electronics and for enabling a new era of personalized healthcare.

ailments.^[2] More than 60% of adults in the United States (US) have a chronic disease such as heart disease, cancer, stroke, and diabetes. Consequently, management of chronic conditions account for 75% of healthcare spending in the US.^[3,4] ≈61 million adults (26%) in the US have some type of disability, such as a mobility impairment, a cognitive disability, hearing loss, or vision loss, and depend on the reliable assistance of one or more medical devices for the rest of their lives.^[5] Worldwide, about three million people are living with a pacemaker and about 0.3 million people are living with a cochlear implant.^[6,7] In order to lower the morbidity rate, it is important to monitor, intervene, and prevent diseases more effectively. Biomedical electronic devices have played a significant role in managing these medical demands. Developing energy-dense power sources is a major challenge for realizing the next generation of personalized biomedical electronics that are multi-functional, compact, and long-lived.

1. Introduction

1.1. Motivation


As the human life expectancy has increased, access to high-quality healthcare has become essential for ensuring a high quality of life.^[1] This increase in lifespan is associated with a rising prevalence of disease, disability, dementia, and other

The energy requirements of biomedical electronic devices are highly dependent on their application and the complexity of the required electrical systems. Biomedical electronic devices can be divided into three main categories depending on their application: diagnostic, therapeutic, and closed-loop systems. Each category has a different degree of complexity in the electronic system, which will be discussed in Section 1.2. Diagnostic devices are used to monitor existing or potential

S. Yang
Department of Electrical Engineering and Computer Science
Massachusetts Institute of Technology
Cambridge, MA 02139, USA

S. Yang, Dr. V. Sencadas, Dr. S. S. You, N. Z.-X. Jia, Dr. S. S. Srinivasan,
Dr. H. Huang, J. Y. Liang
Koch Institute for Integrative Cancer Research
Massachusetts Institute of Technology
Cambridge, MA 02139, USA

S. Yang, Dr. S. S. You, Dr. S. S. Srinivasan, Dr. H. Huang,
J. Y. Liang, Prof. G. Traverso
Department of Mechanical Engineering
Massachusetts Institute of Technology
Cambridge, MA 02139, USA
E-mail: ctraverso@bwh.harvard.edu, cgt20@mit.edu

 The ORCID identification number(s) for the author(s) of this article can be found under <https://doi.org/10.1002/adfm.202009289>.

Dr. V. Sencadas
School of Mechanical
Materials & Mechatronics Engineering
University of Wollongong
Wollongong, NSW 2522, Australia

Dr. S. S. You, Dr. S. S. Srinivasan, Dr. H. Huang, Dr. A. E. Ahmed,
J. Y. Liang, Prof. G. Traverso
Division of Gastroenterology
Hepatology and Endoscopy
Department of Medicine
Brigham and Women's Hospital
Harvard Medical School
Boston, MA 02115, USA

DOI: 10.1002/adfm.202009289

medical conditions, to track disease progression and to evaluate the effects of any medical interventions. Diagnostic biomedical electronics are currently used to monitor the progression of diseases such as diabetes, cancer, hypertension, heart disease, stroke, respiratory disease, chronic kidney disease, arthritis, and obesity. Clinicians can also assess the efficacy of treatment through therapeutic drug monitoring or medication adherence monitoring; therapeutic prescriptions can then be altered to optimize efficacy. Furthermore, diagnostic electronic devices can collect clinical data from patients over an extended period of time without clinical consultations, which enables quicker, more efficient, and more accurate diagnoses and prognoses.

Therapeutic electronic devices enable potentially more efficient and effective therapeutic interventions than conventional treatment methods such as pill-type medications. For example, tissue/nerve stimulation is used to repair neurological dysfunction or to relieve pain by modulating the nervous system: examples include deep brain stimulation for Parkinson's disease, gastric stimulation for gastroparesis, and peripheral nerve and spinal cord stimulation for chronic pain relief. Programmable drug pumps can increase medication adherence and maintain analyte concentrations within a targeted therapeutic window. Therapeutic efficacy can be optimized when the diagnostic and therapeutic devices are combined into a closed-loop system.

In a closed-loop system, diagnostic sensors monitor biomarkers related to a target disease and a central processing unit analyzes the measured data and adjusts the treatment accordingly. A closed-loop algorithm can achieve high therapeutic efficacy in pharmacologic treatment by maintaining the medication levels within a tight predetermined threshold; in electrical stimulation, closed-loop systems support stimulation in response to measured endogenous electrical activity. There are many medical treatments that can be enhanced by closed-loop medical devices: chemotherapy, anesthesia, opioids for postsurgical management of pain, methotrexate for control of rheumatoid arthritis, tacrolimus for post-transplant immunosuppression, phenytoin to control epileptic seizures, and the anticoagulant warfarin.^[8] A well-recognized biomedical closed-loop electronic device is the type 1 diabetes glucose monitoring and insulin pump system, also known as an artificial pancreas, that continuously measures blood glucose levels and delivers the required insulin dose. Another closed-loop electronic medical device is a transgastric sensor and gastric stimulator, which is used to treat obesity. This implantable device detects food intake and triggers a gastric stimulator which makes a patient feel satiated.^[9] Other examples of implantable biomedical closed-loop systems include closed-loop pacemakers, which treat cardiac arrhythmia, and closed-loop deep brain stimulators (DBS), which treat Parkinson's disease. **Table 1** summarizes clinical applications in which implantable/ingestible biomedical electronic devices are used.

Due to recent technological developments, the features available and implantation locations of biomedical electronic devices has increased substantially. Advances in wireless communication enable medical devices to be untethered when in the human body. Advances in minimally invasive or semi-invasive surgical implantation procedures have enabled biomedical devices to be implanted in locations where clinically important biomarkers and physiological signals can be detected; it has

also enabled direct administration of medication or treatment to a target location. This leads to higher therapeutic efficacy and lower levels of patient discomfort. Nevertheless, a significant challenge arises when these electronic devices operate inside the body: power is a fundamental bottleneck. This is because the major functionalities of the device, such as diagnostic/therapeutic modalities, duty cycle, and operation lifetime, are often constrained by the amount of power that is available. Furthermore, additional features are constantly being added to biomedical electronic devices as a result of technological development. For instance, smartphones and internet of things (IoT) technologies facilitate physiological data collection; artificial intelligence (AI) algorithms provide advanced data analysis and personalized medical decision-making. As a result, the power demand for biomedical electronic devices is constantly increasing. Thus, technology related to powering devices is a major determinant in the ability to develop in-body biomedical electronics. **Figure 1** shows the major milestones of implantable and ingestible electronic devices and relevant technologies to power these devices.

1.2. Structure and Power Consumptions of Implantable and Ingestible Biomedical Electronic Devices

The power requirements of implantable and ingestible biomedical electronics are determined by their structure and components. This section discusses the functional blocks that are typically found in a biomedical electronic device and their power requirements.

1.2.1. Structure and Components of Biomedical Electronic Devices

Most biomedical electronic devices are composed of a common set of components, including a power unit, sensors, actuators, a signal processing and control unit, and a data storage unit (**Figure 2**). Implantable and ingestible devices that require a great deal of data manipulation or large quantities of data logging also need to be wirelessly connected to an external device so that data can be transmitted to an external receiver and signal processing, data storage, and display can be performed more efficiently. The power unit, which is composed of one or more energy sources as well as power management circuits, supplies electrical energy to the whole system. The sensors and actuators interface with the biomedical environment to record the external stimuli or generate appropriate medical interventions. The signal processing and control unit is the central processing unit that has many functionalities including input/output (I/O) operations, analog and digital signal conversion and processing, peripheral control, memory, and timing operations. This unit supervises the algorithm and operation of the entire system. Usually, a single mixed-signal microcontroller unit (MCU) is used for biomedical electronics since it enables all functionalities to be integrated onto a single chip that is small in size, requires little power, and is low in cost. The data storage unit can be integrated into a signal processing and control unit like memory is embedded onto an MCU, or it can be added as a separate memory unit if needed. The basic components

Table 1. Clinical applications that use implantable/ingestible biomedical electronic devices.

Device category	Clinical application	Examples	Related diseases or medical conditions	
Diagnostic	Pressure monitoring	Blood pressure monitoring	Hypertension ^[10,11]	
		Intra-cranial pressure (ICP) monitoring	Traumatic brain injury, brain tumor, chronic intracranial hypertension ^[12–15]	
		Intraocular pressure (IOP) monitoring	Glaucoma, ocular hypertension ^[16–18]	
		Intra-abdominal pressure (IAP) monitoring	Abdominal compartment syndrome (ACS), Intra-abdominal hypertension ^[19–21]	
	Temperature monitoring	Bladder pressure monitoring	Neurogenic bladder dysfunction ^[22]	
		Core body temperature monitoring	Infection, Thermoregulatory disorder ^[23,24]	
	Glucose monitoring	Blood glucose level monitoring	Diabetes mellitus ^[25,26]	
	Biomarker monitoring	Cortisol in blood, etc.	Psychiatric disorders ^[27–29]	
	Gas monitoring	Gastrointestinal (GI) gas	Irritable bowel syndrome, Inflammatory bowel disease ^[30,31]	
	Electrical signal monitoring	Electrogastrogram (EGG), Electrocardiogram (ECG)	Gastroparesis, heart failure ^[32–34]	
Medication adherence monitoring	Medication adherence monitoring	Disease treatment monitoring ^[35]		
Therapeutic drug monitoring	Chemotherapy, anticoagulants	Epilepsy, Anticoagulants, Immunosuppression, Cancer ^[36–38]		
Therapeutic	Imaging	Wireless capsule endoscopy	GI bleeding, inflammatory disorder, precancerous tissues ^[39,40]	
		Electrical stimulation	Deep brain stimulation	Parkinson's disease ^[41–43]
			Electric nerve stimulation (spinal cord, vagus nerve, peripheral nerve, etc.)	Diabetic neuropathy, peripheral artery disease, chronic pain relief ^[44–46]
	Drug delivery	Gastric stimulator	Gastroparesis ^[47–50]	
		To GI tract (e.g., IntelliCap) To subcutaneous space (e.g., insulin injection)		
	Visual prosthesis	Retinal prostheses	Degenerative retinal diseases (Retinitis pigmentosa (RP)), Age-related macular degeneration (AMD)) ^[51,52]	
	Hearing assist	Cochlear implants	Hearing loss ^[53]	
Closed-loop	Cardiac assist	Pacemaker	Arrhythmia, heart attack, etc. ^[54–56]	
		Cardioverter defibrillator(ICD)		
		Ventricular assist device		
	Kidney assist	Implantable bioartificial kidney	Kidney failure ^[57,58]	
	Closed-loop drug delivery	Blood glucose monitor-insulin pump	Diabetes mellitus ^[59]	
Chemotherapy		Cancer ^[60]		
	Anesthesia	Surgical process ^[61,62]		

of a wireless communication unit are a transmitter/receiver/transceiver and an antenna.

The system complexity of each of the three biomedical electronic systems is shown in Figure 2. Therapeutic tools are usually the least complex systems and primarily require a controlled actuator. Control of the therapeutic devices can be achieved in one of three ways: wirelessly, by an external user for an on-demand application; by a microcontroller that has a pre-programmed algorithm that operates at a specific time and situation; or by environmental stimuli.^[90–93] Microcontrollers and wireless communication units are optional components for therapeutic devices. However, systems composed of only actuators, which do not have computational elements and communication modules, can only implement simple on-off control. Adding a microcontroller and a radiofrequency (RF) communication module enables more sophisticated therapeutic procedures such as time-controlled drug delivery or feedback control. At the same time, these additional modules increase the power

consumption of the devices and require the power management circuits to be more complex.^[92]

A diagnostic device relies on different modules than a therapeutic device: sensors to collect biological information, a microcontroller to convert the analog inputs into digital data and perform signal processing, and a wireless communication module and/or additional on-board memory to transmit/store the processed data for further analysis.^[80,94–98] Thus, a diagnostic device requires a more complicated circuit design than a therapeutic device. A closed-loop system has the most complex configuration since it must contain a sensor, an actuator, and a microcontroller. The microcontroller plays an important role in coordinating the sensory input with the output of the actuator. An RF communication module is an optional component in a closed-loop system. If the microcontroller unit in a closed-loop system, such as a pacemaker and artificial pancreas, does not require intervention from an external user to make a therapeutic decision, no communication component is




Figure 1. Timeline of major milestones for implantable and ingestible electronic devices and technology for powering such devices. Listed are the years when batteries suitable to power biomedical devices were first commercialized,^[63–69] in vivo experiments of energy harvesting and transfer devices first occurred,^[70–78] ingestible electronics first appeared,^[79,80] and implantable electronics first appeared.^[81–89] (WPT: wireless power transfer, BFC: bio-fuel cell, PENG: piezoelectric nanogenerator, APT: acoustic power transfer, AWS: automatic wristwatch system, PV: photovoltaic, TENG: triboelectric nanogenerator).




Figure 2. a) The system configuration and b) the schematic of functional units of closed-loop, diagnostic, and therapeutic implantable/ingestible electronics.

Table 2. Power requirements of implantable and ingestible biomedical electronic devices.

Implantable/Ingestible device	Power requirement	References
Deep brain stimulator (DBS)	100 μ W	[104,105]
Spinal cord stimulator	1–10 mW	[104]
Intraocular pressure (IOP) monitor	200 nW–200 μ W	[106]
Retinal prosthesis	250 mW	[107]
Cochlear implant	100 μ W–10 mW	[105,108,109]
Pacemaker	10–30 μ W	[79,102]
Implantable cardioverter defibrillator (ICD)	50–500 μ W	[105]
Implantable blood pressure monitor	Passive	
Wireless capsule endoscope	5–30 mW	[110]
Medication adherence monitor	1 mW	[35]
Gastric stimulator	1–30 mW	[111]
Implantable drug delivery system	100 μ W–1 mW	[104,105,112]
Artificial urinary sphincter	200 μ W	[79,102]

needed.^[99,100] However, if a system needs to be highly miniaturized and cannot incorporate a powerful microcontroller due to size and power consumption limitations, then having an RF communication module can shift the heavy computational load to a powerful external device.^[101]

1.2.2. Power Requirements of Biomedical Electronic Devices

For implantable and ingestible devices, power requirements are a critical and often constraining parameter. There is a wide variety of biomedical devices that are currently used in clinical settings; these devices have a range of power requirements (Table 2). Among other factors, the functionality and longevity of the device are characteristics that need to be balanced with energy consumption. Devices that require relatively low power, such as pacemakers (10–30 μ W) and artificial urinary sphincters (200 μ W), can last for 8–12 years before they require a battery replacement or maintenance.^[79,102] These devices can be implanted in the body and only require battery replacement surgery, a low risk and convenient procedure, approximately once every decade.

Similarly, for single-use devices, such as capsule endoscopes, batteries provide enough energy to power the devices for their entire lifetime. On the other hand, devices that consume higher amounts of power or operate over a longer time period cannot rely on simple primary batteries. Muscle stimulators and cochlear implants consume substantial amounts of energy and their batteries need to be recharged regularly. Devices with tight size constraints, such as retinal prostheses or brain implants, are not able to accommodate enough batteries within a single device. Implantable neurostimulators (INS), for example, consist of two parts: one is the network of implantable stimulating electrodes and the other is the external control unit. The external control unit is located in an infraclavicular or abdominal implant site outside the skull; it is connected to the electrodes through external connectors.^[103] Different powering technologies, such as novel energy-dense batteries, energy

harvesting techniques, and energy transfer techniques, can be used to continuously power the device or recharge its batteries which reduces the number of surgical procedures needed, minimizes infection risks, reduces the number of electrical components and connections needed, increases the device's reliability, and lowers costs. Some transient electronic devices, such as medication adherence monitors, use biodegradable batteries or energy harvesting devices rather than conventional lithium (Li) batteries to perform their function.

The rest of this paper discusses three different powering methods for implantable and ingestible electronic devices: the use of batteries, energy harvesting, and energy transfer. In Section 2, we will review the fundamental principles and state-of-the-art technologies of batteries for biomedical electronics. In Section 3, we will cover the working principles and provide examples of energy harvesting systems, which scavenge naturally occurring energy from the human body. We will also thoroughly analyze the characteristics of each available energy source for devices implanted in or ingested into the human body in Section 3. In Section 4, we will review the energy transfer technologies which can deliver energy from outside the body to implanted or ingested devices.

2. Batteries to Power Biomedical Electronic Devices

Since the first pacemaker was implanted in 1958, batteries have been the main source of power for biomedical electronic devices. In this section, we will cover the history and the state of the art of battery technology for biomedical electronic devices. The important characteristics of batteries for biomedical applications will be discussed.

2.1. Important Characteristics of Batteries for Biomedical Electronic Devices

A battery is an electrochemical energy storage system which is composed of four main components: a cathode, an anode, the electrolyte, and a membrane separator. The electrochemical reactions between these components determine the characteristics of the batteries. When evaluating whether a particular battery is appropriate for a specific use, several parameters should be considered: nominal voltage, energy density and capacity, lifetime, and discharge profile. Energy density can be defined as either gravimetric energy density (specific energy), which is energy capacity in weight, or volumetric energy density, which is energy capacity in volume. For secondary or rechargeable batteries, cycle life and charging speed are two additional characteristics to consider. Other major characteristics to consider include the battery's cost, its internal resistance, and the long-term effects of aging.

For biomedical applications, especially for implantable and ingestible electronic devices, the most significant parameters that should be considered are volumetric energy density and safety. Volumetric energy density is more important than specific energy because biomedical electronic devices often have size limitations but rarely have restrictions on their weight.^[113]

Safety factors to be considered include the battery's risk of explosion and leakage, which could potentially lead to toxicity, reduced biocompatibility, and immunogenicity. The battery's lifetime, its long-term stability and reliability, and the predictability of its performance are other important characteristics to consider for in-body applications. Indeed, the safety of implantable/ingestible batteries and battery-powered medical devices are generally regulated by government agencies such as the Food and Drug Administration (FDA, United States of America) and the European Medicines Agency (EMA, European Union). The standards set by the FDA and the EMA are meant to ensure the safe operation of primary and secondary batteries for medical devices under intended use and reasonably foreseeable misuse. FDA-recognized consensus standards for primary and secondary batteries include IEC 60086-4 (primary batteries—Part 4: safety of lithium batteries); IEC 60086-5 (primary batteries—Part 5: safety of batteries with aqueous electrolyte); UL 1642 (lithium batteries); and IEC 62133 (secondary cells and batteries containing alkaline or other non-acid electrolytes—safety requirements for portable sealed secondary cells, and for batteries made from them, for use in portable applications); IEC 62485 (safety requirements for secondary batteries and battery installations); UL 2054 (household and commercial batteries).^[114–123] The standard IEC 60601-1 (medical electrical equipment—general requirements for basic safety and essential performance) also provides the general safety requirement of batteries for medical devices. The EMA has adopted “Regulation (EU) 2017/745 on Medical Devices (MDR)” and harmonized standards such as EN/IEC 60601-1 (EU-adopted version of IEC 60601-1) and EN/IEC 62133 (EU-adopted version of IEC 62133) to regulate the safety and performance of implantable medical devices and batteries.^[117,118,124–126]

2.2. Development of Battery Technologies for Biomedical Electronic Devices

As mentioned above, batteries that power biomedical electronic devices are required to meet specific standards in order to be sold in certain markets. In this section, a brief history and the state of the art of battery technology for implantable and ingestible biomedical electronic devices will be reviewed. Challenges facing battery technology for biomedical devices will be addressed as well as recent technological advances that attempt to resolve these issues.

2.2.1. Batteries to Power Biomedical Electronic Devices

Lithium-Based Batteries for Biomedical Electronic Devices: Since the development of lithium batteries and lithium-ion batteries (LIBs), they have been standard choices for on-board energy supplies in medical devices. Both types of batteries are made with Li metal, which has high theoretical energy densities of 2062 mAh cm⁻³ and 3862 mAh g⁻¹; because of this, lithium-based batteries have a higher cell voltage and energy density than other battery chemistries.^[127] Lithium-based batteries also have a flat, predictable, and reliable discharge profile, which is desirable in medical devices.^[68,128] However, drawbacks include

high manufacturing cost, moderate discharge current, safety issues, and limited recyclability.

Lithium and lithium-ion batteries share several common features; however, they exhibit quite different electrochemical characteristics. All lithium batteries have pure lithium metal as their anodes but they can have many types of cathodes, including iodine (Li/I₂), manganese oxide (Li/MnO₂), carbon monofluoride (Li/CF_x), silver vanadium oxide (Li/SVO) or hybrid cathodes (Li/CF_x-SVO).^[105] Lithium batteries generally have a higher capacity and longer shelf life than lithium-ion batteries, but since pure lithium metal is highly reactive, damage to the batteries can pose a serious safety issue.^[105,128]

LIBs use lithium-intercalated compounds as cathodes, which are more stable than pure lithium metal. Examples of commonly used cathode material in LIBs include lithium cobalt (Co) oxide (LiCoO₂), lithium iron (Fe) phosphate (LiFePO₄), lithium manganese oxide (LiMn₂O₄, Li₂MnO₃, or LMO), and lithium nickel (Ni) manganese cobalt oxide (LiNiMnCoO₂ or NMC).^[129] Lithium-ion batteries are rechargeable, which results in an extended lifetime compared to lithium batteries, which is especially useful for medical devices that have high power requirements. Using rechargeable batteries can significantly improve patient comfort because it reduces the frequency of battery replacement, which often needs to be done surgically. LIBs exhibit the highest battery capacity among existing rechargeable battery technologies, with no memory effect and a low self-discharge rate. Lithium-ion batteries are also safer than lithium batteries, but there are still some safety issues to be addressed. Physical damage, elevated temperatures or electrical abuse such as shorting the circuits and overcharging, can cause the batteries to experience a thermal runaway or explode. Also, if LIBs leak, their electrolytes are toxic to humans.^[130] Adding a battery protection circuit is one way to keep LIBs within a safe operating range.

There is a long history of using lithium and lithium-ion batteries in implantable and ingestible biomedical devices.^[131] A large portion of today's commercial medical devices use lithium-based batteries as their on-board power source due to their reliability.^[132] Lithium-based batteries have been used to power implantable devices such as pacemakers, neurostimulators, cochlear implants, implantable cardiac defibrillators, cardiac resynchronization devices, drug delivery systems, and bone growth generators.^[102] Lithium-based batteries are also the preferred choice for hard-to-retrieve and single-use devices due to their high energy density. The most well-known biomedical devices that utilize lithium batteries as their power sources are cardiac pacemakers. Li/I₂ batteries have been powering pacemakers since they were first developed in 1972 and are still used in pacemakers today due to their reliability and predictability.^[67] Some applications that demand high power often utilize rechargeable lithium-ion batteries to increase the lifetime and reduce the size of the implant. For example, neurostimulators, which operate in the milliwatts power range, are one type of device that use secondary LIBs.^[102]

Silver Oxide (AgO) Batteries for Ingestible Electronic Devices: Other than lithium-based batteries, there are very few battery options for biomedical electronic devices on the market. Silver oxide batteries, which consist of an AgO/zinc (Zn) cathode/anode pair, have energy densities that are similar to or slightly lower than standard LIBs. One advantage of silver oxide batteries for implantable or ingestible medical devices is that they are not

prone to thermal runaway.^[133] Indeed, silver oxide batteries are preferred for on-board power supplies in ingestible electronics and they are the only type of battery that has been approved for clinical use to power capsule endoscopes.^[80,110,133] However, the toxic metal and caustic electrolytes in silver oxide batteries can still be hazardous if the battery is retained or ruptured.^[79]

There are other types of primary cells such as zinc-air batteries, which have the highest energy densities among all commercially available cells. However, these batteries are not suitable for in-body medical devices due to the lack of oxygen flow inside the body. Zinc-air batteries are used for hearing aids and in the external units of cochlear implants. Zinc carbon and alkaline batteries have low energy densities and are considered outdated technologies.

Non-Lithium-Based Rechargeable Batteries: For rechargeable batteries in biomedical applications, there are not many viable alternatives to lithium ion batteries. Before the mid-1990s, nickel cadmium (NiCd) batteries had an overwhelming market share for rechargeable batteries due to their high current discharge rate, fast charging rate, and thermal stability.^[134] However, since cadmium is toxic to humans and poses an environmental hazard, the sale of NiCd batteries has been restricted since 2006 by the EU battery directive.^[124] Nickel metal hybrid (NiMH) batteries was developed as a substitute for NiCd batteries in 1990s.^[134] NiMH batteries have a higher energy density and are less toxic than NiCd batteries but they also have a shorter cycle life and a shelf life. NiMH batteries are considered to be safer than lithium ion batteries under reasonable misuse such as physical, thermal, and overcharging stress. But they suffer from the same problems as NiCd batteries, such as memory effect, a high self-discharge rate, and the risk of explosion when overcharging. Lead acid batteries are the most economical rechargeable batteries for large power applications, but they have a low energy density and a short cycle life, are heavy, and contain hazardous lead, which make them unsuitable for biomedical devices. NiCd, NiMH, and lead acid batteries are still widely used in various types of devices, including industrial applications or motive power systems, but they are considered inferior to lithium ion batteries for implantable and ingestible biomedical devices in terms of both safety and performance.^[135]

The major characteristics of the batteries introduced in this section are summarized in **Table 3**, which also lists the

desirable characteristics of implantable and ingestible biomedical electronic devices.

2.2.2. Efforts toward Current Challenges in Batteries for Biomedical Electronic Devices

In the last few decades, new battery technology has led to increases in the performance, reliability, and lifetime of batteries. However, challenges remain, especially in terms of volumetric energy density and safety. Electronic miniaturization allows more functionalities to be added to devices, which increases power requirements. Recently, new material-based battery systems have been developed with higher energy densities. Also, battery components can be arranged in different geometric orientations in order to efficiently leverage the limited space in biomedical devices. Researchers have also been focused on developing electrolyte and electrode materials that are nonflammable, nontoxic, and biodegradable in order to improve the safety of batteries.

Rechargeable Batteries Based on Non-Lithium Metals: To overcome the inherent danger of lithium-based batteries, there has been a lot of research that has focused on developing new battery technologies that are not based on lithium metals.^[140] Alkali metals and alkaline earth metals such as sodium (Na), potassium (K), calcium (Ca), and magnesium (Mg) have been proposed as alternative materials to Li for batteries. In addition to being safer than Li, they are also less expensive and more abundant in nature. The raw materials which are essential in LIBs, such as Co, Ni, and Li, are limited in supply and would potentially increase the price of LIBs in the near future.^[141,142] Alkali metals, including Li, Na, and K, are very reactive and electropositive monovalent metals, while alkaline earth metals, such as Ca and Mg, are divalent metals. Sodium-ion batteries (NIBs), potassium-ion batteries (KIBs), and calcium-ion batteries (CIBs) are some of the most promising alternatives to LIBs because they have high energy densities and are relatively safer. NIBs and KIBs can be manufactured using the same techniques as LIBs at room temperature due to the chemical-physical similarities of Na and K metals to Li metal.^[143–145] CIBs use multivalent ions as charge carriers, which are capable of transferring multiple electrons per ion.^[146] This means, in

Table 3. Summary of battery technologies in biomedical field.

Battery type	Rechargeability	Cathode material (+)	Anode material (-)	V_{oc} [V]	Gravimetric energy density [mWh g ⁻¹]	Volumetric energy density [mWh cm ⁻³]	Cycle life	Self-discharge time	Safety	Application
Li	Nonrechargeable	I ₂ , MnO ₂ , CF _x , SVO, SOCl ₂	Li	3.1–3.3	200–500 ^[136,137]	500–1000 ^[137]	N/A	Very long (10 years) ^[128]	Risk of thermal runaway	Implantable electronics
Silver oxide	Nonrechargeable	Silver oxide	Zn	1.6	150–250 ^[136]	400–800 ^[136]	N/A	Long (5–7 years)	Free from thermal runaway, hazardous when ruptured	Ingestible electronics, Capsule endoscopy, insulin pump
Li-ion	Rechargeable	LiCoO ₂ , LiFePO ₄ , LiMn _x O _y , LiNiMnCoO ₂	Graphite	3.3–3.8	90–240 ^[136,139,140]	200–700 ^[136,138]	500–2000 ^[136]	Long (3 years) ^[128]	Protection circuit is mandatory, low toxicity ^[136]	Implantable electronics

theory, that the energy capacities of CIBs have the potential to be doubled that of monovalent ion-based batteries. However, CIBs use different materials than LIBs for anodes and cathodes due to the difference between monovalent and multivalent ions.

Na and K, which are alkali metals, are two of the most abundant elements in the earth's crust.^[147] Na is the second alkali metal after Li; Li and Na share some chemical properties. NIBs are more common than KIBs, and high-temperature NIBs, such as the sodium-nickel chloride (ZEBRA) battery, have already been commercialized.^[148] NIBs are considered safer than LIBs and are less prone to thermal runaway.^[149] Potassium has a lower reduction potential than Na: the reduction potential of K is -2.93 V (vs standard hydrogen electrode, SHE) and Na is -2.71 V (vs SHE). With its lower reduction potential, KIBs can theoretically have higher working voltage and energy densities than NIBs. However, there is a fundamental limit on the energy densities that NIBs and KIBs can have. The theoretical energy densities of Na (1166 mAh g⁻¹, 1131 mAh cm⁻³) and K (685 mAh g⁻¹, 590 mAh cm⁻³) metals are small compared to Li (3862 mAh g⁻¹, 2062 mAh cm⁻³).^[127] Furthermore, the common cathode materials for LIBs would be easily disrupted in NIBs or KIBs, because the large radius of Na⁺ ions (0.102 nm) and K⁺ ions (0.138 nm) would cause large changes in the volume of the electrodes due to the frequent insertion and extraction of ions during the charge and discharge process.^[150] This results in a low practical capacity, reduced performance, poor cyclability, and sometimes even electrochemical inactivity. Thus, the selection of host materials for the intercalation cathode in NIBs and KIBs is very limited.^[140,151] Additionally, most NIBs and KIBs are only operational in high temperatures, which inhibit NIBs and KIBs from being used in biomedical applications. Even though there are some commercialized NIBs on the market, they are mostly developed for electromobility or large-scale energy storage and still have high manufacturing costs which make them just as expensive as LIBs.^[152] Hence, understanding the structural and electrochemical properties of different electrode and electrolyte materials for NIBs and KIBs is important for developing fully functional batteries based on non-lithium metals for biomedical electronic devices.^[151,153–157]

Calcium is the third alkaline earth metal, and is the fifth most abundant element in the earth's crust.^[147] The standard reduction potential of Ca (-2.87 V vs SHE) is similar to Li (-3.04 V vs SHE); the theoretical energy densities of Ca (1340 mAh g⁻¹, 2072 mAh cm⁻³) is also similar to that of Li (3862 mAh g⁻¹, 2062 mAh cm⁻³).^[127,158] Calcium has a lower polarizing character than magnesium or aluminum, thus Ca²⁺ ions are more mobile in liquid. Compared to LIBs, CIBs are less toxic and less prone to thermal runaway.^[159] However, the technology is still in its infancy: there are few actual prototypes and their operating temperatures are outside the range that is appropriate for medical applications. Recent efforts have focused on finding suitable Ca metal anodes, Ca intercalation cathodes, electrolytes that can allow CIBs to operate at room temperature, and steadily efficient compatible battery chemistries.^[140,142,146,160] One hurdle to developing rechargeable CIBs for long-term applications is that passivation layers form at the Ca anodic surface during use. Passivation layers reduce the ability to reversibly plate and strip the Ca metal anode. Another challenge is developing an intercalation host material for the Ca cathode that is able to accommodate Ca ions, which, at 0.112 nm, are relatively large;

only a few candidates have been proposed to date.^[146,150] Ca²⁺ ions have a low diffusion rate and a high reduction potential which makes the development of suitable electrolytes for CIBs that operate at room temperature challenging.

There are other non-lithium based battery technologies that have the potential to be used in biomedical devices. For instance, potassium sulfur and sodium-sulfur batteries that do not use pure metal Na and K anodes can offer comparable or even higher energy densities than LIBs, but they do not have the same safety risks as pure alkali metal anodes.^[161,162] Other candidates for next-generation, energy-dense, safe, and cost-efficient batteries for biomedical applications include magnesium batteries, aluminum ion batteries, nickel-zinc batteries, a silicon-based anode for LIBs, proton batteries, and graphite dual ion batteries.^[163–173] However, most of these state-of-the-art battery technologies are being developed for large-scale applications, such as for energy grids or electric vehicles, and they do not reliably and efficiently operate at room temperature yet. Further research and efforts will be needed to achieve not only high volumetric energy density and safety, but also miniaturization, cost efficiency, and efficient operation at room temperature for biomedical applications.

Solid-State Batteries: LIBs, like most other types of batteries, use liquid electrolytes, which are volatile, flammable, and toxic. As such, liquid electrolytes, which in LIBs consist of lithium salts in an organic solvent, are the reason LIBs can be hazardous, especially in biomedical applications. Aqueous electrolytes, which are water-based, are less hazardous than liquid electrolytes, but they limit the cell voltage and energy density.

Solid electrolytes exhibit number of advantages including reduced risk of thermal runaway and leakages. Solid electrolytes are also less flammable, more robust and flexible, and more resilient to shock, vibration, and high temperatures.^[174] They have a slower self-discharge rate, a higher gravimetric energy density, and a more uniform output voltage than conventional liquid electrolytes. They eliminate the need for separators and other packaging restrictions, which enable flexible cell structure designs with various form factors.^[175] As an example, the volumetric energy density of solid-state batteries can be significantly increased when they are made into the form of thin-film cells.^[174] Solid-state primary or secondary batteries are already capable of meeting lifetime and power density requirements for low-power medical devices such as cardiac pacemakers.^[175] Various kinds of materials have been investigated for use as solid-state electrolytes. They can be broadly classified by type: polymers, polymeric gels, ceramics, glassy materials, and hybrid composites.^[176] The thickness of the electrolyte can range from hundreds of nanometers to hundreds of micrometers, depending on the fabrication method.^[174] The most common solid-state electrolyte materials used in lithium-based batteries include oxide-type, sulfide-type, hydride-type, halide-type, borate or phosphate-type, thin film-type, and polymer-type.^[176–178] For example, sodium superionic conductor (NASICON), lithium superionic conductor (LISICON), lithium phosphorus oxynitride (LiPON), and poly(ethylene oxide) (PEO) are some of the most well-known solid-state electrolytes for lithium-ion batteries.^[177,178] One of the first solid-state electrolyte designs was a plastic-based lithium phosphorous oxy-nitride (LiPON or PLiON) glassy thin-film electrolyte; it was

a conventional coin-type cell, which was flexible and easy to use.^[68] For non-lithium based battery systems, ceramics are the most commonly used solid-state electrolytes.^[179] Phosphates, such as NASICON, are the most promising solid-state electrolytes for sodium-ion batteries, and sulfide-based solid-state electrolytes are used in many solid-state battery systems.^[174,180]

However, there are still many issues that are preventing the broad adoption of solid-state batteries in biomedical devices. One major problem is that solid-state electrolytes exhibit high ionic resistance in ambient temperatures, which causes their power density to decrease. In addition, it is not yet cost-effective to replace conventional liquid electrolyte-based LIBs with solid-state batteries: the manufacturing cost of the most common commercial solid-state battery, lithium polymer (LiPo) batteries, is 10% to 30% higher than standard LIBs. Solid-state batteries are not fully biocompatible or biodegradable, which can cause safety issues especially for biomedical applications. Other improvements needed for the wide-spread adoption of solid-state batteries in biomedical devices include increasing the cycle lifespan, preventing dendrite formation on the electrode/electrolyte interface, and increasing mechanical and chemical stability.^[174,181–192]

Transient Batteries: One safety hazard for LIBs, especially when used in implantable or ingestible biomedical devices, is the release of toxic materials upon accidental rupture. Since LIBs and other commercial batteries are not biodegradable, the devices can only be retrieved through invasive or semi-invasive surgical procedures, which can cause complications including patient discomfort and inflammation. To solve these issues, researchers have been developing biocompatible and/or biodegradable batteries for implantable and ingestible biomedical electronic devices.

In order for a battery to be fully biocompatible, all of its components, including the cathode, the anode, the electrolytes, and the packaging, must be made from nontoxic and biodegradable materials. The most promising materials for nontoxic transient anodes are biodegradable metals such as Mg and Zn, since they each possess a high theoretical energy density (Mg: 2200 mAh g⁻¹, Zn: 820 mAh g⁻¹) and excellent biocompatibility (maximum daily allowance Mg: 350 mg day⁻¹, Zn: 40 mg day⁻¹).^[193–196]

Conventional Mg- or Zn-based primary batteries use silver chloride (AgCl), copper chloride (CuCl), or copper (Cu) as cathode materials which are nonbiodegradable and toxic. Biodegradable metals such as Fe, tungsten (W), or molybdenum (Mo) can serve as substitutes for conventional cathode materials.^[197] Utilizing micro/nano-fabrication technology, metal electrodes can be formed into very thin films in order to increase surface area and power output of the battery, if necessary. Note that the redox reaction and degradation rate of the metal electrodes also increases as the surface area increases, so the battery should be designed to keep the amount of metal dissolved into the body within the maximum daily allowance. Moreover, any dissolvable metals being evaluated in the body should undergo rigorous testing in pre-clinical models prior to human translation.

Biocompatible electrolytes, such as a magnesium chloride (MgCl₂) solution, can be used or physiological fluid itself can serve as the electrolyte with support material such as a biodegradable hydrogel or polymer. Biocompatible and degradable packaging made from for example polyanhydrides, polycaprolactone (PCL), or polylactic acid (PLA) could ensure the complete biodegradability, longevity, and stability of the batteries.

In one study, a fully transient biodegradable Mg/Fe battery system with an MgCl₂ electrolytic solution was fabricated using a MEMS process.^[198] Its performance was sufficient to power transient implantable electronic systems, with an energy capacity of 0.7 mAh and a peak power output of 26 μW.

Biocompatible metals can still have the potential to induce adverse effects if the released amount exceeds the daily dose limitation. Other potential sources of electrode materials are biologically derived electrochemically active materials, such as natural melanin pigments and their synthetic analogs (“melanins”). Melanins can be used as both anodes and cathodes, depending on the reduction potential of the opposite electrode. One research group developed edible primary cells consisting of pre-oxidized melanin cathodes, benign ceramic-based anodes, and an aqueous sodium-ion electrolyte; the nominal voltage for these cells was 0.5 V and the nominal specific energy capacity was 25 mWh g⁻¹.^[79] Another group developed a biodegradable, flexible micro-supercapacitor that consisted of melanin drop-casted carbon paper electrodes operating in aqueous electrolytes. This supercapacitor had a power density of 5.24 mW cm⁻², an energy density of 0.44 mJ cm⁻², and a specific capacitance of 4.3 mF cm⁻².^[199] Both examples demonstrate that biologically derived materials have great potential to make fully biocompatible and biodegradable on-board energy supply and storage systems for implantable and ingestible electronic devices.

Batteries with Versatile form Factors: Implantable and ingestible biomedical devices often have size and shape constraints. The dimensions and shape of ingestible electronic devices are especially limited due to the risk of GI obstruction and device retention.^[80] Pill-shaped and round ingestible systems are normally used as a reference point when developing ingestible electronics, since they have a known safety profile:^[80] the largest standard capsule (000) has a diameter of 9.91 mm and a locked length of 26 mm. Ingestible devices that are larger than these dimensions, such as the PillCam COLON capsule, which has a diameter of 11.6 mm and length of 33 mm, are sometimes unable to be passed out of the GI tract: the retention rate of the PillCam is 1.4% and it is often linked to obstruction of the GI tract.^[200–204] In ingestible electronics, rigid batteries occupy more than half of the total volume of the device and are unable to provide power for more than several days.^[80] Designing batteries with various shapes and sizes would reduce the overall size of these devices and reduce the risk of obstruction. Characteristics to consider when selecting batteries include their footprint (micro/large area batteries), thickness (thin film or bulk), mechanical properties (flexibility, bendability, rollability, stretchability, foldability), manufacturing methods (deposition, printing, coating), and technology (solid-state, lithium-polymer, carbon-zinc).

It is challenging to change the shape of bulky and rigid conventional batteries because they have composite electrodes and liquid electrolytes. There has been much research on new electrode and electrolyte materials for the purpose of developing flexible, low profile, or microsized batteries without compromising energy density. One major breakthrough for miniaturized battery (microbattery) and flexible battery technologies was the development of solid-state electrolytes, which was discussed previously. Using thin-film or 3D architecture techniques to overcome low ion conductivities, the thickness of these microbatteries can be reduced to a few micrometers.

Typically, the electrodes of these microbatteries are composed of thin-film solid-state materials such as polymers, silicon, or carbon pillars; they can be fabricated by thick film technology or vapor deposition.^[205–207] In some studies, nanocarbons, graphene, carbon nanotubes, or paper were combined with electrochemically active materials to make flexible electrodes.^[208–211] Most of these flexible batteries are based on well-studied battery chemistry, such as lithium-ion, zinc-carbon, or lithium, but there have been efforts to make flexible batteries based on other battery chemistries, such as NIBs.^[212]

There are a few microbatteries and flexible batteries that are already on the market. Commercial microbatteries available today are able to perform sufficiently well for several biomedical applications, including implantable orthodontic systems.^[213] For example, the smallest lithium-ion microbattery on the market has a size of $1.75 \times 2.15 \times 0.02 \text{ mm}^3$ (EnerChip, Cymbet Corporation).^[214] However, the energy densities are very low ($\approx 5 \mu\text{Ah}$) and typically only allow a few hours of active operation.^[215] Flexible batteries are already widely used in various applications, such as smartphones, wearable healthcare devices, and skin patches; their capacity is comparable to conventional rigid LIBs.^[216] One flexible lithium-ion polymer battery that was recently released to the market is the J.Flex battery by Jenax. This battery can be twisted, bent, and folded like paper and has a capacity of 30 mAh ($27 \times 48 \text{ mm}$, 2.3 mAh cm^{-2} , 3.8 V), making

it suitable for medical devices and consumer electronics.^[217] The market size for flexible batteries was \$98 million in 2020, and in 2025 it is expected to be \$220 million.

There are also several academic groups that are researching ways to develop microbatteries with various shapes, sizes, and other physical characteristics. Kutbee et al. developed a biocompatible flexible LIB using the standard CMOS process; it had an unprecedented energy density of 200 mWh cm^{-3} (6 mWh cm^{-2}), was lightweight at $236 \mu\text{g}$ for each microcell ($2.25 \text{ mm} \times 1.7 \text{ mm} \times 30 \mu\text{m}$), and was mechanically stable during 120 cycles of operation.^[213] These batteries were integrated into an implantable orthodontic system with near-infrared (NIR) LEDs, which demonstrated the potential for flexible microbatteries to be used in biomedical microelectronic applications including medical implants, hearing aids, and wireless sensor networks.^[213] Another group developed gel-based microbatteries that were safe, noncorrosive, and nonflammable and demonstrated that they could be used for low power ingestible and implantable devices.^[218] The energy density of these gel-based microbatteries was 3.94 mAh cm^{-3} , for a total capacity of 0.79 mAh, which is enough to power ingestible sensors requiring 4.69 mA for 168 h. (OCV 0.7 V, $7 \text{ mm} \times 7 \text{ mm}$)

Figure 3 summarizes the major challenges of developing batteries for implantable/ingestible biomedical electronic devices and corresponding examples of technology that address these issues.




Figure 3. Current challenges of developing batteries for implantable/ingestible biomedical electronic devices and corresponding examples of technologies that address these issues. Reproduced with permission.^[140] Copyright 2020, Elsevier. Reproduced with permission.^[219] Copyright 2019, Frontiers Media S.A. Reproduced with permission.^[220] Copyright 2016, Wiley-VCH. Reproduced with permission.^[221] Copyright 2017, American Chemical Society. Adapted with permission.^[222] Copyright 2017, American Chemical Society. Reproduced with permission.^[213] Copyright 2017, Springer Nature.




Figure 4. Energy sources available around the human body and biomedical devices that can be powered by these energy sources. Reproduced with permission.^[223] Copyright 2012, Springer Nature. Adapted with permission.^[224] Copyright 2011, IEEE. Reproduced with permission.^[225] Copyright 2020, Elsevier. Reproduced with permission.^[226] Copyright 2013, Elsevier. Reproduced with permission.^[227] Copyright 2016, Elsevier. Adapted with permission.^[228] Copyright 2010, SAGE Publications. Reproduced with permission.^[229] Copyright 1996, Elsevier. Adapted with permission.^[80] Copyright 2018, Springer Nature. Adapted with permission.^[9] Copyright 2015, Springer Nature. Created with BioRender.com.

3. Energy Harvesting to Power Biomedical Electronic Devices

Different locations and organ systems in the human body have access to different types of energy sources, such as mechanical, chemical, and electromagnetic (EM) energies. Mechanical energy generally refers to the energy associated with the motion and position of an object. The contraction of muscles is a form of mechanical energy; most mechanical energy sources within the body are low in frequency (below 10 Hz). Ultrasound, which is a type of mechanical energy that can be produced artificially, has a frequency range between 20 kHz and 20 MHz. Chemical energy is potential energy stored in the bonds of chemical substances. This energy can be released by undergoing a chemical reaction. Molecules or ions that can act donate or accept electrons can be used as chemical energy sources; glucose, ethanol, and hydrogen ions are examples of electron donors or acceptors that are naturally found in the body.

These energy sources can be classified into endogenous or exogenous energy sources based on how they are produced. Endogenous energy is naturally existing energy inside the body, while exogenous energy is artificially generated from human or external system activities. The circulatory system includes the endogenous mechanical energy of the heartbeat and blood flow and the chemical energy of blood glucose. The contraction and relaxation of the diaphragm generate mechanical energy in the

respiratory system. In the GI tract, or digestive system, gastric motility can be a mechanical energy source. Endogenous chemical energy sources include glucose that is present in the brain's cerebrospinal fluid (CSF) and the interstitial fluids. The pH gradients and nutrients present in GI fluid also possess chemical energy. Bioelectrical energy is another type of endogenous energy, which is a result of the electrochemical gradient found across cell membranes; it is actively maintained by energy (ATP)-consuming cell membrane ion pumps. In mammals, the largest direct current (DC) electrochemical potential can be found in the cochlear endolymphatic spaces, and ranges from 70 to 100 mV. Normally, part of these energies are used to operate and maintain the body, but a large portion of remaining energies are lost to the surroundings through heat or other types of energy. These energies can be collected and converted to electrical energy to power in-body electronics: this is called energy harvesting. If devices are implanted at the locations where there are no accessible endogenous energies, exogenous energies in the form of ultrasonic or electromagnetic waves can penetrate through the biological barriers and wirelessly deliver the energies to the devices: this is called energy transfer, which will be discussed in Section 4.

Figure 4 shows available energy sources present inside and outside the body as well as clinical applications that can be powered by these energy sources, and **Table 4** summarizes the amount of energy available from the endogenous and

Table 4. Amount of energy available from endogenous and exogenous energy sources.

Type	Energy source	Available energy	References
Mechanical	Heartbeat	0.93 W	[104]
	Blood flow	50–150 cm s ⁻¹	[230]
	Breathing	0.41 W	[104]
	GI motility	Table 8	
	Center of mass	20 W	[104]
	Shoulder	2.2 W	[104]
	Knee	36.4 W	[104]
	Ankle	66.8 W	[104]
	Heel strike	20 W	[104]
	Chemical	Blood glucose	4.5 × 10 ⁻³ –10 × 10 ⁻³ M
CSF glucose		4 × 10 ⁻³ –25 × 10 ⁻³ M	[232–234]
GI pH		pH 1–8	[235]
GI nutrients		Table 10	
Electromagnetic	EM wave	10 mW cm ⁻²	[236]
	Ultrasound	Average 10–1000 mW cm ⁻² , max pulse 190 W cm ⁻²	[237]
Bioelectric	Endocochlear potential	70–100 mV	[223]

exogenous energy sources shown in Figure 4. Employing suitable energy harvesting or transfer methods will empower sustainable ways to power in-body electronics.

3.1. Mechanical Energy Harvesting and Energy Sources

3.1.1. Mechanical Energy Harvesting Methods

Piezoelectric Energy Harvesters: Piezoelectric effect is the phenomenon of conversion between mechanical vibration and electrical charges in piezoelectric materials such as quartz, topaz, cane sugar, zinblend, tourmaline, and Rochelle salt.^[239] Applying an electrical voltage to a piezoelectric material will generate a change in its geometry—it will either expand or contract: this is called the converse piezoelectric effect. In addition, when a mechanical stress is applied to a piezoelectric material, it will generate an output voltage that is directly proportional to the amount of pressure applied: this is called the direct piezoelectric effect (Figure 5b).^[239–241] Due to the direct piezoelectric effect, piezoelectric material-based energy harvesters, or piezoelectric nanogenerators (PENGs), can convert the mechanical energy present in small vibrations into electrical energy.




Figure 5. The working principle and operation modes of the PENGs. a) Electrical poling direction and preferential chain direction of the piezoelectric materials. For instance, in poly(vinylidene fluoride) (PVDF), the polar axis (labeled as direction “3”) is the direction of the applied electrical poling field. The polymer stretch direction or the preferential direction of the aligned polymer chains is denominated as direction “1” and is perpendicular to the polar axis. The axis orthogonal to the stretch direction “1” is labeled as “2.” The shear planes of piezoelectricity are indicated by the directions “4,” “5,” “6,” and are perpendicular to the directions to “1,” “2,” “3,” respectively.^[238] The direction of the applied mechanical stress relative to the polar axis largely affects the performance of the piezoelectric energy harvesting device. b) The schematics of direct and converse piezoelectric effects. The direct piezoelectric effect appears when a mechanical stress is applied to a material, and the electric charges are generated proportional to the applied mechanical stress. Before the external stress is applied, the centers of the positive and negative charges of each molecule coincide and the material is in a neutral net electrical polarization. When a mechanical stress is applied and deforms the structure of the material, the positive and negative charges inside of the molecule will be separated and this leads to the generation of dipolar moments. When a mechanical stress is reversed, the polarity of dipolar moments will be reversed. This polarization generates an electric voltage output, which is the transformation of the mechanical vibration applied to the material into useful electrical energy to power electronic devices. The converse piezoelectric effect occurs when the electric field is applied to the piezoelectric material. The external electric field will change the position of electrons and nuclei in each molecule and dipoles will be created. These dipoles will result in the polarization of the material and ultimately induce the deformation of the material. When the electrical field is removed or reversed, the electrons and nuclei will move back to their original position, and the material will return to their initial geometry.

The piezoelectric phenomenon is often associated with non-centrosymmetric crystalline materials: synthetic poly(vinylidene fluoride) (PVDF) and vinylidene fluoride (VDF) copolymers have some of the highest piezoelectric coefficients among polymeric materials.^[240–242] Amorphous polymers can also be piezoelectric; however, their piezoelectric mechanism differs from that in semicrystalline polymers and inorganic materials. To exhibit piezoelectric activity, amorphous polymers must have dipoles present in their polymer chains that are able to rotate and align in the direction of the poling electric field. This process usually occurs when the temperature of the polymer is greater than its glass transition temperature (T_g), during which the polymer chains are adequately mobile so that their dipoles can align in the direction of the applied poling field. A partial orientation of the dipoles can be achieved by lowering the temperature below the T_g in the presence of an electric field, which gives rise to a remanent polarization in the direction of the electric field, and, consequently, induces piezoelectricity in the polymer.^[243]

Due to the nature of the piezoelectric activity in amorphous polymers, electroactivity is only observed below T_g , when the chains are “frozen” and a cooperative movement of the backbone atoms in the polymer is restricted. Above T_g , there are cooperative and segmental movements of the polymer chains which cause depolarization to occur; as a result, amorphous polymers are not electroactive at these temperatures. In semicrystalline polymers like PVDF and its copolymers, the lock-in of the polymerization is supported by the crystalline lamellar structure of the polymer, and for that reason the piezoelectricity is stable above the T_g , and up to the Curie temperature (T_c).^[243]

The piezoelectric effect can be quantified by the piezoelectric coefficients (d_{xy}), which is defined as the ratio between the induced or applied electric polarization and the applied mechanical stress or induced strain of the piezoelectric material. The subscript letter “ x ” represents the direction of the applied mechanical stress or induced strain of the piezoelectric material, and “ y ” represents the direction of the induced or applied electric polarization. The axes to define the piezoelectric coefficients are shown in Figure 5a. The direct piezoelectric coefficients represent the amount of electric charge generated by the mechanical stress. A piezoelectric material with a higher piezoelectric coefficient will generate more electrical energy from the same mechanical stress.

Most of the piezoelectric materials that are commonly used for in-body applications can be categorized into the synthetic or natural polymers. **Table 5** lists characteristic piezoelectric coefficients for the most commonly used synthetic polymers. Biological macromolecules like poly(lactic acid) (PLA) or poly(3-hydroxybutyrate) (PHB) are piezoelectric under shear deformation and have coefficients similar to those observed in bone ($d_{14} = 0.7–10 \text{ pC N}^{-1}$); this property has been explored for use in tissue engineering applications.^[250,255] Furthermore, natural polymers and proteins can be used to create biocompatible energy harvesting devices, which are potentially biodegradable, for on-demand electronic power sources. **Table 6** lists the piezoelectric coefficients of natural electroactive polymers.

PENGs can be worn externally or implanted in the body; they can be used to convert small mechanical vibrations generated by the human body from activities such as walking, breathing,

Table 5. The piezoelectric coefficients of most technologic synthetic polymers. Abbreviations: PVDF: poly(vinylidene fluoride), PVDF-TrFE: poly(vinylidene fluoride trifluoroethylene), PLA: poly(lactic acid), PVC: poly(vinyl chloride), PAN: poly(acrylonitrile), PVDCN-VAc: poly(vinylidenecyanidevinyl acetate), (β -CN)APB/ODPA: nitrile substituted polyimide.

Polymer	Piezoelectric coefficient [pC N^{-1}]	References
PVDF	18–27	[240,241,244,245]
PVDF-TrFE	10–31	[246–248]
PLA	3–10	[245,249,250]
PVC	0.7	[243,251]
PAN	1.7	[243,252]
PVDCN-VAc	7	[243,253]
(β -CN)APB/ODPA	0.3	[243,254]

or fluxes in biofluids, into energy to power implantable medical devices.^[265,266] The manufacturing process is easily scalable and often compatible with CMOS fabrication process. PENGs can also be used for flexible and stretchable devices.^[267] The lifetime, reliability, and high energy density of piezoelectric materials make them ideal for use in implantable energy harvesting devices.

Triboelectric Energy Harvesters: In triboelectric devices, electrostatic charges are generated when two different materials, which have electrically charged surfaces, are brought into contact. A typical triboelectric nanogenerator (TENG) consists of two thin films with opposite tribo-polarity; each film has an electrode attached to its back side. When the materials come into close contact, charges are transferred between the films leaving one side positive and the other negative; when the materials are separated, the transferred charges create a triboelectric potential. This potential then causes electrons to flow in the electrodes at the back side of the materials. The triboelectric series of the most common triboelectric materials used for biomedical applications is shown in **Figure 6a**.

There are four basic modes of operation for a triboelectric generator: vertical separation, lateral sliding, single electrode, and free-standing. In the vertical separation mode, two dissimilar dielectric surfaces face each other and the electrodes are located on the back sides of each surface (Figure 6b). When the dielectric surfaces are brought into physical contact, the

Table 6. The piezoelectric coefficient of most biological macromolecules.

Polymer	Piezoelectric coefficient [pC N^{-1}]	References
Chitin	0.2–1.5	[250,256]
Amylose	2.0	[250]
Cellulose	0.2	[250]
Collagen	0.1–2	[250,257,258]
Elastin	1–54	[250,259,260]
Keratin	0.1–2	[250]
Fibrin	0.2	[250]
Silk fibroin	1–38	[246,261]
Gelatine	20	[262]
PHB	0.3–1.5	[263,264]




Figure 6. a) The triboelectric series of the common triboelectric materials used for biomedical applications.^[270–275] b–e) The working principle and operation modes of TENGs.

surfaces accumulate opposite electrical charges. Separating the charged surfaces generates an electric field, which causes a potential difference across the electrodes. In the lateral sliding mode, two different dielectric surfaces are placed in contact with each other; the tangential movement of one surface with respect to the other changes the contact area of the charged surfaces which leads to transverse polarization along the sliding direction (Figure 6c). This polarization creates an electric potential, causing electrons to flow between the two electrodes.^[268,269]

The single electrode mode is similar to the vertical separation mode in the direction of relative motion, but the two moving parts are not electrically connected (Figure 6d). One of the moving parts is a dielectric layer and the other is an electrode. Separating the dielectric layer from the electrode generates an electric field which induces a current between

the electrode and ground.^[268,269] This mode is widely used for mobile applications like walking, where it is difficult to electrically connect dielectric materials to an external load.^[268] Finally, in the free-standing mode, two identical electrodes coated with a dielectric material are in contact with a sliding dielectric surface, in which triboelectrification and electrostatic induction causes a cyclic movement of charges between the electrodes (Figure 6e).^[268,269]

Wang and co-workers first developed TENGs in 2012 and demonstrated their ability to output high voltages and harvest energy from a variety of vibrational sources.^[276–279] There are many advantages of using triboelectric generators including high output voltages, efficiency, simplicity in their structural design, high versatility in their design and fabrication, stability, and low environmental impact.^[280–283] While PENGs are better at harvesting energy for high-frequency vibrations, TENG




Figure 7. The working principle of electrical generators. The electrical generators can be categorized by the type of relative motion between the magnets and coils: a) Linear or b) rotation. c) Homopolar generator or Faraday disk.

devices are more efficient at converting mechanical energy at frequencies below 4 Hz to electrical energy, which enables them to scavenge energy from the low frequency movement of the human body such as GI motility.^[280,284] TENGs are a promising energy harvesting technology and could soon allow the conversion of mechanical energy from human motion, like walking, typing, and breathing, into useful electrical energy in order to power small electronic devices for various healthcare application.^[285,286]

Electrical Generators: An electrical generator is a device that converts mechanical energy to electrical energy; it consists of a coil of wire surrounded by an array of permanent magnets; an external mechanical force drives the relative movement between the coil of wire and the magnets (Figure 7). The magnetic flux experienced by the coil changes as either the coil or the magnets move, causing electrons to flow through the wire according to Faraday's law.^[287] The first electrical generator was developed by Michael Faraday and consisted of an electrically conductive disk that could be rotated between magnets to induce a current to flow through a wire (Figure 7c).^[288] This type of homopolar generator, also called the Faraday disk, can generate DC without rectifiers or switches, while other types of electrical generator can produce only alternating current (AC). Today, there are many types of electrical generators but the basic principle is the same. The relative movement between the coils and magnets can be linear (Figure 7a) or rotation (Figure 7b), and movement can be induced by various types of motion such as vibrational, shaking, fluid flow, and swirling vortices.^[289–291] The ability of an electrical generator to produce

power from a variety of motion types would be especially advantageous when harvesting energy from human motion, which has many different modes and velocities.^[7] Also, there is no mechanical contact between the moving parts of the device, which enhances the viability and durability of the system by reducing mechanical losses due to friction.^[287] Efforts have been made to harvest energy from a variety of motions produced by the human body such as abdominal movement, body vibration, and walking.^[292–294] However, the power output range of this type of generator is highly variable and depends on the size of the device; it is also less efficient for low frequency movements. Most electromagnetic induction energy harvesters are implemented for wearable devices,^[294] and there are only few examples of implantable electromagnetic induction energy harvesters reported in the literature.

Automatic Wristwatch Systems (AWSs): The AWS, also known as an automatic power-generating system, automatic generating system (AGS), or mass imbalance oscillation generator (MIOG), is a type of self-powered watch that uses wrist motion as the power source. Figure 8 shows the working principle of this device as a biomechanical energy harvester. When external movement causes an eccentric weight to oscillate, a mechanical rectifier transforms this oscillatory movement into a unidirectional rotation; this rotation winds a spring to temporarily store mechanical energy. When the torque reaches the detent torque of the generator, the spring unwinds which drives the electrical generator. This generates an electrical impulse with duration of a few milliseconds. When the spring is completely uncoiled, the whole process is repeated. The amount of energy




Figure 8. The working principle of AWSs.

produced by one electrical impulse depends on several parameters including spring stiffness, transmission gear ratio, and load resistance.^[295] For example, the oscillation weight needs to be deflected about 2.5 rad in order to generate one electrical impulse, and the induced electrical impulse yields an average of 66.0 μJ ($\pm 10.7 \mu\text{J}$).^[295] Furthermore, the energy conversion efficiency of an AWS is significantly affected by its coupling to a mechanical energy source: the original vibration of the mechanical energy source will be significantly dampened if the device is not tightly fixed to the mechanical energy source at the right tilting angle.^[295] This system is commonly used in a wristwatch and the fabrication cost is relatively low. However, like an electrical generator, it is large and bulky compared to other mechanical energy harvesters. This is because it relies on a pendulum configuration which becomes insensitive to mechanical motion if the size is reduced. Researchers have used the energy transforming mechanism of the automatic wristwatch to harvest mechanical energy *in vivo* from cardiac contractions.^[296]

3.1.2. Endogenous Mechanical Energy Sources and Corresponding Energy Harvesting Methods

Heartbeat and Blood Circulation in the Circulatory System: The circulatory system is responsible for transporting nutrients to and removing waste materials from cells in the body. From an energy harvesting perspective, the energy accessible in this system exists either in the form of mechanical energy from the contraction of the heart and the flow and pulses of blood, or in the form of chemical energy from the nutrients being transported in the circulatory system. The cardiac output power for an adult at rest is estimated to be around 0.93–1.4 W; the typical cardiac frequency, or intrinsic heart rate (IHR), for an adult at rest is 60–120 bpm.^[297,298] The output power and frequency of a beating heart can vary depending on numerous factors including fitness and activity level, smoking status, cardiovascular health, metabolic health, ambient air temperature, body position, emotional state, body size, and medication use. The mechanical energy present in blood vessels depends on

the dynamics of the blood flow. The cardiac cycle of the heart causes a cyclic change in blood pressure, which ranges from a maximum pressure while the heart is contracted, called systolic pressure, to a minimum pressure between contractions, called diastolic pressure. The systolic/diastolic blood pressure (SBP/DBP) range can vary depending on age, but the normal ranges are 90–120/60–80 mmHg for SBP/DBP.^[299,300] The velocity of normal human blood flow, which can be measured by 4D flow MRI, varies with age, cardiac output, and anatomical site.^[230] The average blood flow rate in the ascending aorta is 50–75 cm s^{-1} and peak systolic velocity can be up to 100–150 cm s^{-1} .^[230] Devices implanted close to the heart, such as pacemakers, implantable cardioverter defibrillators (ICD), or electrocardiogram (ECG) recorders, can potentially be powered from these mechanical energy sources. PENGs, TENGs, electrical generators, and automatic watch harvesters show promise in their ability to harvest energy from vibrational sources in the circulatory system.

One device, developed by Dagderiven et al., was able to harvest enough mechanical energy from the movement of the heart to continuously power a pacemaker; the monolithic and flexible system used lead zirconate titanate (PZT), a piezoelectric material, to harvest energy (Figure 9a).^[301] Other piezoelectric materials are also being explored to convert the mechanical movement generated by the circulatory system into useful electrical energy. Piezoelectric ceramics like PZT and piezoelectric single crystals like PZN-PT and PMN-PT have high piezoelectric coefficients and electromechanical coupling factors; however, they contain lead, which is toxic and unsuitable in implantable energy harvesting applications.^[302] Furthermore, they are brittle, which creates additional manufacturing challenges since PENG devices should ideally have some degree of flexibility so that they can be attached to soft tissues like the lungs or the heart without creating damage on either the devices or the organs. To overcome these obstacles, new scavenging devices based on piezoelectric polymers and polymer-based TENGs are being explored for energy harvesting applications to power the next generation of implantable medical devices.

Ouyang et al. developed an implantable TENG device that harvests energy from cardiac motion to power cardiac pacemakers (Figure 9b).^[303] This TENG device was able to generate




Figure 9. Examples of systems that harvest mechanical energy from the circulatory system. a) Adapted with permission.^[301] Copyright 2014, National Academy of Science. b) Adapted with permission.^[305] Copyright 2016, American Chemical Society. c) Reproduced with permission.^[307] Copyright 2012, Springer Nature. d) Adapted with permission.^[227] Copyright 2016, Elsevier. e) Adapted with permission.^[309] Copyright 2016, IEEE.

a maximum energy of $0.495 \mu\text{J}$ from each cardiac cycle, which is enough to stimulate the heart to beat (the endocardial pacing threshold energy in humans is $0.377 \mu\text{J}$).^[304] In another study, an implantable and biocompatible multilayered TENG attached to a porcine adult heart was able to achieve a maximum electrical output voltage of 14 V and a current of 5 μA from each heartbeat cycle.^[305] This TENG device was able to power a cardiac monitoring system developed for a real-time remote health assessment. Another group developed a self-powered and multifunctional implantable TENG sensor made of electrodes, spacers, and triboelectric films packed with biocompatible polymer layers; this sensor was able to monitor multiple pathological and physiological parameters continuously and accurately. When tested in large-scale animals, the TENG sensor accurately monitored heart rate, detected arrhythmias, and measured respiratory rates and phases.^[306]

Several studies have used automatic watch energy harvesting systems to harvest vibration energy from the heart. The first in vivo demonstration of such a system was realized in 1999 on the right ventricular wall of a mongrel dog.^[74] More recent studies, which used computational and MRI-based analysis to optimize coupling between the heart motion and the AWSs, have led to higher energy conversion efficiencies and power outputs (Figure 9c).^[295,307] The power output harvested by AWSs ranges from 16.7 to 44 μW and the approximate conversion efficiency is 16.8%.^[74,295,307] Since the power consumption of a low-power cardiac pacemaker can be reduced to 8 μW , AWSs could power pacemakers by harvesting energy from the heart's motion.^[308]

Electrical generators have also been proposed to harvest energy generated by blood flow.^[289,309–312] In one study, an

electrical generator was designed to allow blood to flow through a housing to drive the rotation of a rotor (Figure 9e).^[309] When the rotor, which contained permanent magnet bars, rotated inside the housing, which contained four pairs of coils, electricity could be generated. The conversion efficiency of the device was 1.04% with a maximum electrical power output of 3.4 mW at a blood pressure drop of 54.75 mmHg and a blood flow of 2.68 L min^{-1} . The device had a diameter of 23 mm and a thickness of 10 mm. This electrical generator was rigid and bulky compared to PENG and TENG devices, which can be flexible and thinned down to $100 \mu\text{m}$.^[301,305] These energy harvesters are not only able to power cardiac electronic implants but could also be used to power blood pressure monitoring systems.

Breathing Motion in the Respiratory System: The respiratory system is the group of organs and tissues that are responsible for gas exchange. One way to access mechanical energy during respiratory motion is through the change in airway pressure during inhalation and exhalation. This pressure varies depending on the lung volume: the approximate maximum pressure for females is 66 cmH₂O and for males is 102 cmH₂O.^[313] The most ideal location to place an energy harvester is near the diaphragm, which is the muscle that induces the contraction and relaxation of the lungs. The power output of the diaphragm is estimated to be 0.41 W.^[104] The normal respiratory rate is 12–20 bpm for an adult at rest.^[314,315] The energy harvested from the diaphragm could be used to power nearby devices such as a pacemaker or a subcutaneous drug delivery system.

The cyclic movement of the lungs and diaphragm makes them desirable places to harvest mechanical energy and




Figure 10. Examples of systems that harvest mechanical energy from the respiratory system. a) Adapted with permission.^[301] Copyright 2014, National Academy of Science. b) Adapted with permission.^[77] Copyright 2014, Wiley-VCH. c) Adapted with permission.^[292] Copyright 2011, IEEE.

convert it into useful electrical energy to power small biomedical devices. Dagdeviren et al. developed a device made from flexible piezoelectric PZT elements, rectifiers and microbatteries to store energy harvested from respiratory movements (Figure 10a).^[301] A mechanical-to-electrical energy conversion efficiency of $\approx 2\%$ was achieved in in vivo experiment. The overall energy generated was enough to power pacemakers without being assisted by external batteries.

Zheng et al. introduced the first application of an implanted triboelectric nanogenerator (iTENG) that harvested energy from the mechanical movement of breathing to directly drive a pacemaker (Figure 10b).^[77] The energy harvested by the iTENG was stored in a capacitor which powered a pacemaker that regulated the heart rate of a mouse. This approach demonstrated the feasibility of scavenging biomechanical energy and converting it to useful mechanical energy and represents a milestone in the pursuit of a completely self-powered implantable medical device.

In another study, an electrical generator with two linear permanent magnet arrays was developed to harvest energy from respiration (Figure 10c).^[292] The device, which consisted of four pairs of permanent magnets and a coil loaded on a spring, was designed to harvest the mechanical energy from the diaphragm muscle in the abdominal wall. Vibration caused the coil loaded on the spring to move relative to the magnets that were fixed on the platform, which generated electrical power. The total volume of this device was 279 cm^3 . At its resonant frequency, which was 0.3 Hz , the device reached its highest efficiency and had a maximum power output voltage of 1.5 V . With an external load of $1 \text{ k}\Omega$, the maximum power output was 1.1 mW .

GI Motility in the Digestive System: In the GI tract, there is a wide range of mechanical motion that aids in the passage, mixing, and mechanical digestion of ingested foods. At a fundamental level, this mechanical motion arises from the smooth muscle cells present in the lining of the gut; these cells can depolarize, triggering an influx of Ca^{2+} which activates tropomyosin, resulting in cell contraction.^[316] The selective contraction of cells results in the endogenous activities of the GI tract. In general, the GI wall consists of several layers of mucosa,

muscle, and connective tissue (Figure 11a).^[317] Of particular interest are the layers of radial and longitudinal muscle which contract together to generate mechanical motion for enabling peristalsis, or the passage of food, as well as segmentation, which is the mechanical digestion of the food bolus.

The current clinical standard for measuring GI mechanical motion is to use manometry, in which pressure waves generated by GI contraction are measured by a pressure-sensitive catheter. Manometry studies have been extensively conducted in most regions of the GI tract in humans including the esophagus, stomach, small intestine, and colon, and the measured pressure amplitudes and waveforms can be used to represent mechanical activity (Figure 11b, Table 7).^[320–324] Electrical impedance and electrogastragram measurements have also been used to characterize GI motility, but their use is less widespread clinically.^[318,325] Electrical measurements can be used to characterize GI motility because the extracellular potential of smooth muscle cells in the GI tract changes during contraction, which is called the slow-wave or basal electrical rhythm (Figure 11c, Table 7).^[319,326]

Each section of the GI tract has its own unique mechanical characteristics, which depends on its particular function. Food first enters the esophagus, which functions to transport food into the stomach for digestion. The oral end of the esophagus contains striated muscle which can be controlled directly by the central nervous system (unlike the majority of the GI tract), while the lower end contains primarily smooth muscle which undergo distension-induced peristalsis to transport the food bolus to the stomach.^[328] Since the top end of the esophagus is under voluntary control, it is not a desirable location for device placement; however, the distal end of the esophagus has been demonstrated as an acceptable location for the placement of electronic sensors.^[320] The peristalsis in the esophagus is divided into two phases: in Phase I, the esophagus expands its luminal diameter to allow the passage of food; in Phase II, the esophagus contracts and the luminal diameter is reduced.^[331] When an adult swallows 5 mL of water, the luminal radius of the esophagus can expand from 3.5 to 12 mm during the Phase I distension. The wall thickness drops from 5 to 3 mm




Figure 11. Mechanical physiology of the GI tract. a) Cross-section of cells in the GI tract. Reproduced with permission.^[317] Copyright 2009, Elsevier. b) Manometry example showing a migrating myoelectric complex (MMC). Reproduced with permission.^[318] Copyright 2020, Springer Nature. c) Example waveforms of the slow waves that regulate mechanical contraction. Reproduced with permission.^[319] Copyright 2006, Annual Reviews Inc.

and the pressure drops as well. Afterward, in Phase II contraction, the luminal radius goes back to 3.5 mm. The wall thickness increases from 3 to 6 mm. After Phase II contraction, the wall thickness goes back to its original thickness. Since a typical human esophagus is 180–250 mm in length and esophagus transit time for liquid is around 8 s, the velocity of digested food or liquid is $22.5\text{--}31.25\text{ mm s}^{-1}$.^[332,333]

The stomach is a j-shaped muscular organ containing the fundus, corpus, and antrum, all which have separate mechanical activities. The fundus, the region closest to the esophagus, relaxes and distends to allow food to enter, while peristaltic

contractions occur circumferentially, from the corpus to the antrum, which allows the food to mix with digestive juices and be transported through the pylorus into the small intestine.^[334] Given these properties, the corpus could be a potential source for harvesting mechanical energy. Notably, the stomach contains three types of muscle layers: radial, longitudinal, and oblique. Oblique muscle layers aid in the mechanical digestion of food via grinding. The small intestine contains three separate parts: the duodenum, which releases additional digestion enzymes and is connected to the stomach by the pylorus; the jejunum, which is responsible for the absorption of sugars,

Table 7. Mechanical characteristics of GI motility.

System	Pressure wave amplitude	Contraction phenomenon	Pressure wave frequency	Electrical activity	References
Esophagus	40–180 mmHg (swallowing), 5–10 mmHg (peristaltic amplitude)	Connected to CNS	Swallowing, $1\text{--}2\text{ min}^{-1}$		[327,328]
Stomach	<10 mmHg (antral), $60.5 \pm 8.9\text{ mmHg}$ (Pylorus, Phase III)	MMC	$1\text{--}3\text{ min}^{-1}$ (antral, Phase III)	$\approx 3\text{ min}^{-1}$ (Slow wave)	[329]
Small intestine	18–62 mmHg (Phase III)	MMC	11 min^{-1} (Phase III)	$10\text{--}20\text{ min}^{-1}$	[318,322]
Large Intestine	$14.6 \pm 11.1\text{ mmHg}$ (simultaneous pressure waves)	Peristalsis/retroperistalsis, giant migrating contractions	Simultaneous pressure wave, $1.4 \pm 0.6\text{ min}^{-1}$, $1\text{--}2\text{ day}^{-1}$ (giant migrating contractions)	$3\text{--}8\text{ min}^{-1}$ (Slow wave)	[330]




Figure 12. Examples of devices that harvest mechanical energy from GI tract. a) Adapted with permission.^[343] Copyright 2017, Springer Nature. b) Adapted with permission.^[93] Copyright 2018, Springer Nature.

amino acids, and fatty acids; and the ileum, which absorbs any remaining nutrients. Mechanical motion in the small intestine aids in the digestion and absorption of nutrients.

The stomach and small intestine together as a system undergo state changes between an active “interdigestive state” and a more passive “fed state.” During the interdigestive state, in the period between meals, a migrating myoelectric complex (MMC) passes along the stomach, small intestine, and large intestine every 80–110 min.^[335] When it passes an individual segment, that region undergoes intense contractions of variable frequencies ranging from 2–3 contractions per minute in the antrum of the stomach to 11–12 contractions per minute in the duodenum.^[335] Following MMC contractions (termed Phase III), the region undergoes a period of lower activity (Phase IV), followed by quiescence (Phase I), and then irregular contractions (Phase II), before returning to intense activity. During the “fed state,” the MMC cycle disappears, but irregular phasic contractile activities continue in the stomach and small intestine. In the lower part of the stomach, the contraction is called antral contraction waves, which are controlled by electrical slow waves generated by the interstitial cells of Cajal.^[334] The slow waves originate from the mid part of the corpus at the greater curvature and propagate toward the pylorus.^[336] Slow waves, which have been measured via electrical mapping, have a frequency of around three cycles per minute and a propagation velocity of around 3 mm s⁻¹. In the small intestine, the contraction propagates at a velocity of about 0.25 cm s⁻¹ and the duration of each contraction is around 5 s.^[337] When the contraction happens in the stomach, the lumen wall squeezes the liquid in the stomach and produces a repulsive jet, which can reach a peak velocity of 5 cm s⁻¹.^[338] It is worth noting that the velocity of the liquid passing through the pylorus is an order of magnitude higher than in other parts of the GI tract. In a human subject

experiment, it was shown that 45 min after taking 800 mL of a 5% glucose liquid, 40% of the liquid meal was left.^[338] Assuming the pyloric ring has a diameter of 1 cm, the average velocity of liquid passing through the pylorus is 0.23 cm s⁻¹ if the secretion/absorption in the stomach is neglected.^[339]

The large intestine extracts water and salts from the waste that passes through the small intestine. The large intestine undergoes periodical low amplitude motions at a frequency of ≈1 min⁻¹ as measured by manometry; this motion has been hypothesized to induce segmentation and optimize the extraction of water and salts via continuous mixing.^[324,330] The large intestine also undergoes mass movements, also known as giant migrating contractions, which occur once or twice per day during which sudden, uniform peristaltic contractions rapidly push feces toward the rectum to be emptied. In one study, which recorded pressure waves for 24 h using manometry with a sampling resolution of 1 cm, antegrade pressure waves occurred 73 times while retrograde pressure waves occurred 144 times.^[340] The average propagation speed of the contraction waves inside the colon is 25 cm min⁻¹.^[341] Depending on the phase of contraction and the viscosity of the feces, the maximum antegrade volume flow rate can be as large as 34 mL s⁻¹.^[342]

There are only a few reports within the literature about harvesting mechanical energy from the GI tract. In one study, a flexible implantable triboelectric nanogenerator was attached to the surface of the stomach; it was used to stimulate gastric nerves in order to reduce food intake and achieve weight control (Figure 12b).^[93] The electrical pulses were generated in response to the peristaltic movement of the stomach, which were delivered to the vagal afferent fibers. In another study, a flexible piezoelectric device was delivered to the stomach for gastric motility sensing; this principle could be repurposed for power generation (Figure 12a).^[343] The corpus of the stomach is

Table 8. Summary of mechanical energy harvester: in vivo examples.

Year	Organism	Implant site	Mechanical energy source	Frequency/available energy of energy source	Materials of energy harvester	Power output	Power density	Output current	Output voltage	Test period	Application	References
PENGs												
2014	Bovine	Heart	Heartbeat	80–120 bpm	PZT	–	0.18 $\mu\text{W cm}^{-2}$	–	4.06–4.32 V	–	Pacemaker	[301]
2014	Bovine/ ovine	Lung	Breathing	12–18 bpm	PZT	–	–	–	4 V	–	Pacemaker	[227]
2016	Pig	Ascending aorta	Pulsation of aorta	Systolic BP: 160–220 mmHg, HR: 108 bpm	PVDF	10–40 nW	–	–	2 V (Peak V)	–	BP monitoring	[343]
2017	Pig	Stomach	Gastric motility	–	PZT	–	–	–	0.06–0.1 V	48 h	Gastric motility sensor	
TENGs												
2016	Pig	Heart (left ventricular)	Heartbeat	80 bpm	Kapton-Al	–	–	5 μA	14 V	72 h	Wireless HR monitoring	[305]
2016	Pig	Heart	Heartbeat	60–120 bpm	PTFE-Al	–	–	4 μA	10 V	2 weeks	ECCG/HR/BP monitoring	[306]
2014	Rat	Respiratory system (under left chest skin)	Breathing (motion of thorax)	50 bpm	Kapton-Al	–	–	0.14 μA	3.73 V	–	Pacemaker	[77]
2018	Rat	Digestive system (stomach)	GI motility	0.05 Hz	PTFE-Cu	–	–	–	0.1 V (V at 0.3 M Ω)	15 days	Vagus nerve stimulation for weight control	[93]
Electrical generators												
2009	Human	Ankle	Walking	1–1.7 Hz	Magnet (NdFeB)	3.9 μW	2.6 $\mu\text{W cm}^{-3}$	–	0.0594 V	–	–	[294]
2016	Goat	Circulatory system (left ventricular apex)	Blood circulation	BP: 54.75 mmHg, Blood flow: 2.68 L min $^{-1}$	Magnet (NdFeB), ferrite core	3.4 mW	1.08 mW cm $^{-3}$	77.4 mA (Peak I)	7.6 V (Peak-to-peak V)	–	–	[309]
AWSs												
1999	Dog	Heart (right ventricular wall)	Heartbeat	200 bpm	AWS system ^[344] with polyvinyl case	44 μW	–	–	0.6 (Peak-to-peak V)	30 min	Pacemaker	[74]
2013	Sheep	Heart (left ventricular mid lateral wall)	Heartbeat	90 bpm	ETA 204 (ETA SA, Switzerland)	16.7 μW	–	–	–	1 h	Pacemaker	[307]
2016	Pig	Heart (left ventricle)	Heartbeat	90 bpm	ETA 204 (ETA SA, Switzerland)	37 μW	–	–	–	40 min	Pacemaker	[295]

an ideal location for harvesting energy: its large volume enables devices to reside there without obstructing flow and it undergoes significant distension (from 15 to 1500 mL), which can be a source of mechanical energy for a piezoelectric or triboelectric generator.^[334] The fluid flow in the esophagus and the retro-pulsive jet in the stomach near the pylorus are two mechanical energy sources that are worth further investigation. In addition to the stomach, parts of the small intestine or the distal end of the esophagus could be potential candidates for harvesting energy, due to their relatively high contraction frequency. However, there are still significant challenges to be overcome in order to harvest mechanical energy from the GI tract. Devices must be designed to minimize obstruction and must not significantly alter the function of organs. Furthermore, they need

to conform to the surface of the target organ in order to optimize mechanical coupling and energy transfer; mechanical energy harvesting in other organs is relatively inefficient ($\approx 1\%$), and consequently their applicability is limited to electronics with low power requirements.^[301] Additionally, motion in the GI tract tends to be irregular, dependent on feeding patterns and food bolus transition, and the direction of mechanical contractions is unpredictable, especially in the stomach, since it is designed to mix and break down food. Even though mechanical energy remains an abundant energy source in the GI tract, there are considerable challenges to harvesting it.

Table 8 summarizes recent studies which have implemented in vivo mechanical energy harvesters that scavenge energy from various mechanical energy sources inside the body.




Figure 13. The working principle of galvanic cells. a) The electrons flow from the oxidation reaction of anode to the reduction reaction of H^+ (acidic physiological fluid) or O_2 (neutral physiological fluid) at the cathode. b) Standard reduction potential (E^0) of typical redox reactions at the anode and cathode.^[345]

3.2. Chemical Energy Harvesting and Energy Sources

3.2.1. Chemical Energy Harvesting Methods

Galvanic Cells: A galvanic cell, also known as a voltaic cell, is an electrochemical cell that derives electrical energy from redox reactions. It is a building block of today's battery, which is comprised of single or multiple galvanic cells. A galvanic cell consists of two electrodes, the electrolyte, and the salt bridge or membrane (Figure 13a). The electrodes, where the substances are oxidized or reduced, are called the anode and the cathode, respectively. When the anode and cathode are electrically connected, the electrons flow from the anode to the cathode, which enables the redox reactions to continue to occur at each electrode. This electron flow is electrical energy which has been converted from the chemical energy stored in the redox substances.

The voltage generated from a galvanic cell is determined by the chemical potential difference between the redox reactions at the anode and cathode. The standard reduction potentials of typical redox reactions at the anode and cathode are listed in Figure 13b. In practice, the cell voltage is governed by the extended version of the Nernst equation, in which the cell voltage is a function of not only the concentration of the active substances and the temperature, but also the current, overpotential, and inner resistance of the cell. The magnitude of the current flow from the cathode to the anode depends on the number of chemical substances oxidized or reduced at the surface of electrodes. Overpotential is the potential difference between the thermodynamically determined reduction potential and the experimentally observed potential of a half-reaction.^[346] In other words, it is additional energy required for the reaction to occur. There are three common forms of overpotential: activation overpotential, which is activation energy required to transfer an electron from an electrode to an analyte; concentration overpotential, which is caused by the depletion of charge carriers at the electrode surface; and resistance overpotential, which is affected by the conductivity of the electrolyte and geometry of the cell. Thus, to maximize power output, a

galvanic cell should be designed with the following characteristics: a large potential difference between the reduction potential of the anode and cathode, a high concentration of chemical substances, a large surface area, a short distance between the electrodes, and highly conductive electrolytes.

When the electrodes of a galvanic cell are in contact with physiological fluid, chemicals in the fluid can be leveraged as either redox substances and/or electrolytes. The chemical substances in human physiological fluid are sometimes called biogalvanic energy sources and an electrochemical cell that uses human physiological fluid is called a biogalvanic cell. Hydrogen ions and oxygen in gastric juice or interstitial fluid can be utilized as reducing substances for the cathode of a biogalvanic cell. Biocompatible and benign metals, such as Mg, Zn, Fe, W, Mo, and AZ31B Mg alloy, are the most common materials for the anode; inert metals, such as Au, Pt, Pd, and Cu, are commonly used for the cathode.^[347] The oxidized form of a metal such as CuCl can also be used for the cathode.^[35] In a biogalvanic cell, the salt bridge or membrane is often omitted for a simpler and more compact design. A biogalvanic cell can continuously harvest a large amount of power once it contacts the redox fuel but several limiting factors can potentially deteriorate its performance. The power output of a biogalvanic cell is highly dependent on the fluid composition, which often varies with external conditions such as food intake and circadian rhythm.^[78] The diffusion rate of the reducing substances can be decreased due to protein absorption, biofouling, or anodic-corrosion deposits on the cathode.^[348] To mitigate this effect, one can introduce semipermeable coatings to the electrodes, which restrict diffusion of external contaminants without preventing diffusion of redox substances to the electrodes. The lifetime of a biogalvanic cell is determined by both the anode oxidation rate and the anodic corrosion rate: the anode oxidizes and dissolves into the physiological fluid as a cell generates energy. Consequently, a commercial product that utilizes a biogalvanic cell as its power source is limited to short-term use: for instance, ingestible event markers.^[35] The cell life can be prolonged by increasing the amount of anode metal and limiting the anodic corrosion products.




Figure 14. The working principle of biofuel cells. a) Abiotic biofuel cell, b) enzymatic biofuel cell, and c) microbial fuel cell. The ion exchange membranes are often omitted for implantable and ingestible biofuel cells to simplify the cell structure.

Biofuel Cells: One promising endogenous energy source that can be used to power electronics are biological molecules, in the form of carbohydrates and fats, which the human body naturally utilizes to store and transport energy. Converting this chemical energy into electricity for powering biomedical devices can be accomplished via oxidation/reduction reactions involving the biomolecules. Biofuel cells operate based on this principle: the target load is connected to an anode and a cathode and the biomolecular fuel source is oxidized at the anode, which drives electron transfer; oxygen reduction occurs at the cathode.^[349–352] Glucose is a common fuel for these biofuel cells, since it is relatively abundant and continuously replenished in the body. The oxidation/reduction reaction of glucose and oxygen provides a theoretical cell voltage of 1.24 V for complete oxidation and 1.18 V for oxidation to gluconic acid. However, the observed voltage is significantly lower in physiological conditions (0.1–0.7 V) and must be increased via the use of a boost converter or by connecting multiple cells in series to be able to provide voltages sufficiently high to power conventional electronic systems.^[71,353–355]

Biofuel cells can be classified into three separate types, depending on the mechanism which enables oxidation/reduction: 1) abiotic fuel cells, which use inorganic mediating species (Figure 14a); 2) enzymatic biofuel cells (EBFC), which use biological enzymes such as glucose oxidase or lactase to catalyze the breakdown of the biological fuel and enable electron transfer (Figure 14b); and 3) microbial fuel cells (MFCs) which utilize electrochemically active microorganisms, which donate electrons from their surface after consuming biofuel (Figure 14c). Abiotic fuel cells have been demonstrated in implantable devices in dogs and used extracorporeally in sheep; however, low current densities and undesirable side reactions on the electrode surfaces resulted in overpotential issues which limited voltage output.^[356] More recently, enzymatic fuel cells have been miniaturized and were demonstrated in vivo with a variety of different materials and enzymes (Table 10) where the enzyme was immobilized physically or mechanically on the electrode. Enzymatic fuels have been demonstrated for both short-term and long-term implantation in invertebrate organisms including snails, lobsters, clams, and insects, as well as in mammals such as rats and rabbits (Table 10).^[76,353,354,357–362] Microbial fuel cells have been proposed for implants but are currently too large for in vivo applications and require that the microorganisms from the surrounding environment be maintained and segregated.

Another notable limitation of biofuel cells is their reliance on local concentrations of oxygen at the anode: current density may be limited by oxygen diffusion and local oxygen depletion could further exacerbate any fibrosis caused by the implant and may induce hypoxia in the tissue surrounding the implant.^[363]

3.2.2. Endogenous Chemical Energy Sources and Corresponding Energy Harvesting Methods

As shown in Figure 4, chemical energy sources such as glucose and electrolytes are distributed throughout the human body. Once glucose is absorbed from food in the digestive system, it is transported throughout the body by the circulatory system. Physiological fluids also contain various dissolved ions, which are essential nutrients for the body to function.

Blood Glucose in the Circulatory System: About 4 g of glucose circulates in the bloodstream in a 70 kg human adult; blood glucose concentration ranges from 4.5×10^{-3} to 10×10^{-3} M, depending on the prandial state.^[231] Glucose also exists in the form of glycogen in the liver (100 g) and in the muscle (400 g).^[364] If 1% of this available energy (5.04 g of glucose, 20 kCal of energy) is used in a biofuel cell, which operates at an efficiency of 1%, the biofuel cell would be able to provide 7750 mAh of capacity at 3 V. This compares favorably with coin cell batteries, which have capacities of 10–500 mAh at 1.5–3.7 V, since blood glucose can also be replenished from ingestible foods.

Biofuel cells have been implanted into animals, such as lobsters, clams, and snails, where they successfully harvested energy from the hemolymph, a fluid equivalent to blood for invertebrates.^[353,357,358] Furthermore, several studies have demonstrated the use of biofuel cells for harvesting energy from mammalian blood under in vitro conditions as well as ex vivo via an extracorporeal arteriovenous shunt in sheep.^[365] One study demonstrated that I_{oc} and peak power levels in biofuel cells implanted in the thoracic vein were noticeably higher than biofuel cells implanted in other locations (Figure 15b, Table 10).^[366] This is possibly because the circulatory system contains a higher glucose concentration and blood flow and oxygenation mitigates local oxygen depletion.^[366] However, the scarcity of implants that harvest energy from the bloodstream may be due to the potential for such devices to induce scarring, cause damage, or obstruct the blood flow. These issues are




Figure 15. Examples of devices (biofuel cells) that harvest chemical energy from glucose in a) cerebrospinal fluid (CSF), b) blood, c) interstitial fluid (IF), and d) e) gastrointestinal fluid (GIF). a) Adapted with permission.^[371] Copyright 2013, Springer Nature. b) Adapted with permission.^[366] Copyright 2013, Royal Society of Chemistry. c) Adapted with permission.^[362] Copyright 2018, Elsevier. d) Adapted with permission.^[387] Copyright 2018, Royal Society of Chemistry. e) Reproduced with permission.^[388] Copyright 2013, Elsevier.

not insurmountable: recently, flexible electronics used for the placement of “smart” catheters and stents have been developed which can operation *in vivo* over the long-term without inducing obstruction or damage.^[367,368] These advances demonstrate that harvesting energy from the circulatory system to power self-contained implantable electronics is feasible.

Glucose in Cerebrospinal Fluid of the Brain: Electrical sensors and stimulators integrated within the brain can be used to study the biological basis for perception, memory, learning, and other higher-order brain functions.^[369] From the clinical perspective, implanting neural stimulators for deep brain stimulation is an effective treatment for tremors resulting from Parkinson’s disease or other mobility and affective disorders. Also, brain-machine interfaces have the potential to be used to control prosthetic limbs. Given the relative ease with which the brain can be physically accessed, these devices have traditionally been powered by a transcranial physical tether with replaceable batteries; more recently, wireless power transfer (WPT) strategies have been used. Harvesting endogenous energy from glucose in the brain could provide an alternative strategy to power these devices: according to measurements made using ¹³C magnetic resonance spectroscopy, the plasma glucose level in healthy human brains is between 4×10^{-3} and 25×10^{-3} M and it is well

known that $\approx 20\%$ of the body’s glucose-derived energy is used in the brain.^[232–234]

Researchers have demonstrated the *in vitro* viability of using an abiotic biofuel cell to harvest energy from artificial cerebrospinal fluid.^[370] A separate research group demonstrated the acute implantation of an enzymatic glucose biofuel cell into the brain of a rat, which achieved a power density of $2 \mu\text{W cm}^{-2}$ (Figure 15a).^[371] Interestingly, the authors of this study noted that when a barbiturate was administered to the animal, the open-circuit voltage (V_{oc}) dropped by 50%; they hypothesized that this drop was the result of the cession of blood flow, which consequently depleted oxygen around the implanted tissue. Currently, the low power density achieved, the risks associated with hypoxia of brain tissue, and the comparative ease of access for wireless power transfer makes biofuel cell technologies for brain implants undesirable for clinical applications.

Glucose in Interstitial Fluid in the Subcutaneous Space: The abdominal cavity, and in particular the peritoneal space, is commonly used for biomedical implants; implanting devices in this space is associated with lower surgical risks and high mechanical stability. Implantable insulin pumps are commonly placed in the peritoneal space so that it causes minimal interference with patients’ daily life.^[372,373]




Figure 16. Intraluminal physicochemical composition of GI tract.

The retroperitoneal space has been a popular target for implanting glucose fuel cells, most likely because it is easy to access for surgical implantation, particularly in rodent models. The retroperitoneal space contains peritoneal fluid, which has about the same concentration of glucose as the bloodstream in healthy dogs, cats, and horses; this suggests that harvesting energy from the retroperitoneal space could be a viable strategy for powering electronic devices.^[374] However, fuel cells implanted in the retroperitoneal space have not been able to generate nearly the same power as fuel cells powered by the blood: in one study, a retroperitoneal space fuel cell generated an order of magnitude less power than blood-powered fuel cells (Table 10).^[361,366] A possible explanation of this disparity is that power generation is limited by local concentrations of oxygen, which are replenished more slowly in the retroperitoneal space than in the bloodstream. Nevertheless, for electronics with lower power requirements, biofuel harvesting from the retroperitoneal space/abdominal cavity may still be viable, as devices implanted in this region have shown long-term stability of 10 days to 2 weeks in rats, and up to 2 months in rabbits.^[76,354,361]

The interstitial fluids in the subcutaneous space of living organisms can also be the source of electrolytes and energy for biogalvanic cells. Oxygen and hydrogen ions act as reduction substrates at the cathode. There are several *in vivo* studies on implantable biogalvanic cells from the 1960s, which aimed to power implantable cardiac pacemakers (Figure 17c).^[348,375–378] Zn, Mg, Al were used as anode materials and platinum (Pt) black cathode material. Recently, most of the studies on implantable galvanic cells have been focused on fabrication techniques to make the galvanic cells thin and flexible or on creating biodegradable electrode or electrolyte materials.^[194,197,379–381] However, galvanic cells that harness energy from interstitial fluid produce less power compared to those that harness energy from gastric fluid. This can be potentially explained by the higher pH, or lower concentration of hydrogen ions, of the interstitial fluid. Additionally, beyond interstitial fluid adjacent sweat glands in the dermis and specifically sweat has been shown recently to serve as a potential biofuel for wearable electronics. Though given the location of sweat glands, this may also serve as a bio-

fuel source for implants.^[382–386] Examples of implantable biogalvanic cells and their features are summarized in Table 10.

pH and Nutrients in GIF of the Digestive System: The GI tract contains a complex mixture of substances, which include electrolytes, nutrients, microbes, hormones, and enzymes. Among these substances, hydrogen ions and nutrients are the most promising chemical energy sources. When paired with a redox reaction, they can act as electron donors or acceptors and convert chemical energy to electrical energy in an electrochemical cell.

An abundant amount of electrolytes is secreted into the lumen of the GI tract by different glands, making it a valuable organ system for energy harvesting. Hydrogen ions have distinctive functions in the stomach: they activate pepsin and destroy potentially harmful pathogens or bacteria. Hydrogen ions can also act as electron acceptors in an electrochemical cell to generate electrical energy. The power output will increase as the concentration of hydrogen ions increases and the GI pH decreases. GI pH varies depending on the location in the GI tract, the prandial state, and diet. The approximate mean pH values for each prandial state in each location are shown in **Figure 16** and **Table 9**. The pH at the entrance of the GI tract, in the mouth, and in the esophagus are close to neutral for both fasted and fed states. The stomach has the lowest pH in the entire GI tract because hydrochloric acid is secreted into the stomach by parietal cells in the gastric glands. Abundant hydrogen ions make the stomach an ideal place for a galvanic cell to harvest energy. Gastric pH is maintained around 1.4 to 2.1 in the fasted state but it can increase to between 3 and 7 in the fed state. The upper and lower parts of the stomach can have different acidity levels, which can be due to swallowed saliva or sporadic duodenogastric reflux.^[403] After the stomach, gastric chyme enters the duodenum and the pH starts to increase due to the bicarbonate in bile acid. The pH gradually increases throughout the small intestine and the pH becomes slightly alkaline in the distal ileum. The pH at the upper small intestine is more acidic in the fed state than in the fasted state due to gastric acid, which is transported from the stomach. After the small intestine, the pH drops again in

Table 9. Intraluminal physicochemical composition of GI tract. ^{a)} LOD: Limit of Detection.

Location	pH		Dietary nutrients				O ₂		Gut microbial load [mL]		Electrolyte				Transit time				
	Fasted	Fed	Carbohydrate [mg mL ⁻¹]		Protein [mg mL ⁻¹]		Lipid (triglyceride) [mm]		PO ₂ [mmHg]	Gut microbial load [mL]	Osmolality [mOsm kg ⁻¹]		Buffer capacity [mmol L ⁻¹ pH]			Na ⁺ [mm]	K ⁺ [mm]	Cl ⁻ [mm]	HCO ₃ ⁻ [mm]
			Fasted	Fed	Fasted	Fed	Fasted	Fed			Fasted	Fed							
Esophagus	7 ^[389]	7 ^[389]	-	-	-	-	-	-	150 ^[390]	-	-	-	-	-	40 ^[391]	20 ^[391]	40 ^[391]	0 ^[391]	Few minutes
Stomach	1.4–2.1 ^[235]	3.0–7.0 ^[235]	49.1–152.1 ^[392]	11.2–23.3 ^[392]	42.7–157.1 ^[393]	77 ^[394]	-	-	10 ^{2–3} ^[395]	83–278 ^[392,396,397]	32–600 ^[398]	4.8–23.8 ^[392,397]	14–28 ^[392]	10 ^[399]	10 ^[399]	90 ^[399]	0 ^[399]	Few minutes–3 hrs ^[400]	
	6.2 ^[235]	5.2 ^[235]	62.7–74.3 ^[393]	1.1–2.8 ^[393]	1.16–4.7 ^[393]	32 ^[394]	0.6–63.3 ^[393]	32 ^[394]	10 ⁵ ^[395]	115–206 ^[398]	215–423 ^[398]	5.7–11.5 ^[398]	20–30 ^[398]	120 ^[399]	15 ^[399]	120 ^[399]	30 ^[399]	3–6 hrs ^[400]	
Small intestine	6.9 ^[235]	6.1 ^[235]	62.7–74.3 ^[393]	1.1–2.8 ^[393]	1.16–4.7 ^[393]	30–45 ^[394]	0.6–63.3 ^[393]	30–45 ^[394]	10 ⁵ ^[395]	115–206 ^[398]	215–423 ^[398]	5.7–11.5 ^[398]	20–30 ^[398]	120 ^[399]	15 ^[399]	120 ^[399]	30 ^[399]	3–6 hrs ^[400]	
	8.1 ^[398]	8.1 ^[398]	0.56–2.54 ^[392]	1.8–8.4 ^[392]	<LOD ^{[392,401]a)}	33 ^[394]	<LOD ^{[392,401]a)}	<LOD ^{[392,401]a)}	10 ^{3–7} ^[395]	60 ^[398]	252 ^[398]	5–10 ^[398]	10–20 ^[398]	120 ^[399]	15 ^[399]	120 ^[399]	30 ^[399]	3–6 hrs ^[400]	
Large intestine	7.8 ^[398]	6 ^[398]	0.5–16.7 ^[392,401]	5.1–14.3 ^[392,401]	<LOD ^[392,401]	11 ^[394]	<LOD ^[392,401]	11 ^[394]	10 ^{9–12} ^[395]	100 ^[398]	200 ^[398]	10–20 ^[398]	20–35 ^[398]	120 ^[399]	15 ^[399]	90 ^[399]	50 ^[399]	10–40 hrs ^[400]	
	6.3–7.7 ^[402]	6.3–7.7 ^[402]	-	-	-	3 ^[394]	-	3 ^[394]	10 ^{9–12} ^[395]	-	-	-	-	-	-	-	-	-	

the caecum, which is caused by short-chain fatty acids produced by bacterial fermentation.^[403] In the distal ileum and proximal colon, the pH in the fed state is lower than the fasted state due to an increase in bacterial fermentation activity after meal consumption.^[398] GI pH values also vary from person to person: usually, a wide range of values are observed.

The GI tract is responsible for the digestion and absorption of food. Carbohydrates, proteins, and fats are broken down into simpler forms, such as monosaccharides, amino acids, and fatty acids, by enzymes and gut microorganisms in different locations. Most nutrients are absorbed in the small intestine and used as energy sources to power the human body. But the remaining intraluminal nutrients make the human gut a substantially reductive environment for enzymes and fermentative microbes. Any biodegradable organic material, either complex or simple, such as carbohydrates, amino acids, and alcohols can be oxidized by enzymes or fermentative microbes and used as energy sources for electrochemical cells. The intraluminal concentration of specific nutrients is determined by the digestion and absorption rates of the nutrients in each organ. The median values of carbohydrate, protein, and lipid concentrations in each GI organ for both prandial states are shown in Figure 18 and Table 10. The amount of nutrients in the intraluminal space tends to stay near the baseline concentration in the fasted state, but it is highly dependent on the specific meal composition in the fed state, especially in the stomach and upper small intestine. In one study, the carbohydrate and protein content in the stomach was measured to be 49.1–152.1 and 11.2–23.3 mg mL⁻¹ when a liquid meal with a carbohydrate and protein content of 202 and 62 mg mL⁻¹, respectively, was administered.^[392] The concentration of carbohydrates, proteins, and lipids gradually decreases as they are digested into their final metabolites and absorbed by the small intestine. When the food chyme reaches the colon, the concentration of proteins and lipids is very low, since the digestion and absorption of proteins and lipids is mostly completed in the small intestine. However, undigested polysaccharides and starch can reach the colon: according to one study, ≈30% of the carbohydrates that reach the upper small intestine end up reaching the colon.^[393]

In addition to hydrogen ions and nutrients, physicochemical factors also affect the performance of electrochemical cells (Figure 16 and Table 9). Oxygen acts as an electron acceptor in the cathode of biofuel cell. Thus, its concentration is directly related to the power output of the electrochemical cell and is often a limiting factor. The partial pressure of oxygen decreases along the GI tract; the colon environment exhibits near anaerobic conditions. Nitrate or sulfate can also serve as electron acceptors for microbial fuel cells, but their concentration is usually below 10 × 10⁻³ M. Total osmolality of electrolytes also affects performance, since electrochemical cells utilizes the intraluminal fluid as its electrolyte. Lower osmolality will increase the internal resistance of electrochemical cells and, as a result, the power output will decrease. Osmolality in the fed stomach and upper intestine is highly dependent on diet: it can vary from 200 to 600 mOsm kg⁻¹. Total osmolality decreases slightly as one descends in the GI tract in both prandial states (100–200 mOsm kg⁻¹ in the fasted state and 200 mOsm kg⁻¹ in the fed state). The buffer capacity of a fluid is the amount of

Table 10. Summary of chemical energy harvester: in vivo examples.

Year	Organism	Location	Fuel	Anode material	Anode modification	Cathode material	Cathode modification	Power	Power density	Output current [I_{sc}]	Output voltage (V_{oc}) [V]	Test period	References
Biofuel cells													
1970	Dog	Subcutaneous space	Glucose	Porous noble metal alloy black	–	Pt	–	–	2–4 $\mu\text{W cm}^{-2}$	19 $\mu\text{A cm}^{-2}$	0.58	30 days	[356]
1976	Dog	Abdominal cavity	Glucose	Pt black	–	Activated carbon	–	–	4 $\mu\text{W cm}^{-2}$	0.003 $\mu\text{A cm}^{-2}$	0.8–0.3	200 days	[417]
2010	Rat	Retropertitoneal space	Glucose	Graphite	Ubiquinone, glucose oxidase, catalase	Graphite	Quinone, hydroquinone, polyphenol oxidase	–	7.52–24.4 $\mu\text{W cm}^{-3}$	–	0.27–0.22	Several hours	[76]
2010	Rat	Retropertitoneal space	Glucose / Urea	Carbon Felt	Glucose Oxidase, catalase	Carbon Felt	Urease	2.65 μW	–	–	0.265	–	[76]
2012	Clam	Hemocoel/hemolymph	Glucose	Compressed MWCNT	PQQ-dependent glucose dehydrogenase	Compressed MWCNT	Laccase	6.2–37 μW	–	0.120–400 mA cm^{-2}	0.8–0.36	–	[358]
2012	Snail	Hemocoel/hemolymph	Glucose	Compressed MWCNT	PQQ-dependent glucose dehydrogenase	Compressed MWCNT	Laccase	7.45 μW	–	170 $\mu\text{A cm}^{-2}$	0.530	–	[357]
2012	Cockroach	Hemolymph	Trehalose	Carbon fiber	Trehalase glucose oxidase trehalose	Carbon fiber	Bilirubin oxidase dioxygen	–	55 $\mu\text{W cm}^{-2}$	460 $\mu\text{A cm}^{-2}$	<0.2 (Not stated)	–	[359]
2013	Rat	Retropertitoneal space	Glucose	CNT	Glucose oxidase	CNT	Laccase	–	161 $\mu\text{W cm}^{-3}$	400 μA , 530 $\mu\text{A cm}^{-2}$	0.55	–	[354]
2013	Lobster	Retropertitoneal space	Glucose	Carbon fiber	PQQ-dependent glucose dehydrogenase	–	Laccase	160 μW	–	4 mA cm^{-2}	0.54	–	[353]
2013	Rat	Thoracic vein	Glucose	Carbon fiber	Glucose oxidase, neutral red	Carbon fiber	Pt nanoparticles, poly-amidoamine dendrimer	–	95 $\mu\text{W cm}^{-2}$	5 mA cm^{-2}	0.125	–	[366]
2013	Rat	Brain	Glucose	Au/Au nanoparticle	Corynascus thermophilus cellobiose dehydrogenase (CtCDH)	Au/Au nanoparticle	Myrothecium verucaria bilirubin oxidase (MvBOx)	–	2 $\mu\text{W cm}^{-2}$	–	0.55	–	[371]
2014	Rat	Retropertitoneal space	Glucose	MWCNT	Glucose oxidase, catalase, 1,4 naphthoquinone	MWCNT	Laccase, chitosan	–	6.2–20.7 $\mu\text{W cm}^{-2}$, 207 $\mu\text{W cm}^{-3}$	–	0.32	–	[361]
2018	Rabbit	Abdominal cavity	Glucose	MWCNT	Glucose oxidase, catalase, naphthoquinone	MWCNT	Laccase, chitosan-geni-pin	–	2–16 $\mu\text{W cm}^{-3}$	–	0.42–0.18	60 days	[362]
Galvanic cells													
1968	Rabbit	subcutaneous space (dorso-lateral thorax and lumbar) regions and intraperitoneal sites	$\text{H}_2\text{O}/\text{H}^+$	Al	–	Platinum black	–	40–60 μW	2–3 $\mu\text{W cm}^{-2}$	–	0.6–0.7 (Peak V)	18–200 days	[376]
1971	Rabbit/dog	Subcutaneous space	$\text{H}_2\text{O}/\text{H}^+$	Mg	–	Platinum black	–	46.5–91 μW	1.4–2.8 $\mu\text{W cm}^{-2}$	1.19–1.85 $\mu\text{A cm}^{-2}$	0.98–1.65 (Peak V)	60 days	[377]
1971	Rat	subcutaneous space (ventral flank area)	$\text{H}_2\text{O}/\text{H}^+$	Al	–	Platinum black	–	74–120 μW	3.0–4.8 $\mu\text{W cm}^{-2}$	–	1.5	Over 12 months	[378]
1976	Dog	Abdominal cavity	$\text{H}_2\text{O}/\text{H}^+$	Al	–	Activated carbon	–	80 μW	–	74 μA , 3 $\mu\text{A cm}^{-2}$	0.2–0.8	2 years	[417]
2015	Human	Stomach	H^+	Mg	–	CuCl	–	–	–	0.1 mA	1.85	1–10 min	[35]
2017	Pig	Stomach	H^+	Zn	–	Cu	–	–	23 $\mu\text{W cm}^{-2}$	–	0.1–0.2 (Peak V)	6.1 days	[78]

an acid or base that is needed to change the pH of a solution by 1. When the buffer capacity of the intraluminal contents is higher, the electrochemical cell will have a lower effect on the physicochemical characteristics of the GI tract. The baseline buffer capacity of the GI tract lies in the range of tens of mmol L⁻¹ ΔpH⁻¹ but in the fed state, it is usually two times higher.

Considering the abundant chemical energy that exists in the GI tract, the most promising energy harvesting methods are galvanic cells and biofuel cells. There are several studies that have utilized galvanic cells to harvest energy in the stomach, where hydrogen ions are most abundant. The idea of utilizing gastric juice as both a chemical energy source and an electrolyte for the galvanic cell was first proposed in 2008.^[404] This proof-of-concept prototype used zinc as the anode, platinum as the cathode, and a porous ceramic filter to retain gastric juice. It achieved 2 mW cm⁻³ of maximum power density in an in vitro verification test with synthetic gastric fluid that had a pH of 1.2. Other proof-of-concept in vitro examples include a flexible Zn/Pd gastric battery that had a surface power density of 8.3 mW cm⁻².^[405] Mg/Au tablet-shaped cells that had an output voltage of 1.2 V successfully powered ingestible core-body thermometers and transmitted data via a magnetic-field coupling telecommunication system through pork meat blocks. In another study, edible, biodegradable, and flexible current sources utilized activated carbon/MnO₂ as the anode/cathode pair and gastric juice as the electrolyte.^[406] Potentials up to 0.6 V and currents in the range of 5–20 mA were generated in a 1 M Na₂SO₄ buffer. The first in vivo device that demonstrated the ability to harvest chemical energy from the GI tract was reported in 2015. This prototype used Mg/CuCl for the electrode pair and used gastric fluid as the electrolyte. Upon contact with gastric fluid, sufficient power was generated to allow an integrated circuit to transmit a signal for 2 s (Figure 17b).^[35] In 2017, an in vivo galvanic cell was

demonstrated to be able to operate for one week. This cell used Zn/Cu as the electrode pair and the device had an average (surface) power density of 23 μW cm⁻² for an average of 6.1 days. The galvanic cell was used to power a device that measured and transmitted the temperature in the porcine GI tract to an outside receiver (Figure 17a).^[78] Even though galvanic cells have been successful at harvesting energy from gastric juice, there are two major hurdles that need to be addressed to improve their performance: chemical interference and lifetime. Integrating semipermeable membranes such as Nafion coatings to galvanic cells would mitigate the effects of other chemicals such as mucus or albumin which can change ion diffusion characteristics at the electrode surface.^[405] Extending the lifetime of the metal anode is key for a prolonged operation of the galvanic cell. In contrast to the performance of galvanic cells in the stomach, a galvanic cell in the small intestine and colon can only generate nanowatts of power due to the neutral pH environment.^[78]

Even though the abundant chemical energy sources make GI tract an appropriate place for a biofuel cell to harvest energy, the application of biofuel cells to GI tract has not been sufficiently explored. Very few proof-of-concept studies have been able to harvest energy from nutrients in GI tract utilizing biofuel cells. To date, we have not found an example in the literature of an in vivo validation of enzymatic or microbial biofuel cells, but several in vitro proof-of-concept studies have shown that biofuel cells have the potential to be used to power implantable/ingestible devices in the GI tract. While the stomach is abundant in nutrients in the fed state,^[398] its acidic environment inhibits operation of most of the enzymes or microbes, so neither enzymatic nor microbial biofuel cells would be able to efficiently harvest energy in the stomach.^[407] Complex nutrients and their metabolites coexist in the small intestine in the fed state, since the small intestine is the place where final digestion occurs; therefore, the small intestine is an ideal environment




Figure 17. Examples of devices (galvanic cells) that harvest chemical energy from electrolytes in a,b) gastric fluid and c) interstitial fluid (IF). Adapted with permission.^[78] Copyright 2017, Springer Nature. Adapted with permission.^[35] Copyright 2015, IEEE. Reproduced with permission.^[378] Copyright 1969, Springer Nature.

for both enzymes and microbes. In contrast to the stomach, the neutral or slightly acidic environment of the small intestine also allows enzymes and microbes to oxidize substrates. One research group developed a fully edible EBFC, based on biocompatible food-driven materials, which targeted ethanol in the small intestine (Figure 15d).^[387] It had a (surface) power density of $282 \mu\text{W cm}^{-2}$ with V_{oc} of 0.24 V when placed in a pH of 7.4 PBS that contained $500 \times 10^{-3} \text{ M}$ of ethanol. However, for in vivo implementation of implantable or ingestible EBFCs, there are several challenges to be solved: the deficiency of electron acceptors needs to be reduced, enzymes need to be stabilized in the intestinal fluid, and enzymes need to be protected from gastric acid. Oxygen, the major electron acceptor for a biofuel cell, is scarce in the small intestine compared to the concentration of electron donors. Thus, the oxygen level could be a potential limiting factor for power output, even when the intestinal fluid flows to replenish oxygen. One solution is to increase the surface area of the cathode to mitigate the effect of oxygen deficiency. Enzyme stability in physiological fluids can be enhanced by immobilizing enzymes in carbon paste electrodes or by using semipermeable membranes. Utilizing enzymes and mediators that have optimum pH values that match the pH of the location in which they operate would be also improve the performance of EBFCs. Biofuel cells are generally not suitable for the stomach since enzymes can be unstable and denature in highly acidic environments, but some studies have shown that carbon paste electrodes can protect glucose oxidase from a harsh acidic environment and confine enzymes to a nonpolar environment to a certain degree: after 90 min of incubation in synthetic gastric fluid with a pH of 1.5, glucose oxidase activity declined only about 50%.^[408] Some studies have sought to deliver enzymatic biofuel cells to the small intestine; pH-responsive enteric coating is one method that has been used to protect enzymes during passage through the stomach and only allow exposure to fluid once it enters the intestines.^[408] Since the power output of the EBFCs is dependent on the fuel concentration, it can be used not only as a power supply for ingestible electronics but also as a self-powered sensor for monitoring intestinal health.

Compared to enzymes, which have specificity to certain molecules, microbes can oxidize a broader range of substrates. Gut microorganisms catabolize carbohydrates, amino acids, and some lipids, and produce a variety of metabolites: short-chain fatty acids and alcohols are produced from monosaccharides; ammonia, branched-chain fatty acids, amines, sulfur compounds, phenols, and indoles are produced from amino acids; and glycerol and choline derivatives are produced from lipids.^[409] Some gut microbes, called exoelectrogenic microorganisms, exhibit extracellular electron transfer (EET), a phenomenon in which electrons generated by nutrient fermentation are transferred from inside their surface to the extracellular space. A recent study showed that a large portion of healthy human gut microbiota is exoelectrogenic.^[410] One of the most abundant gut microbes, *Faecalibacterium prausnitzii*, which comprises of 5% to 20% of the total gut microbiota, is capable of EET when it produces butyrate from a carbon-based source.^[411] Exoelectrogenic gut microbes could be used for microbial fuel cells since they exhibit excellent biocompatibility; using the microbes could also reduce the cost of manufacturing implantable medical devices.^[412] Implantable microbial fuel

cells that harvest energy from the human colon have also been tested in several in vitro studies. In 2010, a MFC consisting of immobilized gut microbes as the cathode and a Pt anode, was investigated for use in the transverse colon (Figure 15e).^[413] Utilizing nutrients and oxygen in simulated intestinal fluid (SIF) as energy sources, the MFC was able to generate power after two months of inoculation; it produced V_{oc} of 522 mV, a maximum (surface) power density of $73 \mu\text{W cm}^{-2}$, and an average voltage of 308 mV. Moreover, the changes in environmental conditions in the chambers of the MFC did not have a significant impact on the human body, as demonstrated by an analysis of pH and dissolved oxygen (DO) values. Another MFC implantable prototype was demonstrated in 2013, which exhibited a maximum (surface) power density of $1.173 \mu\text{W cm}^{-2}$ at a voltage of 155 mV for over 100 h of operation in simulated colonic content with fresh feces at a flow rate of 31.2 mL h^{-1} .^[388] Using human microorganisms such as white blood cells or mitochondria for microbial fuel cells has also been suggested as a possibility to power implantable devices.^[414–416] However, an in vivo validation needs to be demonstrated. To deliver an MFC through ingestible devices, immobilized microorganisms should be protected from the various environments during its passage through the GI tract to the colon. Despite the low partial pressure of oxygen inside the large intestine, studies have shown that it does not disturb the electricity-generating reactions of colonic microorganisms since most of them are anaerobes.^[413]

4. Energy Transfer to Power Biomedical Electronic Devices

4.1. Mechanical Energy Transfer Methods: Acoustic Power Transfer (APT)

APT, also called acoustic wireless powering or ultrasonic-based wireless power transmission, is another novel solution that can be used to power in-body electronics. Ultrasound, which is also called sound waves or acoustic waves, is pressure waves traveling through a medium. It has frequencies greater than 20 kHz, which is the frequency of the upper limit of human hearing.^[418] Ultrasound propagates through various media and transfers energy through mechanical vibrations. Acoustic wireless powering utilizes a mechanical vibration energy harvester to convert ultrasonic energy into electricity.^[419]

In an ultrasonic power transfer system, the transducer mechanically vibrates to generate pressure waves; the pressure waves propagate through the human tissue layer, hit the receiver, and force the receiver to vibrate (Figure 18a).^[421] Ultrasound has high directivity: ultrasonic energy tends to be concentrated in a single direction.^[422] To maximize transfer efficiency, ultrasonic transducers can be designed to focus ultrasound to a focal line or focal point and the power carried by the ultrasound can be concentrated to a small area of interest.^[423–425] Since ultrasonic imaging is so common, off-the-shelf ultrasonic sources are easy to access. The most common ultrasound frequencies used in medical diagnostics range from 3 to 10 MHz, but lower frequency bands are often selected in order to reduce attenuation.^[426–429] Inside the body, ultrasonic waves attenuate less than electromagnetic waves; however, attenuation is still a




Figure 18. a) Working mechanism of an APT. Ultrasound, which carries acoustic power, are emitted from an ultrasonic power transducer, propagate through tissue layers, and are received by an ultrasonic power receiver located inside the body. In an ultrasonic power transducer, a signal generator generates an AC electrical signal and the Amplifier/Impedance matching circuitry amplifies and filters the signal. This signal causes the piezoelectric element to vibrate, generating ultrasonic waves with desired frequencies and amplitudes. Ultrasound travels through acoustic matching layers, which provide smooth transition of the acoustic impedance from the acoustic source to the medium. Without the matching layers, ultrasound will experience a large change in acoustic impedances when it propagates from the piezoelectric element to the medium (human tissue layers); this will cause the ultrasound to attenuate or even reflect back to the interface between the acoustic source and the medium. Ultrasound attenuates as it propagates through the human tissue layers. The attenuation rate depends on the frequency of ultrasound. b) The normalized power of transferred acoustic waves is a function of the tissue depth and ultrasound frequency.^[420] When ultrasound reaches the receiver in the body, it vibrates the piezoelectric element and generate an AC electrical signal. The rectifier converts the AC signal to a DC signal and this harvested electrical energy can drive the electrical load to perform the desired task. Reproduced with permission.^[420] Copyright 2014, Elsevier.

significant factor that affects the power transfer efficiency. The approximate one-way attenuation rate for ultrasound inside the body is $0.5 \text{ dB cm}^{-1} \text{ MHz}^{-1}$; it indicates that low-frequency waves penetrate farther than high-frequency waves.^[430] For instance, 2 MHz waves can travel 30 mm in tissue before losing half of their power; 2 GHz waves lose half their power after traveling 3 mm. Figure 18b shows the normalized acoustic power of ultrasound with various frequencies as they propagate through the tissue. Standing waves, which occur when ultrasound reflects off the surfaces of a transmitter and receiver, can also affect the transfer efficiency of sound waves.^[431] One way to address this problem is to modify the input ultrasonic frequency when standing wave formation occurs as demon-

strated in the broadband piezoelectric ultrasonic energy harvester (PUEH).^[431] In the past, ultrasonic receivers were based on mechano-electrical energy converters which were usually too bulky and large to be implanted. But flexible and thin ultrasonic receivers have been developed for biomedical implants, which use piezoelectric, triboelectric, capacitive, or electrostatic materials, as discussed in other sections.^[419,431–436] The transducer and receiver are equipped with a matching layer and an impedance matching circuit to ensure that they vibrate at the same frequencies.

Acoustic wireless powering has several favorable characteristics, including high power transfer and deep penetration.^[437] Exposure to ultrasound must be limited since high-intensity

Table 11. Spatial-peak temporal-average intensity of diagnosis acoustic transfer for nonfetal Doppler application^[441].

Location/use	Intensity [mW cm ⁻²]
Peripheral vessel	720
Cardiac system	430
Fetal imaging and other	94
Ophthalmic sites	17

ultrasound can increase body temperature and induce cavitation.^[438] The FDA regulations for the acoustic exposure for imaging can also be used as a guideline for ultrasonic power transfer.^[237] The maximum exposure intensity varies depending on the part of the body, the duration of exposure, and how the temperature of the body responds to ultrasound. The FDA has established peak temporal average intensity limits for acoustic transfer for different parts of the body, which are listed in **Table 11**. FDA regulations allow the transmission up to 190 W cm⁻² of spatial peak pulse-averaged power density in order to deliver power to an implanted device, but more in-depth studies are necessary to determine the safety and thermal impact of acoustic transfer on the tissue. Nevertheless, using ultrasound to deliver power to implanted devices has been tested in vivo: a micro-oxygen generator was successfully powered via ultrasound in mice.^[439] In another study, devices implanted in pigs were able to be repeatedly recharged via ultrasound over the course of five weeks.^[440]

Ultrasound generated from exogenous ultrasound transmitters can reach most of the organs inside the human body using safe frequency and power levels, since ultrasonic energy attenuates far less than EM radiation in tissue.^[442] Furthermore, ultrasound does not introduce a large amount of unwanted power into tissue via scattering or absorption, which makes ultrasound transmission safer than EM transmission for a

given power.^[442] The power threshold for ultrasound in the human body is 72 times greater than that for radio waves.^[441,443] For these reasons, ultrasound technologies have been used for diagnostic and therapeutic purposes for a long time.

The power transmission efficiency of ultrasound is highest for subcutaneous implants, but ultrasound can also deliver energy to deeper areas within the body, such as the brain or heart.^[442,444] The thickness of the tissue layers is the major factor that affects transfer efficiency. There have been a few in vivo studies that demonstrated the use of ultrasonic power transmission to charge implanted devices.^[440,442,444,445] In one, ultrasonic power was transferred to the subcutaneous tissue in swine in order to repeatedly charge a lithium battery (**Figure 19c**).^[440] The authors demonstrated that 1 MHz of externally supplied ultrasound was able to deliver about 300 mW of power to a battery implanted 10–15 mm under the tissue; they were able to charge a 50% depleted, 4.1 V battery within 2 h with an average efficiency of 20%.

The thickness of ultrasonic receivers can be scaled down to hundreds of micrometers without sacrificing their transfer efficiency since the wavelength of ultrasound in the frequency range of 3–10 MHz in soft tissue is on the order of hundreds of micrometers. The minimum thickness that an ultrasonic receiver can be is ≈ 1 wavelength of the transmitted ultrasound; the thickness of the piezoelectric element is typically half of the wavelength and the optimal thickness of the matching layer is one-fourth of the wavelength.^[446] For example, the wavelength of ultrasound at 10 MHz is ≈ 150 μm in tissue while the wavelength of a radio wave at 1 GHz is 0.3 m; the size of implanted receiver for ultrasound can be much smaller than the one for radio waves.^[447] Thus, sub-millimeter scale implantable devices, such as neural probes, could potentially be charged using ultrasonic power transfer. In one study, an ultrasound backscattering system was developed for peripheral nerve neural recording in rats (**Figure 19a**).^[442] The device was powered by an external




Figure 19. Examples of devices that harvest mechanical energy from exogenous ultrasonic energy source. a) Adapted with permission.^[442] Copyright 2016, Elsevier. b) Adapted with permission.^[444] Copyright 2013, Oxford University Press. c) Reproduced with permission.^[440] Copyright 2016, Elsevier.




Figure 20. Electromagnetic spectrum.

ultrasonic transceiver which included modulated data in the ultrasonic waves. It used low-power ultrasound at 120 μW and had a transfer efficiency of 25%. A simulation conducted in the same study indicated that a 100 μm receiver embedded at a 2 mm depth into the brain would receive around 500 μW of ultrasonic power with a 7% efficiency, which would be sufficient for high power applications such as neurostimulation.^[447]

The idea of acoustic power transfer was first proposed in 1958, but its applicability was often overlooked because of the superior efficiency of radiofrequency transfer at short distances with large apertures.^[447,448] However, ultrasonic power transfer has many advantages over electromagnetic power transfer in tissue and is gaining favor for powering subcutaneous or deep medical implants such as retinal electrical stimulation devices, cardiac pacing stimulation devices, and ingestible electronics.^[427,428,444,449]

4.2. Electromagnetic Energy Transfer Methods

Electromagnetic waves, or electromagnetic radiation, refer to the waves of oscillating electric and magnetic fields, which mutually induce each other. Electromagnetic waves propagate through space carrying electromagnetic radiant energy, which is the principle used for wireless powering via electromagnetic waves; the behavior of an electromagnetic wave is highly dependent on its wavelength. In general, an electromagnetic wave with a wavelength of 400 to 700 nm is classified as visible light, 0.7 to 10 μm is NIR light, and 1 mm to 100 km is RF radiation.^[450] The electromagnetic spectrum in **Figure 20** lists the different frequency ranges for each category. The transmission mechanism and the interaction between the human body and electromagnetic radiation vary significantly depending on the type of electromagnetic radiation. Generally, radiofrequency radiation has the greatest penetration depth compared to visible and near-infrared light. To receive and harvest energy from radiofrequency waves, both antennas and radio frequency wave harvesters are needed; to harvest visible and near-infrared radiation, photovoltaic materials are used.

4.2.1. WPT

WPT, RF power transfer, or electromagnetic power transfer, is the transmission of electrical energy from a transmitter to a receiver that are not physically wired. The energy is carried in the form of an electromagnetic field. One common type of electromagnetic radiation used for wireless power transfer is radiofrequency radiation.^[451] Using RF waves to wirelessly

power a device was first proposed and tested by Tesla in the 1890s.^[451] In Tesla's experimental setup, which is now referred to as a Tesla coil, a transmitter coil was connected to a capacitor-inductor oscillating loop and a receiving coil was connected to the load. The power transfer principle of his setup was very similar to an electrical inductor: the time-varying magnetic field from the transmitter coil induced the curl of the electrical field in the receiving coil. Tesla successfully powered incandescent bulbs connected to the receiving coil over a short distance. Although the Tesla coil does not have much practical use anymore, it was the precursor for today's wireless powering.

Depending on the distance from the electromagnetic source, electromagnetic fields can be classified into near-field and far-field regions.^[452] In the near-field region, which is defined as the area within a wavelength from the source, there is interference between the source and the electromagnetic field. The energy does not propagate but bounce back and forth between the source and the field in reactive near-field region. In the furthest part of the near-field region, which is called radiative near-field region (or Fresnel region), the energy starts to radiate but the electric and magnetic fields are still out of phase due to the interference. The behavior of the electromagnetic fields in the near-field region is complicated due to wave interference. However, near-field amplitudes decay in proportion to the inverse square to cube of the distance ($1/r^2 - 1/r^3$), so near-field components are confined to the area very close to the source. In the far field, which is the region that is more than one wavelength from the source, electromagnetic radiation can be modeled as originating from a point source and propagating through space. In the far field, amplitudes decay in proportion to the inverse of the distance ($1/r$). The intermediate region between the near-field and far-field region is called transition region. The near-field and far-field regions are shown in **Figure 21a**.

WPT can be categorized as using near-, mid-, and far-field techniques by comparing the distance between the energy emitter and the energy receiver with the wavelength of electromagnetic waves (**Figure 21b**).^[454] If the distance between the emitter and receiver is less than the wavelength being emitted, then near-field techniques should be used, which transfer power through the coupling of magnetic or electric field. Since these near-field behavior decays rapidly as distance increases from the source, the receiver for the near-field regime should be located as close as possible to the source to ensure a high coupling ratio and transfer efficiency. Thus, its application is limited to the location near the skin such as subcutaneous implants. Near-field powering techniques usually employ relatively low frequencies—Hz to MHz—in order to ensure reasonable transfer ranges, which, in air, are often a few centimeters. If the distance is much greater than one wavelength, the




Figure 21. The working principle of WPT. a) Electromagnetic waves can be classified into near-field and far-field regions depending on the distance from the electromagnetic source. The area within $\lambda/2\pi$ is called the reactive near-field region, $\lambda/2\pi \sim \lambda$ is the radiative near-field region, $\lambda \sim 2\lambda$ is the transition region, and over 2λ is the far-field region. b) The schematics of different WPT techniques: near-, mid-, and far-field WPT. Inductive coupling near-field WPT employs coils as antennas for a power transmitter and a receiver, and the power transfer happens through magnetic field coupling. Capacitive coupling near-field WPT employs a pair of electrodes as antennas, and the electric field coupled between the electrodes transfer the energy from one to the other. Mid- and far-field WPT uses antennas (e.g., monopole, dipole, loop antennas) that can emit and receive radiative electromagnetic field. c) The penetration depths of electromagnetic or RF waves with different frequencies are shown.^[453] The level of attenuation of RF waves varies slightly depending on tissue types. Adapted with permission.^[453] Copyright 2016, Society for reproduction and fertility.

near-field behavior decays out and the far-field behavior dominates, so that the operation is governed by far-field behavior. Since far-field behavior decays more slowly than near-field behavior, using far-field techniques enables more flexibility in the operation range in air. Since the radiation energy of an electromagnetic wave is proportional to the square of its frequency, far-field techniques generally use a high frequency—MHz to GHz or THz. For systems that use far-field techniques, emitters can be designed to have high directivity, so placing the receiver in the right location is important to maximize energy transfer. Mid-field techniques, used for systems in which the emitter and receiver are separated by ≈ 1 wavelength, is an emerging field in wireless powering of medical devices. Devices that rely on mid-field techniques require less power than far-field techniques but can be larger than near-field devices.^[455]

To power implantable devices via electromagnetic waves, one should consider penetration depth, safety, and directivity when choosing the frequency of the EM source. One obstacle to WPT is attenuation of the electromagnetic waves in tissue. Penetration depth, the depth where the field strength reduces to $1/e$ of its original value, where e is Euler's number (≈ 2.71828), is the most common measurement used to evaluate the field attenuation in materials. For high-frequency waves of 40–90 GHz, the penetration depth is only 1–3 mm in fat and 0.2–0.4 mm in muscle.^[456] In contrast, the penetration depth can be as large as ≈ 30 mm for lower frequency RF waves such as 434 MHz, which is a common frequency for wireless RF transmitters.^[457] This is one of the reasons why high-frequency RF waves are rarely used to wirelessly power implantable devices. Thus, far-field WPT, which generally operates at GHz range, is not suitable to power most of the implantable or ingestible devices even though far-field WPT has long transfer range in air; one exception is ocular implants since the attenuation is less significant in the transparent vitreous body of the eyes. Mid-field WPT has a shorter transfer range than far-field WPT in air, but the attenuation in tissue is less significant; mid-field WPTs are used to power the devices located deep inside the body such as in the brain, heart, or GI tract. Figure 21c shows the penetration depth of RF waves with different frequencies in various tissues. However, since low-frequency RF waves have longer wavelengths, the size of the receiving antenna needs to be larger in order to allow the waves to oscillate, which is essential for optimal performance.^[458] There is a reasonable trade-off between the attenuation effect and the size of the in-body receiving antenna when using RF waves with frequencies around 1–10 GHz. For example, in one study, electronics inside the GI tract of swine were powered with RF waves at 1.2 GHz.^[459] The wavelength at this frequency is 0.25 m. The distance between the emitting antenna and the receiving antennas was the same order of magnitude as the wavelength. Thus, the system was able to operate using mid-field techniques.

When choosing the operating frequency for wireless transfer, one must also consider the maximum safe dose. In general, the specific absorption rate (SAR) should not be larger than 1.6 mW cm^{-3} under IEEE guidelines,^[460] which provides safety standards for RF exposure.^[236] With frequencies higher than 5 MHz, thermal effects on biological tissue is the biggest safety concern. The safety standard includes both dose limits and exposure limits. Dose limits set the maximum power density that can

be absorbed by the tissue; exposure limits set the maximum incident electromagnetic field strength and power density allowed by an RF source. In an unrestricted environment, within a frequency range of 100 kHz to 6 GHz, the dose limit for whole-body exposure is 0.08 W kg^{-1} ; for the head and torso, the dose limit is 2 W kg^{-1} ; and for the limbs and pinnae, the dose limit is 4 W kg^{-1} . For radiation with frequencies between 6 and 300 GHz, the dose limit for the surface of the body is 20 W m^{-2} in an unrestricted environment. The maximum safe exposure limits depend on multiple factors, including the frequency, body part, and exposure time, but cannot exceed a maximum of 10 mW cm^{-2} .^[236]

Another consideration in choosing the frequency of RF waves is the directivity of the transmitter. Some transmitters are better than others at emitting RF waves in a particular direction. Directivity depends on the geometry of the transmitter as well as the frequency of waves being emitted.^[458] Recent advances in electromagnetism modeling allow researchers to predict directivity via *in silico* models, which facilitates the development process.^[461–463] The final consideration of wireless powering is that the transmitter and receiver are working as a pair. The impedances of the transmitter and receiver need to match in order to maximize transfer efficiency.^[451] It has been reported that efficiency can be as high as 70% depending on wave attenuation in the tissue.^[464]

RF power transfer is becoming a popular choice to power implantable and ingestible devices. Many RF-powered devices have been tested *in vivo* inside the GI tract, skull, and eye.^[106,459,465,466] RF power transfer has a large powering capacity and a high efficiency. The amount of power that can be delivered through wireless power transfer can be hundreds of microwatts if the device is deeply implanted, or hundreds of milliwatts if superficially implanted.^[106,459] Still, one of the biggest challenges for using RF power transfer for implantable devices is miniaturizing the devices. There is a physical limit to the transmitter design: the device must be large enough (on the order of a wavelength of the RF wave) to receive sufficient power. In general, RF transmitters/receivers have a minimum feature size of 1–10 mm. Attempts are being made to miniaturize RF transfer devices.^[462,467] **Table 12** summarized the characteristics of each WPT regimes.

RF waves are one of the most popular power sources used to recharge medical electronic devices inside the body without surgical intervention. The design of a WPT system depends on many factors, including the thickness of the tissue layer between the transmitter and the location of the device on the body.

Implants close to the skin can be powered using near-field WPT techniques since the distance between the emitter and receiver is small. In one study, near-field wireless powering techniques were used to power a peripheral nerve prostheses in rats.^[470] The implanted receiver coil was 20 mm in diameter and the operating frequency was 1 MHz (**Figure 22a**). The receivers were implanted in two locations: 5 mm beneath skin and 10 mm beneath the muscle. When the separation between the transmitter and the implanted receiver coils reached 5 mm and the two coils were perfectly aligned, 127 mW of power was able to be transferred to the implanted coil. The power transfer was highly dependent on the alignment: increasing the misalignment significantly reduced power transfer efficiency. In another study, a small antenna was implanted in a swine to power a

Table 12. Summary of WPT regimes.

WPT regime	Technology	Types of RF wave	Frequency	Transfer distance in air ^{a)}	Attenuation in tissue	Transfer distance through tissue ^{a)}	Directivity ^[468]	Receiver	Common target location
Near-field	Inductive coupling	Magnetic field	Hz–MHz	Short	Low	Short	Low	Coil	Subcutaneous space
	Capacitive coupling	Electric field	Hz–MHz	Short	Low	Short	Low	Metal plate electrode	Subcutaneous space
Mid-field		Electromagnetic radiation	MHz–GHz	Mid–long	Mid	Mid–long	Mid	Antenna (dipole, monopole, etc.)	Deep implant location (GI tract, brain, heart, etc.)
Far-field		Electromagnetic radiation	>GHz	Long	High	Short	High	Antenna (dipole, monopole, etc.)	Eyes

^{a)}Definition of distance range: short (distance < a wavelength & distance < size of transmitter), Mid (distance < a wavelength & distance < 10 × size of transmitter), and long (distance > a wavelength).^[469]

brain–machine interface device using radio-frequency identification (RFID)-inspired backscattering via near-field inductive links (Figure 22b).^[466] A 1 × 1 × 1 mm³ loop was placed in the skull of the swine to receive radio waves with a frequency of 907.5 MHz; the device was continuously powered with 15.8 μW of RF to operate the RFID backscattering circuitry.

Using mid-field wireless powering techniques to transfer energy to deeply implanted electronics has been previously

demonstrated. In one study, a 1.6 GHz radio wave was chosen to transfer power to various locations in swine and rabbit models (Figure 22c).^[91] The device was 2 mm in diameter and 3.5 mm in height, which was small enough to fit into a catheter. In the swine study, when the animal was exposed to the maximum permitted exposure of radio waves, the device was able to receive 2.191 mW of power when implanted in the porcine chest and 1.709 mW when implanted inside the porcine




Figure 22. Examples of electromagnetic energy harvesting devices: WPT. a) Near-field power transfer to brain implants. Adapted with permission.^[470] Copyright 2015, IEEE. b) Near-field power transfer to the peripheral nerve prosthesis implanted in the subcutaneous region. Adapted with permission.^[466] Copyright 2015, IEEE. c) Mid-field power transfer to heart and brain implants to power a pacemaker. Adapted with permission.^[91] Copyright 2014, National Academy of Sciences. d) Mid-field power transfer to GI tract to power ingestible electronics. Adapted with permission.^[459] Copyright 2017, Springer Nature. e) Far-field power transfer to ocular implants. Reproduced with permission.^[106] Copyright 2011, IEEE.




Figure 23. The working principle of optical transfer. a) The energy band diagram of p–n junction. b) The typical structure of photovoltaic cell. c) Attenuation of the visible and NIR light in different tissues. Reproduced with permission.^[487] Copyright 2016, Springer Nature.

brain. In the rabbit model, researchers also showed that cardiac pacers implanted on the rabbit heart can be powered by their WPT system. In another study, mid-field WPT was used to power a device in the GI tract of a swine model (Figure 22d).^[459] Using a 6.8 mm × 6.8 mm antenna which emitted a 1.2 GHz radio wave, the device was able to transfer 375, 123, and 173 μW of power to the esophagus, stomach, and colon, respectively, which is sufficient to operate low-power ingestible electronics while keeping radiation exposure levels below safety thresholds.

Even though wireless powering can operate over long distances in the air, electromagnetic waves are significantly attenuated in living tissue. A 10 GHz RF wave transmitted through 2 mm of tissue will attenuate by about 20 dB, even without considering additional loss caused by misalignment or antenna efficiency.^[447] Thus, devices powered by WPT must be implanted at shallow depths or within transparent tissue. For example, in one study, an intraocular sensor, implanted in a New Zealand white rabbit, was powered using WPT (Figure 22e).^[106] To fit into the anterior chamber of the eye, a discrete device was constructed in which all of the components were connected on a string. The total size of the device was 8 × 4 × 2 mm³. A 3 GHz radio wave was chosen to transfer the power and 1 V was generated across a 27 kΩ load at a distance of 5 cm. The average power transmitted was estimated to be as high as 300 mW, which is enough to operate a low-power ocular implant such as an intraocular pressure (IOP) sensor.

4.2.2. Optical Transfer

Converting light to electrical energy occurs via the photovoltaic effect, wherein electrons in semiconductor material jump from lower to higher energy levels upon exposure to light. The most widely used structure for a photovoltaic device is a semiconductor p–n junction.^[471] When an electron is excited from the lower energy band (valence band) to a higher energy band (conduction band) in the p-type region, the electron will move to the n-type region due to the potential difference formed in the area near the junction; this generates an electric current (Figure 23a,b). The bandgap energy, which is the energy gap between the valence band and conduction band in the semiconducting material, dictates the voltage generated by a photovoltaic cell. The bandgap energy of a semiconductor must be smaller than the energy of the incident light in order to allow the transition of electrons from the valence band to the conduction band. Choosing the right type of material, which can include silicon and gallium arsenide (GaAs), depends on the wavelengths of the incident light, which is directly related to its energy.^[472,473] For instance, silicon is used for retinal prosthesis implants because it can receive both visible and near-infrared light; on the other hand, GaAs is more efficient when used with near-infrared light.^[474–476] In the interest of widescale power generation, tremendous resources have been devoted in the last few decades to develop photovoltaic materials that generate energy from




Figure 24. Examples of electromagnetic energy harvesting devices for optical transfer. a) Silicon-based PV cells implanted in subretinal region which harvest energy from NIR light. Adapted with permission.^[474] Copyright 2015, Springer Nature. b) GaInP/GaAs-based flexible PV arrays implanted in the subcutaneous region which harvest energy from sunlight. Adapted with permission.^[489] Copyright 2016, Wiley-VCH.

a wide spectrum of sunlight.^[477] Furthermore, recent developments in flexible photovoltaic materials have enabled the powering of wearable/epidermal electronics where there is readily available access to direct sunlight.^[478]

Using photovoltaics to power biomedical electronic devices inside the body is possible; however, the attenuation and absorption of visible light in the tissue presents unique challenges (Figure 23c). The penetration depth of visible light is generally less than 2 mm.^[479] However, there are two near-infrared “windows” in the tissue, near 800 and 1000–1400 nm, where the attenuation of light is relatively low. For wavelengths close to 800 nm, the penetration depth in muscle is around 3.5 mm.^[479,480] The near-infrared light in the second window is believed to have a penetration depth of 1 to 2 cm.^[481] Overexposure to visible or near-infrared light can cause damage to the eyes and skin; thus, staying under the safe limit for light intensity is important for implantable or ingestible photovoltaic devices. The International Commission on Non-Ionizing Radiation Protection (ICNIRP) provides guidelines on the maximum recommended exposure of visible/near-infrared light on the eyes and skin.^[482] For a normal continuous light source, the exposure limit for skin is 200–1600 mW cm⁻²; the retinal thermal exposure limit is 2800 mW cm⁻² in flux and 710 mJ cm⁻² in dose.^[483] To address these limitations, utilizing photovoltaics for light energy harvesting in implantable systems has focused on tissues where optical attenuation is reduced compare to the other parts of the body, such as in the retina, where photovoltaics have been used for sight restoration, or superficially under the skin.^[474–476,484,485]

Alternatively, harvesting energy from endogenous thermal radiation emitted by the body in the near-infrared region has been proposed for deeper implants. One report used custom quantum-dot-sensitized PV cells to directly harvest emitted thermal radiation (2.2 μW cm⁻²) from the surface of the human body; these cells could potentially be developed to power deeper implants or ingestible systems.^[486] However, these approaches are still in their infancy, and require more experimentations in material choice and upconversion strategies in order to convert the long wavelengths available in the body to wavelengths suitable for commonly used photovoltaic materials.

Visible light is abundant in nature. The intensity of solar radiation can be as much as 1000 W m⁻², which is sufficient for powering many in-body electronic devices.^[488] Biomedical electronics implanted at shallow depths can harvest energy either from natural sunlight or an artificial light source. Subdermal implants have shown promise but energy harvesting capabilities are significantly determined by the depth of the implant and the wavelength being harvested.^[476,489–491] For example, in one study, a flexible GaInP/GaAs solar cell array was subcutaneously implanted at the depth of 600 μm in mice (Figure 24b).^[489] The device was able to harvest 0.1 mW mm⁻² when exposed to standard sunlight; it successfully powered a pacemaker that consumed about 284 μAh per day when exposed to a light source for 126 min each day.

NIR light is a promising energy source for the implants due to its extended penetration depth. A detailed study was conducted to determine the conversion efficiency of silicon and

Table 13. Summary of energy transfer devices: in vivo examples.

Year	Organism	Location	Material	Frequency or wavelength	Distance between source and receiver	Critical feature size of implant	Power	Power density	Efficiency	Operation regime	Application	Duration	References
APT													
2001	Goat	Subcutaneous space	PZT	1 MHz	15 mm	30 mm (diameter), 5 mm (height)	34 mW	–	–	–	Implants	–	[445]
2013	Human	Heart	WCS-LV system (commercial)	–	≈10 cm	–	Successfully derived cardiac pacing devices	–	–	–	Cardiac pacing	–	[444]
2016	Pig	Subcutaneous space	PZT (commercial)	1 MHz	10–15 mm	70 mm (diameter)	300 mW	–	–	–	Implants	5 weeks	[440]
2016	Rat	Peripheral nervous system and skeletal muscle	PZT	1.85 MHz	8.8 mm	0.8 × 3 × 1 mm ³	40 μW	–	–	–	Peripheral nerve neuro recording	–	[442]
WPT													
2015	Rat	Near stomach	–	1 MHz	5–10 mm	20 mm (diameter)	127 mW	40.4 mW cm ⁻²	–	Near-field	Peripheral nerve prostheses	–	[470]
2009	Pig	Lower abdomen	–	7 MHz	10 cm	41 mm	Lighting an LED	–	–	Near-field	Brain and subcutaneous implants	–	[465]
2015	Pig	Skull	–	907.5 MHz	27 mm	1 mm ³	26.8 mW	26.8 W cm ⁻³	–	Near-field	Brain-machine interface	–	[466]
2014	Pig	Chest and brain	–	1.6 GHz	5 cm	2 mm (diameter), 3.5 mm (height)	2.2, 1.7 mW (brain, heart)	200, 155 mW cm ⁻³ (brain, heart)	–	Mid-field	Cardiac pacing	–	[91]
2014	Rabbit	Heart	–	1.6 GHz	5 cm	2 mm (diameter), 3.5 mm (height)	Powering a cardiac pacer	–	–	Mid-field	Cardiac pacing	–	[91]
2017	Pig	GI tract	–	1.2 GHz	–	6.8 × 6.8 mm ²	37.5, 123, and 173 μW (esophagus, stomach, colon)	81, 266, and 374 μW cm ⁻² (esophagus, stomach, colon)	–	Mid-field	Ingestible electronics	–	[459]
2011	Rabbit	Eye	–	3 GHz	5 cm	8 × 4 × 2 mm ³	300 mW	4.69 W cm ⁻³	–	Far-field	IOP monitoring	–	[106]
Optical power transfer													
2012	Rats	Eye (subretinal region)	Silicon	880 nm	–	0.8 mm × 1.2 mm	480 μW	50 mW cm ⁻²	–	NIR	Retinal prosthesis	90 days	[492]
2013	Rats	Eye (subretinal region)	Silicon	915 nm	–	0.8 mm × 1.2 mm	240 μW–2 mW	25–210 mW cm ⁻²	–	NIR	Retinal prosthesis	6 months	[493]
2015	Rats	Eye (subretinal region)	Silicon	880–915 nm	–	1 mm × 1 mm	550 μW	55 mW cm ⁻²	–	NIR	Retinal prosthesis	–	[474]
2016	Rats	Subcutaneous space (back)	GaNP/CaAs	Standard solar spectrum (AM1.5g)	539–675 μm	760 μm × 760 μm × 14	647 μW	10 mW cm ⁻²	6.9–9.5%	Sunlight	Pacemaker	4 weeks	[489]
2017	Rats	Subdermal, bone, muscle, organs, thorax	Silicon	850 nm	15–4 mm	1.23 mm ²	0.21–9.53 μW	17–77.5 μW cm ⁻²	0.12–5.79%	NIR (low intensity)	Mm scale depth implants	–	[476]
2017	Rats	Subdermal, bone, muscle, organs, thorax	GaAs	850 nm	15–4 mm	1.23 mm ²	0.36–15.1 μW	29–1224 μW cm ⁻²	0.21–9.13%	NIR (low intensity)	Mm scale depth implants	–	[476]
2018	Rats	Infrascapular region	Silicon	780 nm	2 mm	390 μm × 410 μm × 72	64.4 μW	560 μW cm ⁻²	0.28%	NIR (low intensity)	Biodegradable implants	4 months	[491]

GaAs photovoltaic cells implanted in the subcutaneous tissue of mice.^[476] Using an NIR source with a frequency of 850 nm and an intensity of 134 $\mu\text{W mm}^{-2}$, the conversion efficiencies were 5.79% for silicon and 9.13% for GaAs at a depth of 4 mm and 0.12% for silicon and 0.21% for GaAs at a depth of 15 mm. NIR light is also preferred over visible light for retinal prosthesis because an NIR laser image projection system can produce pulsed illumination of sufficient intensity to drive a photodiode array and directly stimulate neurons while remaining invisible to any remaining photoreceptors.^[475] Several studies have demonstrated the stability of photovoltaic cells implanted in the retina, which are used for sight restoration. PV retinal implants can be repurposed for energy harvesting since the operating principles are the same.^[474,475,492,493] However, even NIR light cannot reach tissue located deeper than 2 cm, such as the GI tract, which limits the implant location of photovoltaic cells (Table 13).

5. Outlook

Here, the broad range of technologies to power biomedical electronic devices are presented, specifically focused on implantable and ingestible devices. In this paper, various powering methods are reviewed, limitations and challenges are discussed, and the potential trajectories of different powering technologies are given. Several common challenges of powering methods are covered in this review: improving power output, increasing energy conversion efficiency, creating more durable devices, and ensuring their safety. To improve energy storage, it is essential to increase the volumetric energy density and improve the safety of batteries for biomedical electronics. In addition, low energy conversion efficiency and power output are the fundamental bottlenecks of energy harvesting and transfer devices. Additional studies are needed to improve the power output of energy harvesting and transfer devices so that they can be used to power various biomedical electronics. For example, there is room to improve the mechanical coupling between mechanical energy sources and energy harvesters in order to enhance the conversion efficiency of mechanical energy harvesting. Furthermore, durability studies of promising energy harvesters should be performed to evaluate their use in long-term applications. For degradable energy harvesting devices, such as friction-based energy harvesters and galvanic cells, improving the device lifetime is essential for use in real-life applications. Manufacturing cost is another factor to consider when commercializing novel batteries, energy harvesters, or energy transfer devices as power sources for medical devices.

Implantable and ingestible medical devices such as pacemakers, neurostimulators, subdermal blood sensors, capsule endoscopes, and drug pumps have been undergoing continuous and rapid development in recent years. Development of technologies that store, harvest and transfer energy to power these implantable and ingestible, biomedical electronics will enable such devices to be more efficient, more powerful, and to perform a range of diagnostic and therapeutic treatments that are difficult to perform from outside the body.

Acknowledgements

This work was funded in part by grants from Novo Nordisk, NIH Grant No. EB-000244, a grant from the Leona M. and Harry B. Helmsley Charitable Trust. S.-Y.Y. was supported by Kwanjeong Educational Foundation through Study Abroad Scholarship program (Award number: 19AmB32G). V.S. was supported by the University of Wollongong, Australia. N.Z.-X.J. was supported by Whitaker Health Sciences Fund Fellowship (Massachusetts Institute of Technology). S.S. was funded by the Schmidt Science Fellows program. J.Y.L. was supported by the Department of Mechanical Engineering at the Massachusetts Institute of Technology and the Division of Gastroenterology at Brigham and Women's Hospital. G.T. was also supported in part by the Division of Gastroenterology, Brigham and Woman's Hospital and the Department of Mechanical Engineering, Massachusetts Institute of Technology and the Karl van Tassel (1925) Career Development Professorship.

Conflict of Interest

G.T. is a co-inventor on multiple patent applications involving energy harvesting systems as well as systems involving electronics for therapeutic applications. G.T. reports receiving consulting fees from Novo Nordisk, Verily, Merck. G.T. has a financial interest in Lyndra Therapeutics, Suono Bio and Celero Systems which are all biotechnology companies developing therapeutics via the gastrointestinal tract which can include electronics in some embodiments. Complete details of all relationships for profit and not for profit for G.T. can be found at the following link: <https://www.dropbox.com/sh/szi7vnr4a2ajb56/AABs5N5i0q9AfT1IqIJAE-T5a?dl=0>.

Keywords

batteries, energy harvesting, energy transfer, implantable electronics, ingestible electronics

Received: October 30, 2020

Revised: December 20, 2020

Published online: February 4, 2021

- [1] J. Oeppen, J. W. Vaupel, *Science* **2002**, 296, 1029.
- [2] G. C. Brown, *EMBO Rep.* **2015**, 16, 137.
- [3] Chronic Diseases in America | CDC, **2020**.
- [4] L. LeRoy, E. Bayliss, M. Domino, B. F. Miller, G. Rust, J. Gerteis, T. Miller, A. M. R. Network, *Med. Care* **2014**, 52, S15.
- [5] CDC, Disability Impacts All of Us Infographic | CDC, **2019**.
- [6] A. Wood Mark, A. Ellenbogen Kenneth, *Circulation* **2002**, 105, 2136.
- [7] Cochlear Implants, **2015**.
- [8] J. Li, J. Y. Liang, S. J. Laken, R. Langer, G. Traverso, *Trends Chem.* **2020**, 2, 319.
- [9] T. Horbach, A. Thalheimer, F. Seyfried, F. Eschenbacher, P. Schuhmann, G. Meyer, *Obes. Surg.* **2015**, 25, 1779.
- [10] CDC, Facts About Hypertension | cdc.gov, **2020**.
- [11] G. Parati, *J. Hypertens.* **2005**, 23, S19.
- [12] R. M. Chesnut, N. Temkin, N. Carney, S. Dikmen, C. Rondina, W. Videtta, G. Petroni, S. Lujan, J. Pridgeon, J. Barber, J. Machamer, K. Chaddock, J. M. Celix, M. Cherner, T. Hendrix, *N. Engl. J. Med.* **2012**, 367, 2471.
- [13] M. Smith, *Anesth. Analg.* **2008**, 106, 240.
- [14] A. A. Patkar, K. P. Hill, S. P. Weinstein, S. L. Schwartz, *J. ECT* **2000**, 16, 189.
- [15] M. Czosnyka, J. D. Pickard, *Journal of Neurology, J. Neurol., Neurosurg. Psychiatry* **2004**, 75, 813.

- [16] A. Sommer, *Am. J. Ophthalmol.* **1989**, *107*, 186.
- [17] A. Heijl, M. C. Leske, B. Bengtsson, L. Hyman, B. Bengtsson, M. Hussein, *Arch. Ophthalmol.* **2002**, *120*, 1268.
- [18] F. A. Medeiros, R. N. Weinreb, L. M. Zangwill, L. M. Alencar, P. A. Sample, C. Vasile, C. Bowd, *Ophthalmology* **2008**, *115*, 934.
- [19] J. D. Hunter, Z. Damani, *Anaesthesia* **2004**, *59*, 899.
- [20] M. L. Cheatham, M. W. White, S. G. Sagraves, J. L. Johnson, E. F. J. Block, *J. Trauma Acute Care Surg.* **2000**, *49*, 621.
- [21] R. R. Ivatury, L. Diebel, J. M. Porter, R. J. Simon, *Surg. Clin. North Am.* **1997**, *77*, 783.
- [22] J. Webb Ralph, J. Griffiths Clive, D. Ramsden Peter, E. Neal David, *J. Urol.* **1992**, *148*, 1477.
- [23] R. D. Fealey, P. A. Low, J. E. Thomas, *Mayo Clin. Proc.* **1989**, *64*, 617.
- [24] W. P. Cheshire, *Auton. Neurosci.* **2016**, *196*, 91.
- [25] Y. Groeneveld, H. Petri, J. Hermans, M. P. Springer, *Diabetic Med.* **1999**, *16*, 2.
- [26] I. Stranders, M. Diamant, R. E. van Gelder, H. J. Spruijt, J. W. R. Twisk, R. J. Heine, F. C. Visser, *Arch. Intern. Med.* **2004**, *164*, 982.
- [27] J. V. Zorn, R. R. Schür, M. P. Boks, R. S. Kahn, M. Joëls, C. H. Vinkers, *Psychoneuroendocrinology* **2017**, *77*, 25.
- [28] A. H. Young, *Stress* **2004**, *7*, 205.
- [29] R. Yehuda, D. Boisoineau, J. W. Mason, E. L. Giller, *Biol. Psychiatry* **1993**, *34*, 18.
- [30] S. F. Shepherd, N. D. McGuire, B. P. J. de L. Costello, R. J. Ewen, D. H. Jayasena, K. Vaughan, I. Ahmed, C. S. Probert, N. M. Ratcliffe, *J. Breath Res.* **2014**, *8*, 026001.
- [31] T. Ljung, S. Lundberg, M. Varsanyi, C. Johansson, P. T. Schmidt, M. Herulf, J. O. Lundberg, P. M. Hellström, *World J. Gastroenterol.* **2006**, *12*, 3386.
- [32] J. D. Chen, Z. Lin, J. Pan, R. W. McCallum, *Dig. Dis. Sci.* **1996**, *41*, 1538.
- [33] E. Piotrowicz, A. Jasionowska, M. Banaszak-Bednarczyk, J. Gwilkowska, R. Piotrowicz, *J. Telemed. Telecare* **2012**, *18*, 193.
- [34] N. K. Khan, K. M. Goode, J. G. F. Cleland, A. S. Rigby, N. Freemantle, J. Eastaugh, A. L. Clark, R. de Silva, M. J. Calvert, K. Swedberg, M. Komajda, Vi. Mareev, F. Follath, *Eur. J. Heart Failure* **2007**, *9*, 491.
- [35] H. Hafezi, T. L. Robertson, G. D. Moon, K.-Y. Au-Yeung, M. J. Zdeblick, G. M. Savage, *IEEE Trans. Biomed. Eng.* **2015**, *62*, 99.
- [36] J.-S. Kang, M.-H. Lee, *Korean J. Intern. Med.* **2009**, *24*, 1.
- [37] L. Alnaim, *J. Oncol. Pharm. Pract.* **2007**, *13*, 207.
- [38] M. Bernier, S. L. Lancrerot, N. Parassol, T. Lavrut, J. Viotti, F. Rocher, M.-D. Drici, *J. Cardiovasc. Pharmacol.* **2020**, *76*, 472.
- [39] C. Ell, S. Remke, A. May, L. Helou, R. Henrich, G. Mayer, *Endoscopy* **2002**, *34*, 685.
- [40] L. Gueye, S. Yildirim-Yayilgan, F. A. Cheikh, I. Balasingham, *2015 IEEE Int. Conf. on Image Processing (ICIP)*, IEEE, Piscataway, NJ **2015**, pp. 1061–1064.
- [41] M. C. Rodriguez-Oroz, P. Krack, R. Kumar, A. E. Lang, *N. Engl. J. Med.* **2001**, *345*, 956.
- [42] G. Deuschl, C. Schade-Brittinger, P. Krack, J. Volkmann, H. Schäfer, K. Bötzel, C. Daniels, A. Deuschländer, U. Dillmann, W. Eisner, D. Gruber, W. Hamel, J. Herzog, R. Hilker, S. Klebe, M. Kloß, J. Koy, M. Krause, A. Kupsch, D. Lorenz, S. Lorenzl, H. M. Mehdorn, J. R. Moringlane, W. Oertel, M. O. Pinsker, H. Reichmann, A. Reuß, G.-H. Schneider, A. Schnitzler, U. Steude, V. Sturm, L. Timmermann, V. Tronnier, T. Trottenberg, L. Wojtecki, E. Wolf, W. Poewe, J. Voges, *N. Engl. J. Med.* **2006**, *355*, 896.
- [43] G. Tinkhauser, A. Pogosyan, S. Little, M. Beudel, D. M. Herz, H. Tan, P. Brown, *Brain* **2017**, *140*, 1053.
- [44] S. Tesfaye, J. Watt, S. J. Benbow, K. A. Pang, J. Miles, I. A. MacFarlane, *Lancet* **1996**, *348*, 1698.
- [45] P. Jéhanin, M. Craughwell, L. Omarjee, A. Donnelly, V. Jaquinandi, G. Mahé, A. Le Faucheur, *Vasc. Med.* **2020**, *25*, 354.
- [46] R. F. Young, R. Kroening, W. Fulton, R. A. Feldman, I. Chambi, *J. Neurosurg.* **1985**, *62*, 389.
- [47] T. L. Abell, E. van Cutsem, H. Abrahamsson, J. D. Huizinga, J. W. Konturek, J. P. Galmiche, G. Voeller, L. Filez, B. Everts, W. E. Waterfall, W. Domschke, S. B. des Varannes, B. O. Familoni, I. M. Bourgeois, J. Janssens, G. Tougas, *Digestion* **2002**, *66*, 204.
- [48] T. Abell, R. McCallum, M. Hocking, K. Koch, H. Abrahamsson, I. LeBlanc, G. Lindberg, J. Konturek, T. Nowak, E. M. M. Quigley, G. Tougas, W. Starkebaum, *Gastroenterology* **2003**, *125*, 421.
- [49] R. W. McCallum, W. Snape, F. Brody, J. Wo, H. P. Parkman, T. Nowak, *Clin. Gastroenterol. Hepatol.* **2010**, *8*, 947.
- [50] Z. Lin, J. Forster, I. Sarosiek, R. W. McCallum, *Diabetes Care* **2004**, *27*, 1071.
- [51] T.-C. Lin, H.-M. Chang, C.-C. Hsu, K.-H. Hung, Y.-T. Chen, S.-Y. Chen, S.-J. Chen, *J. Chin. Med. Assoc.* **2015**, *78*, 501.
- [52] D. Yanai, J. D. Weiland, M. Mahadevappa, R. J. Greenberg, I. Fine, M. S. Humayun, *Am. J. Ophthalmol.* **2007**, *143*, 820.
- [53] F.-G. Zeng, *Trends Amplif.* **2004**, *8*, 1.
- [54] S. Lee, M. Y. Su, M. Liang, Y. Chen, C. Hsieh, C. Yang, H. Lai, J. Lin, Q. Fang, *IEEE Trans. Biomed. Circuits Syst.* **2011**, *5*, 511.
- [55] M. R. Gold, D. A. Theuns, B. P. Knight, J. L. Sturdivant, R. Sanghera, K. A. Ellenbogen, M. A. Wood, M. C. Burke, *J. Cardiovasc. Electrophysiol.* **2012**, *23*, 359.
- [56] G. K. Klute, U. Tasch, D. B. Geselowitz, *IEEE Trans. Biomed. Eng.* **1992**, *39*, 394.
- [57] H. D. Humes, D. Buffington, A. J. Westover, S. Roy, W. H. Fissell, *Pediatr. Nephrol.* **2014**, *29*, 343.
- [58] S. Kim, W. H. Fissell, H. D. Humes, S. Roy, *Front. Biosci.* **2015**, *7*, 215.
- [59] R. M. Bergenstal, S. Garg, S. A. Weinzimer, B. A. Buckingham, B. W. Bode, W. V. Tamborlane, F. R. Kaufman, *JAMA, J. Am. Med. Assoc.* **2016**, *316*, 1407.
- [60] B. Muluneh, M. Schneider, A. Faso, L. Amerine, R. Daniels, B. Crisp, J. Valgus, S. Savage, *J. Oncol. Pract.* **2018**, *14*, e324.
- [61] A. R. Absalom, N. Sutcliffe, G. N. Kenny, *Anesthesiology* **2002**, *96*, 67.
- [62] A. R. Absalom, R. De Keyser, M. M. R. F. Struys, *Anesth. Analg.* **2011**, *112*, 516.
- [63] A. Volta, *Philos. Trans. R. Soc. London* **1800**, *90*, 403.
- [64] BA) Website | The history of the battery : 2) Primary batteries.
- [65] M. V. Reddy, A. Mauger, C. M. Julien, A. Paoletta, K. Zaghbi, *Materials* **2020**, *13*, 1884.
- [66] C. Holmes, *ECS Trans.* **2007**, *6*, 1.
- [67] B. Scrosati, *J. Solid State Electrochem.* **2011**, *15*, 1623.
- [68] J.-M. Tarascon, M. Armand, *Materials for Sustainable Energy: A Collection of Peer-Reviewed Research and Review Articles from Nature Publishing Group*, World Scientific, Singapore **2011**, pp. 171–179.
- [69] World's First Environmentally Friendly Mercury Free Silver Oxide Battery Commercialised by Sony, **2004**.
- [70] J. S. Ho, A. S. Y. Poon, *Prog. Electromagn. Res.* **2014**, *148*, 151.
- [71] S. Shleev, *ChemPlusChem* **2017**, *82*, 522.
- [72] E. Häsler, L. Stein, G. Harbauer, *Ferroelectrics* **1984**, *60*, 277.
- [73] G. V. B. Cochran, M. W. Johnson, M. P. Kadaba, F. Vosburgh, M. W. Ferguson-Pell, V. R. Palmeiri, *J. Orthop. Res.* **1985**, *3*, 508.
- [74] H. Goto, T. Sugiura, Y. Harada, T. Kazui, *Med. Biol. Eng. Comput.* **1999**, *37*, 377.
- [75] T. Laube, C. Brockmann, R. Buß, C. Lau, K. Höck, N. Stawski, T. Stieglitz, H. A. Richter, H. Schilling, *Clin. Exp. Ophthalmol.* **2004**, *242*, 661.
- [76] P. Cinquin, C. Gondran, F. Giroud, S. Mazabrard, A. Pellissier, F. Boucher, J. P. Alcaraz, K. Gorgy, F. Lenouvel, S. Mathé, P. Porcu, S. Chonier, *PLoS One* **2010**, *5*, e10476.
- [77] Q. Zheng, B. Shi, F. Fan, X. Wang, L. Yan, W. Yuan, S. Wang, H. Liu, Z. Li, Z. L. Wang, *Adv. Mater.* **2014**, *26*, 5851.
- [78] P. Nadeau, D. El-Damak, D. Gletting, Y. L. Kong, S. Mo, C. Cleveland, L. Booth, N. Roxhed, R. Langer, A. P. Chandrakasan, G. Traverso, *Nat. Biomed. Eng.* **2017**, *1*, 0022.

- [79] C. J. Bettinger, *Angew. Chem., Int. Ed.* **2018**, *57*, 16946.
- [80] C. Steiger, A. Abramson, P. Nadeau, A. P. Chandrakasan, R. Langer, G. Traverso, *Nat. Rev. Mater.* **2019**, *4*, 83.
- [81] O. Aquilina, *Images Paediatr. Cardiol.* **2006**, *8*, 17.
- [82] W. Greatbatch, C. F. Holmes, *IEEE Eng. Med. Biol. Mag.* **1991**, *10*, 38.
- [83] 510(k) Premarket Notification.
- [84] J. Gardner, *Soc. Stud. Sci.* **2013**, *43*, 707.
- [85] J. F. Patrick, G. M. Clark, *Ear Hear.* **1991**, *12*, 3S.
- [86] MetaCure treats diabetes without meds, **2011**.
- [87] Humanitarian Device Exemption (HDE).
- [88] Premarket Approval (PMA).
- [89] O. of the Commissioner, FDA approves first automated insulin delivery device for type 1 diabetes, FDA, **2020**.
- [90] A. Bansal, F. Yang, T. Xi, Y. Zhang, J. S. Ho, *Proc. Natl. Acad. Sci. USA* **2018**, *115*, 1469.
- [91] J. S. Ho, A. J. Yeh, E. Neofytou, S. Kim, Y. Tanabe, B. Patlolla, R. E. Beygui, A. S. Y. Poon, *Proc. Natl. Acad. Sci. USA* **2014**, *111*, 7974.
- [92] N. D. Trani, A. Silvestri, G. Bruno, T. Geninatti, C. Y. Xuan Chua, A. Gilbert, G. Rizzo, C. S. Filgueira, D. Demarchi, A. Grattoni, *Lab Chip* **2019**, *19*, 2192.
- [93] G. Yao, L. Kang, J. Li, Y. Long, H. Wei, C. A. Ferreira, J. J. Jeffery, Y. Lin, W. Cai, X. Wang, *Nat. Commun.* **2018**, *9*, 1.
- [94] Y. Y. Lee, A. Erdogan, S. S. C. Rao, *J. Neurogastroenterol. Motil.* **2014**, *20*, 265.
- [95] Z. Xiao, X. Tan, X. Chen, S. Chen, Z. Zhang, H. Zhang, J. Wang, Y. Huang, P. Zhang, L. Zheng, H. Min, *IEEE J. Biomed. Health Inf.* **2015**, *19*, 910.
- [96] K. Kalantar-zadeh, N. Ha, J. Z. Ou, K. J. Berean, *ACS Sens.* **2017**, *2*, 468.
- [97] K. Kalantar-Zadeh, K. J. Berean, N. Ha, A. F. Chrimes, K. Xu, D. Grando, J. Z. Ou, N. Pillai, J. L. Campbell, R. Brkljača, K. M. Taylor, R. E. Burgell, C. K. Yao, S. A. Ward, C. S. McSweeney, J. G. Muir, P. R. Gibson, *Nat. Electron.* **2018**, *1*, 79.
- [98] M. Mimeo, P. Nadeau, A. Hayward, S. Carim, S. Flanagan, L. Jerger, J. Collins, S. McDonnell, R. Swartwout, R. J. Citorik, V. Bulović, R. Langer, G. Traverso, A. P. Chandrakasan, T. K. Lu, *Science* **2018**, *360*, 915.
- [99] P. Cutruf, R. T. Yin, K. B. Lee, J. Ausra, J. A. Brennan, Y. Qiao, Z. Xie, R. Peralta, O. Talarico, A. Murillo, S. W. Chen, J. P. Leshock, C. R. Haney, E. A. Waters, C. Zhang, H. Luan, Y. Huang, G. Trachiotis, I. R. Efimov, J. A. Rogers, *Nat. Commun.* **2019**, *10*, 5742.
- [100] B. Kovatchev, *Bioelectron. Med.* **2018**, *4*, 14.
- [101] A. D. Mickle, S. M. Won, K. N. Noh, J. Yoon, K. W. Meacham, Y. Xue, L. A. McIvried, B. A. Copits, V. K. Samineneni, K. E. Crawford, D. H. Kim, P. Srivastava, B. H. Kim, S. Min, Y. Shiuang, Y. Yun, M. A. Payne, J. Zhang, H. Jang, Y. Li, H. H. Lai, Y. Huang, S.-I. Park, R. W. Gereau, J. A. Rogers, *Nature* **2019**, *565*, 361.
- [102] D. C. Bock, A. C. Marschilok, K. J. Takeuchi, E. S. Takeuchi, *Electrochim. Acta* **2012**, *84*, 155.
- [103] R. J. Coffey, *Artif. Organs* **2009**, *33*, 208.
- [104] H.-J. Yoon, S.-W. Kim, *Joule* **2020**, *4*, 1398.
- [105] A. B. Amar, A. B. Kouki, H. Cao, *Sensors* **2015**, *15*, 28889.
- [106] E. Y. Chow, C.-L. Yang, Y. Ouyang, A. L. Chlebowski, P. P. Irazoqui, W. J. Chappell, *IEEE Trans. Antennas Propag.* **2011**, *59*, 2379.
- [107] J. D. Weiland, W. Liu, M. S. Humayun, *Annu. Rev. Biomed. Eng.* **2005**, *7*, 361.
- [108] S. Kim, N. Cho, S.-J. Song, D. Kim, K. Kim, H.-J. Yoo, *2006 Symp. on VLSI Circuits, 2006. Digest of Technical Papers*, IEEE, Piscataway, NJ **2006**, pp. 55–56.
- [109] R. Sarpeshkar, C. Salthouse, Ji-Jon Sit, M. W. Baker, S. M. Zhak, T. K.-T. Lu, L. Turicchia, S. Balster, *IEEE Trans. Biomed. Eng.* **2005**, *52*, 711.
- [110] M. R. Basar, F. Malek, K. M. Juni, M. S. Idris, M. I. M. Saleh, *Ingestible Wireless Capsule Technology: A Review of Development and Future Indication*, Vol. 2012, Hindawi, London, UK **2012**, p. e807165.
- [111] A. Arriagada, A. S. Jurkov, E. Neshev, G. Muench, M. P. Mintchev, C. N. Andrews, *Neurogastroenterol. Motil.* **2011**, *23*, 271.
- [112] S. Saati, R. Lo, P.-Y. Li, E. Meng, R. Varma, M. S. Humayun, *Curr. Eye Res.* **2010**, *35*, 192.
- [113] N. A. Kyeremateng, R. Hahn, *ACS Energy Lett.* **2018**, *3*, 1172.
- [114] Recognized Consensus Standards IEC 60086-5.
- [115] Recognized Consensus Standards IEC 60086-4.
- [116] Recognized Consensus Standards UL 1642.
- [117] Recognized Consensus Standards IEC 62133-1.
- [118] Recognized Consensus Standards IEC 62133-2.
- [119] Recognized Consensus Standards IEC 62485-1.
- [120] Recognized Consensus Standards IEC 62485-2.
- [121] Recognized Consensus Standards IEC 62485-3.
- [122] Recognized Consensus Standards IEC 62485-4.
- [123] Recognized Consensus Standards UL 2054.
- [124] EUR-Lex-32017R0745-EN-EUR-Lex.
- [125] IEC 60601-1:2020 SER | IEC Webstore | electromagnetic compatibility, EMC, smart city.
- [126] E. Standards, ISO/IEC 14771.
- [127] N. Yabuuchi, K. Kubota, M. Dahbi, S. Komaba, *Chem. Rev.* **2014**, *114*, 11636.
- [128] C. A. Vincent, *Solid State Ionics* **2000**, *134*, 159.
- [129] A. Mauger, C. Julien, *Ionics* **2017**, *23*, 1933.
- [130] J. A. Townsend, R. Curran, *J. Dent. Child.* **2016**, *83*, 42.
- [131] P. Li, R. Bashirullah, *IEEE Trans. Circuits Syst. II: Express Briefs* **2007**, *54*, 912.
- [132] K. Clemens, The Vital Role of Lithium Ion Batteries in the Medical Device Market, <https://www.designnews.com/electronics-test/vital-role-lithium-ion-batteries-medical-device-market>, (accessed: August 2020).
- [133] G. Ciuti, A. Menciassi, P. Dario, *IEEE Rev. Biomed. Eng.* **2011**, *4*, 59.
- [134] F. Putois, *J. Power Sources* **1995**, *57*, 67.
- [135] U. Koehler, in *Electrochemical Power Sources: Fundamentals, Systems, and Applications* (Eds: J. Garche, K. Brandt), Elsevier, Amsterdam **2019**, pp. 21–46.
- [136] T. Reddy, *Linden's Handbook of Batteries*, 4th ed., McGraw Hill Professional, New York **2010**.
- [137] R. J. Brodd, K. R. Bullock, R. A. Leising, R. L. Middaugh, J. R. Miller, E. Takeuchi, *J. Electrochem. Soc.* **2004**, *151*, K1.
- [138] M. S. Whittingham, *Proc. IEEE* **2012**, *100*, 1518.
- [139] D. E. Demirocak, S. S. Srinivasan, E. K. Stefanakos, *Appl. Sci.* **2017**, *7*, 731.
- [140] A. El Kharbachi, O. Zavorotynska, M. Latroche, F. Cuevas, V. Yartys, M. Fichtner, *J. Alloys Compd.* **2020**, *817*, 153261.
- [141] C. Vaalma, D. Buchholz, M. Weil, S. Passerini, *Nat. Rev. Mater.* **2018**, *3*, 18013.
- [142] Z. Li, O. Fuhr, M. Fichtner, Z. Zhao-Karger, *Energy Environ. Sci.* **2019**, *12*, 3496.
- [143] J. Molenda, C. Delmas, P. Hagenmuller, *Solid State Ionics* **1983**, *9–10*, 431.
- [144] C. Delmas, A. Nadiri, J. L. Soubeyroux, *Solid State Ionics* **1988**, *28–30*, 419.
- [145] M. M. Doeff, Y. Ma, S. J. Visco, L. C. D. Jonghe, *J. Electrochem. Soc.* **1993**, *140*, L169.
- [146] M. E. Arroyo-de Dompablo, A. Ponrouch, P. Johansson, M. R. Palacin, *Chem. Rev.* **2020**, *120*, 6331.
- [147] M. Fleischer, *Recent Estimates of the Abundances of the Elements in the Earth's Crust*, Geological Survey Circular 285, United States Department of the Interior, Washington, D.C., USA **1953**.
- [148] J. L. Sudworth, *J. Power Sources* **2001**, *100*, 149.
- [149] X. Xia, J. R. Dahn, *J. Electrochem. Soc.* **2012**, *159*, A515.
- [150] R. D. Shannon, *Acta Crystallogr.* **1976**, *A32*, 751.

- [151] R. Rajagopalan, Y. Tang, X. Ji, C. Jia, H. Wang, *Adv. Funct. Mater.* **2020**, *30*, 1909486.
- [152] J. W. Choi, D. Aurbach, *Nat. Rev. Mater.* **2016**, *1*, 16013.
- [153] A. M. Skundin, T. L. Kulova, A. B. Yaroslavtsev, *Russ. J. Electrochem.* **2018**, *54*, 113.
- [154] L. Chen, M. Fiore, J. E. Wang, R. Ruffo, D.-K. Kim, G. Longoni, *Adv. Sustainable Syst.* **2018**, *2*, 1700153.
- [155] X. Zou, P. Xiong, J. Zhao, J. Hu, Z. Liu, Y. Xu, *Phys. Chem. Chem. Phys.* **2017**, *19*, 26495.
- [156] J.-Y. Hwang, S.-T. Myung, Y.-K. Sun, *Adv. Funct. Mater.* **2018**, *28*, 1802938.
- [157] J. C. Pramudita, D. Sehrawat, D. Goonetilleke, N. Sharma, *Adv. Energy Mater.* **2017**, *7*, 1602911.
- [158] *Classification and Nomenclature of Electroanalytical Techniques*, Elsevier, Amsterdam **1976**, pp. 83–95.
- [159] R. Cohen, Y. Lavi, E. Peled, *J. Electrochem. Soc.* **1990**, *137*, 2648.
- [160] A. Ponrouch, M. R. Palacin, *Curr. Opin. Electrochem.* **2018**, *9*, 1.
- [161] J.-Y. Hwang, H. M. Kim, C. S. Yoon, Y.-K. Sun, *ACS Energy Lett.* **2018**, *3*, 540.
- [162] D. Kumar, S. K. Rajouria, S. B. Kuhar, D. K. Kanchan, *Solid State Ionics* **2017**, *312*, 8.
- [163] Y. Cen, R. D. Sisson, Q. Qin, J. Liang, *C. J. Carbon Res.* **2018**, *4*, 18.
- [164] J. Luo, X. Zhao, J. Wu, H. D. Jang, H. H. Kung, J. Huang, *J. Phys. Chem. Lett.* **2012**, *3*, 1824.
- [165] J. Andrews, S. Seif Mohammadi, *Int. J. Hydrogen Energy* **2014**, *39*, 1740.
- [166] K. V. Kravchik, P. Bhauriyal, L. Piveteau, C. P. Guntlin, B. Pathak, M. V. Kovalenko, *Nat. Commun.* **2018**, *9*, 4469.
- [167] Z. Li, J. Liu, B. Niu, J. Li, F. Kang, *Small* **2018**, *14*, 1800745.
- [168] J. Fan, Q. Xiao, Y. Fang, L. Li, W. Yuan, *Ionics* **2019**, *25*, 1303.
- [169] S. Wang, K. V. Kravchik, A. N. Filippin, U. Müller, A. N. Tiwari, S. Buecheler, M. I. Bodnarchuk, M. V. Kovalenko, *Adv. Sci.* **2018**, *5*, 1700712.
- [170] M. Walter, K. V. Kravchik, C. Böfer, R. Widmer, M. V. Kovalenko, *Adv. Mater.* **2018**, *30*, 1705644.
- [171] C. Cui, M. Li, X. Zhang, *Sci. Rep.* **2018**, *8*, 5657.
- [172] S.-B. Son, T. Gao, S. P. Harvey, K. X. Steirer, A. Stokes, A. Norman, C. Wang, A. Cresce, K. Xu, C. Ban, *Nat. Chem.* **2018**, *10*, 532.
- [173] P. Canepa, S.-H. Bo, G. Sai Gautam, B. Key, W. D. Richards, T. Shi, Y. Tian, Y. Wang, J. Li, G. Ceder, *Nat. Commun.* **2017**, *8*, 1759.
- [174] J. G. Kim, B. Son, S. Mukherjee, N. Schuppert, A. Bates, O. Kwon, M. J. Choi, H. Y. Chung, S. Park, *J. Power Sources* **2015**, *282*, 299.
- [175] J. Garcke, C. K. Dyer, P. T. Moseley, Z. Ogumi, D. A. J. Rand, B. Scrosati, *Encyclopedia of Electrochemical Power Sources*, Newnes, Oxford **2013**.
- [176] Q. Zhang, K. Liu, F. Ding, X. Liu, *Nano Res.* **2017**, *10*, 4139.
- [177] A. Manthiram, X. Yu, S. Wang, *Nat. Rev. Mater.* **2017**, *2*, 16103.
- [178] F. Zheng, M. Kotobuki, S. Song, M. O. Lai, L. Lu, *J. Power Sources* **2018**, *389*, 198.
- [179] J. W. Fergus, *J. Power Sources* **2010**, *195*, 4554.
- [180] P. Knauth, *Solid State Ionics* **2009**, *180*, 911.
- [181] P. P. Soo, B. Huang, Y.-I. Jang, Y.-M. Chiang, D. R. Sadoway, A. M. Mayes, *J. Electrochem. Soc.* **1999**, *146*, 32.
- [182] Y. Zhang, Y. Liu, M. Liu, *Chem. Mater.* **2006**, *18*, 4643.
- [183] Y. Li, B. Tan, Y. Wu, *Nano Lett.* **2008**, *8*, 265.
- [184] Y. Nishio, H. Kitaura, A. Hayashi, M. Tatsumisago, *J. Power Sources* **2009**, *189*, 629.
- [185] K. Takada, N. Ohta, L. Zhang, K. Fukuda, I. Sakaguchi, R. Ma, M. Osada, T. Sasaki, *Solid State Ionics* **2008**, *179*, 1333.
- [186] M. Tatsumisago, M. Nagao, A. Hayashi, *J. Asian Ceram. Soc.* **2013**, *1*, 17.
- [187] A. Sakuda, A. Hayashi, T. Ohtomo, S. Hama, M. Tatsumisago, *Electrochemistry* **2012**, *80*, 839.
- [188] Y. Sakurai, A. Sakuda, A. Hayashi, M. Tatsumisago, *Solid State Ionics* **2011**, *182*, 59.
- [189] A. Hayashi, K. Noi, A. Sakuda, M. Tatsumisago, *Nat. Commun.* **2012**, *3*, 856.
- [190] A. Sakuda, A. Hayashi, M. Tatsumisago, *Sci. Rep.* **2013**, *3*, 2261.
- [191] A. Hayashi, Y. Nishio, H. Kitaura, M. Tatsumisago, *Electrochem. Commun.* **2008**, *10*, 1860.
- [192] Y. Lu, L. Li, Q. Zhang, Z. Niu, J. Chen, *Joule* **2018**, *2*, 1747.
- [193] F. Wang, O. Borodin, T. Gao, X. Fan, W. Sun, F. Han, A. Faraone, J. A. Dura, K. Xu, C. Wang, *Nat. Mater.* **2018**, *17*, 543.
- [194] M. Tsang, A. Armutlulu, A. W. Martinez, S. A. B. Allen, M. G. Allen, *Microsyst. Nanoeng.* **2015**, *1*, 15024.
- [195] Office of Dietary Supplements—Zinc.
- [196] Office of Dietary Supplements—Magnesium.
- [197] L. Yin, X. Huang, H. Xu, Y. Zhang, J. Lam, J. Cheng, J. A. Rogers, *Adv. Mater.* **2014**, *26*, 3879.
- [198] M. Tsang, A. Armutlulu, A. Martinez, F. Herrault, S. A. B. Allen, M. G. Allen, *2014 IEEE 27th Int. Con. on Micro Electro Mechanical Systems (MEMS)*, IEEE, Piscataway, NJ **2014**, pp. 358–361.
- [199] P. Kumar, E. D. Mauro, S. Zhang, A. Pezzella, F. Soavi, C. Santato, F. Cicoira, *J. Mater. Chem. C* **2016**, *4*, 9516.
- [200] F. Li, S. R. Gurudu, G. De Petris, V. K. Sharma, A. D. Shiff, R. I. Heigh, D. E. Fleischer, J. Post, P. Erickson, J. A. Leighton, *Gastrointest. Endosc.* **2008**, *68*, 174.
- [201] L. Xin, Z. Liao, Y. Du, Y.-P. Jiang, Z.-S. Li, *J. Interv. Gastroenterol* **2012**, *2*, 15.
- [202] A. M. Rogers, E. Kuperman, F. J. Puleo, T. R. Shope, *J. Sci. Lett.* **2008**, *12*, 85.
- [203] A. P. Skovsen, J. Burcharth, S. K. Burgdorf, *Capsule Endoscopy: A Cause of Late Small Bowel Obstruction and Perforation*, Vol. 2013, Hindawi, London, UK, **2013**, p. e458108.
- [204] Y. Tashiro, M. Kawai, K. Takehara, S. Munakata, S. Ishiyama, K. Sugimoto, M. Takahashi, Y. Kojima, M. Goto, Y. Tomiki, T. Shibuya, T. Osada, S. Watanabe, K. Sakamoto, *Case Rep. Gastroenterol.* **2014**, *8*, 206.
- [205] M. D. Fleischauer, J. Li, M. J. Brett, *J. Electrochem. Soc.* **2008**, *156*, A33.
- [206] G. T. Teixidor, R. B. Zaouk, B. Y. Park, M. J. Madou, *J. Power Sources* **2008**, *183*, 730.
- [207] H. Kim, R. C. Y. Auyeung, A. Piqué, *J. Power Sources* **2007**, *165*, 413.
- [208] N. Li, Z. Chen, W. Ren, F. Li, H.-M. Cheng, *Proc. Natl. Acad. Sci. USA* **2012**, *109*, 17360.
- [209] L. Noerchim, J.-Z. Wang, S.-L. Chou, D. Wexler, H.-K. Liu, *Carbon* **2012**, *50*, 1289.
- [210] V. L. Pushparaj, M. M. Shaijumon, A. Kumar, S. Murugesan, L. Ci, R. Vajtai, R. J. Linhardt, O. Nalamasu, P. M. Ajayan, *Proc. Natl. Acad. Sci. USA* **2007**, *104*, 13574.
- [211] L. Hu, H. Wu, F. La Mantia, Y. Yang, Y. Cui, *ACS Nano* **2010**, *4*, 5843.
- [212] C. Zhao, Y. Lu, L. Chen, Y.-S. Hu, *InfoMat* **2020**, *2*, 126.
- [213] A. T. Kutbee, R. R. Bahabry, K. O. Alamoudi, M. T. Ghoneim, M. D. Cordero, A. S. Almuslem, A. Gumus, E. M. Diallo, J. M. Nassar, A. M. Hussain, N. M. Khashab, M. M. Hussain, *npj Flexible Electron.* **2017**, *1*, 7.
- [214] EnerChip™ Solid State Batteries.
- [215] P. M. Lee, Z. Xiong, J. Ho, *Bioelectron. Med.* **2018**, *1*, 201.
- [216] R. and M. Ltd, Flexible Battery Market with COVID-19 Update by Type (Thin-film, Printed), Voltage, Capacity, Rechargeability (Primary Batteries, Secondary Batteries), Application (Medical Devices, Smart Packaging), Region—Global Forecast to 2025.
- [217] Jenax | Flexible Batteries | Thin Film Rechargeable Lithium Ion Battery.
- [218] F. N. Crespilho, G. C. Sedenho, D. D. Porcellinis, E. Kerr, S. Granados-Focil, R. G. Gordon, M. J. Aziz, *J. Mater. Chem. A* **2019**, *7*, 24784.
- [219] P. Yao, H. Yu, Z. Ding, Y. Liu, J. Lu, M. Lavorgna, J. Wu, X. Liu, *Front. Chem.* **2019**, *7*, 522.

- [220] Y. J. Kim, A. Khetan, W. Wu, S.-E. Chun, V. Viswanathan, J. F. Whitacre, C. J. Bettinger, *Adv. Mater.* **2016**, *28*, 3173.
- [221] X. Jia, C. Wang, V. Ranganathan, B. Napier, C. Yu, Y. Chao, M. Forsyth, F. G. Omenetto, D. R. MacFarlane, G. G. Wallace, *ACS Energy Lett.* **2017**, *2*, 831.
- [222] J. Lin, C. Zhang, Z. Yan, Y. Zhu, Z. Peng, R. H. Hauge, D. Natelson, J. M. Tour, *Nano Lett.* **2013**, *13*, 72.
- [223] P. P. Mercier, A. C. Lysaght, S. Bandyopadhyay, A. P. Chandrakasan, K. M. Stankovic, *Nat. Biotechnol.* **2012**, *30*, 1240.
- [224] M. Ghannad-Rezaie, L. J. Yang, H. J. L. Garton, N. Chronis, *J. Microelectromech. Syst.* **2012**, *21*, 23.
- [225] L. N. Ayton, N. Barnes, G. Dagnelie, T. Fujikado, G. Goetz, R. Hornig, B. W. Jones, M. M. K. Muqit, D. L. Rathbun, K. Stingl, J. D. Weiland, M. A. Petoe, *Clin. Neurophysiol.* **2020**, *131*, 1383.
- [226] A. Kral, *Neuroscience* **2013**, *247*, 117.
- [227] X. Cheng, X. Xue, Y. Ma, M. Han, W. Zhang, Z. Xu, H. Zhang, H. Zhang, *Nano Energy* **2016**, *22*, 453.
- [228] J. Mastrototaro, J. B. Welsh, S. Lee, *J. Diabetes Sci. Technol.* **2010**, *4*, 733.
- [229] J. J. Kowalczyk, D. L. Spicer, J. J. Mulcahy, *J. Urol.* **1996**, *156*, 1300.
- [230] J. Garcia, R. L. F. van der Palen, E. Bollache, K. Jarvis, M. J. Rose, A. J. Barker, J. D. Collins, J. C. Carr, J. Robinson, C. K. Rigsby, M. Markl, *Magn. Reson. Imaging* **2018**, *47*, 487.
- [231] CDC, Manage Blood Sugar, **2019**.
- [232] R. Gruetter, E. J. Novotny, S. D. Boulware, D. L. Rothman, G. F. Mason, G. I. Shulman, R. G. Shulman, W. V. Tamborlane, *Proc. Natl. Acad. Sci. USA* **1992**, *89*, 1109.
- [233] P. Mergenthaler, U. Lindauer, G. A. Dienel, A. Meisel, *Trends Neurosci.* **2013**, *36*, 587.
- [234] K. C. C. Van De Ven, M. Van Der Graaf, C. J. Tack, A. Heerschap, B. E. De Galan, *Diabetes* **2012**, *61*, 1974.
- [235] M. Wahlgren, M. Axenstrand, Å. Håkansson, A. Marefati, B. Lomstein Pedersen, *Pharmaceutics* **2019**, *11*, 95.
- [236] IEEE Standard for Safety Levels with Respect to Human Exposure to Electric, Magnetic, and Electromagnetic Fields, 0 Hz to 300 GHz, IEEE Std C95.1-2019 (Revision of IEEE Std C95.1-2005) Incorporates IEEE Std C95.1-2019/Cor 1-2019) **2019**, *1*.
- [237] C. for D. and R. Health, *Marketing Clearance of Diagnostic Ultrasound Systems and Transducers*, **2019**.
- [238] A. Arnau, D. Soares, In *Piezoelectric Transducers and Applications* (Ed: A. A. Vives), Springer, Berlin **2008**, pp. 1–38.
- [239] J. Curie, P. Curie, *Bull. Mineral.* **1880**, *3*, 90.
- [240] H. Kawai, *Jpn. J. Appl. Phys.* **1969**, *8*, 975.
- [241] A. J. Lovinger, In *Developments in Crystalline Polymers—1* (Ed: Bassett, D. C.), Springer, Dordrecht, Netherlands **1982**, pp. 195–273.
- [242] Influence of the β -phase content and degree of crystallinity on the piezo- and ferroelectric properties of poly(vinylidene fluoride)—IOPscience.
- [243] Z. Ounaies, *Design Requirements for Amorphous Piezoelectric Polymers*, NASA Langley Research Center, Hampton, VA, USA **1999**.
- [244] J. Gomes, J. S. Nunes, V. Sencadas, S. Lanceros-Mendez, *Smart Mater. Struct.* **2010**, *19*, 065010.
- [245] V. Sencadas, C. Ribeiro, I. K. Bdikin, A. L. Kholkin, S. Lanceros-Mendez, *Phys. Status Solidi A* **2012**, *209*, 2605.
- [246] H. S. Nalwa, *J. Macromol. Sci., Part C: Polym. Rev.* **1991**, *31*, 341.
- [247] L. Burianova, P. Hana, Y. I. Tyagur, J. Kulek, *Ferroelectrics* **1999**, *224*, 29.
- [248] Y. Bar-Cohen, *Electroactive Polymer (EAP) Actuators as Artificial Muscles: Reality, Potential, and Challenges*, Society of Photo Optical, Bellingham, WA **2001**.
- [249] A. Sultana, S. K. Ghosh, V. Sencadas, T. Zheng, M. J. Higgins, T. R. Middy, D. Mandal, *J. Mater. Chem. B* **2017**, *5*, 7352.
- [250] E. Fukada, *Biorheology* **1995**, *32*, 593.
- [251] V. Bharti, T. Kaura, R. Nath, *IEEE Trans. Dielectr. Electr. Insul.* **1995**, *2*, 1106.
- [252] H. von Berlepsch, M. Pinnow, W. Stark, *J. Phys. D: Appl. Phys.* **1989**, *22*, 1143.
- [253] S. Tasaka, N. Inagaki, T. Okutani, S. Miyata, *Polymer* **1989**, *30*, 1639.
- [254] J. Simpson, Z. Ounaies, C. Fay, *Polarization and Piezoelectric Properties of a Nitrile Substituted Polyimide*, Springer, Berlin **1996**.
- [255] E. Fukada, I. Yasuda, *J. Phys. Soc. Jpn.* **1957**, *12*, 1158.
- [256] E. Fukada, S. Sasaki, *J. Polym. Sci., Polym. Phys. Ed.* **1975**, *13*, 1845.
- [257] E. Fukada, I. Yasuda, *Jpn. J. Appl. Phys.* **1964**, *3*, 117.
- [258] E. Fukada, H. Ueda, R. Rinaldi, *Biophys. J.* **1976**, *16*, 911.
- [259] Y. Liu, H.-L. Cai, M. Zelisko, Y. Wang, J. Sun, F. Yan, F. Ma, P. Wang, Q. N. Chen, H. Zheng, X. Meng, P. Sharma, Y. Zhang, J. Li, *Proc. Natl. Acad. Sci. USA* **2014**, *111*, E2780.
- [260] M. Zelisko, J. Li, P. Sharma, *Extreme Mech. Lett.* **2015**, *4*, 162.
- [261] V. Sencadas, C. Garvey, S. Mudie, J. J. K. Kirkensgaard, G. Gouadec, S. Hauser, *Nano Energy* **2019**, *66*, 104106.
- [262] S. K. Ghosh, P. Adhikary, S. Jana, A. Biswas, V. Sencadas, S. D. Gupta, B. Tudu, D. Mandal, *Nano Energy* **2017**, *36*, 166.
- [263] E. Fukada, Y. Ando, *Int. J. Biol. Macromol.* **1986**, *8*, 361.
- [264] J. C. Knowles, F. A. Mahmud, G. W. Hastings, *Clin. Mater.* **1991**, *8*, 155.
- [265] Z. Yang, S. Zhou, J. Zu, D. Inman, *Joule* **2018**, *2*, 642.
- [266] M. Haq, *Mater. Res. Express* **2018**, *6*, 022002.
- [267] H. Li, C. Tian, Z. D. Deng, *Appl. Phys. Rev.* **2014**, *1*, 041301.
- [268] O. Molnar, *Electrotech. Rev.* **2018**, *1*, 169.
- [269] A. Ahmed, I. Hassan, M. F. El-Kady, A. Radhi, C. K. Jeong, P. R. Selvaganapathy, J. Zu, S. Ren, Q. Wang, R. B. Kaner, *Adv. Sci.* **2019**, *6*, 1802230.
- [270] Y. J. Kim, J. Lee, S. Park, C. Park, C. Park, H.-J. Choi, *RSC Adv.* **2017**, *7*, 49368.
- [271] H. Zou, Y. Zhang, L. Guo, P. Wang, X. He, G. Dai, H. Zheng, C. Chen, A. C. Wang, C. Xu, Z. L. Wang, *Nat. Commun.* **2019**, *10*, 1427.
- [272] F. Galembeck, T. A. L. Burgo, L. B. S. Balestrin, R. F. Gouveia, C. A. Silva, A. Galembeck, *RSC Adv.* **2014**, *4*, 64280.
- [273] M. Kanik, M. G. Say, B. Daglar, A. F. Yavuz, M. H. Dolas, M. M. El-Ashry, M. Bayindir, *Adv. Mater.* **2015**, *27*, 2367.
- [274] S. Liu, W. Zheng, B. Yang, X. Tao, *Nano Energy* **2018**, *53*, 383.
- [275] F. Invernizzi, S. Dulio, M. Patrini, G. Guizzetti, P. Mustarelli, *Chem. Soc. Rev.* **2016**, *45*, 5455.
- [276] C. Zhang, T. Zhou, W. Tang, C. Han, L. Zhang, Z. L. Wang, *Adv. Energy Mater.* **2014**, *4*, 1301798.
- [277] C. Han, C. Zhang, W. Tang, X. Li, Z. L. Wang, *Nano Res.* **2015**, *8*, 722.
- [278] T. Zhou, C. Zhang, C. B. Han, F. R. Fan, W. Tang, Z. L. Wang, *ACS Appl. Mater. Interfaces* **2014**, *6*, 14695.
- [279] T. Zhou, L. Zhang, F. Xue, W. Tang, C. Zhang, Z. L. Wang, *Nano Res.* **2016**, *9*, 1442.
- [280] Z. L. Wang, *Faraday Discuss.* **2015**, *176*, 447.
- [281] X. Cao, Y. Jie, N. Wang, Z. L. Wang, *Adv. Energy Mater.* **2016**, *6*, 1600665.
- [282] Y. Zi, Z. L. Wang, *APL Mater.* **2017**, *5*, 074103.
- [283] Q. Zheng, B. Shi, Z. Li, Z. L. Wang, *Adv. Sci.* **2017**, *4*, 1700029.
- [284] Y. Wang, Y. Yang, Z. L. Wang, *npj Flexible Electron.* **2017**, *1*, 10.
- [285] C. Wu, A. C. Wang, W. Ding, H. Guo, Z. L. Wang, *Adv. Energy Mater.* **2019**, *9*, 1802906.
- [286] X. Chen, X. Xie, Y. Liu, C. Zhao, M. Wen, Z. Wen, *Adv. Funct. Mater.* **2020**, *30*, 2004673.
- [287] T. Ghomian, S. Mehraeen, *Energy* **2019**, *178*, 33.
- [288] T. Valone, *The Homopolar Handbook: A Definitive Guide to Faraday Disk and N-Machine Technologies*, Integrity Research Institute, Beltsville, MD **1998**.
- [289] D.-A. Wang, C.-Y. Chiu, H.-T. Pham, *Mechatronics* **2012**, *22*, 746.
- [290] D.-A. Wang, K.-H. Chang, *Microelectron. J.* **2010**, *41*, 356.

- [291] M. A. Halim, H. Cho, J. Y. Park, *Energy Convers. Manage.* **2015**, *106*, 393.
- [292] A. Nasiri, S. A. Zabalawi, D. C. Jeutter, *IEEE Trans. Power Electron.* **2011**, *26*, 192.
- [293] M. Han, Q. Yuan, X. Sun, H. Zhang, *J. Microelectromech. Syst.* **2014**, *23*, 204.
- [294] E. Romero, R. O. Warrington, M. R. Neuman, *2009 Ann. Int. Conf. of the IEEE Engineering in Medicine and Biology Society*, IEEE, Piscataway, NJ **2009**, pp. 2752–2755.
- [295] A. Zurbuchen, A. Haerberlin, A. Pfenniger, L. Bereuter, J. Schaefer, F. Jutzi, C. Huber, J. Fuhrer, R. Vogel, *IEEE Trans. Biomed. Circuits Syst.* **2016**, *11*, 78.
- [296] B. Shi, Z. Li, Y. Fan, *Adv. Mater.* **2018**, *30*, 1801511.
- [297] A. Pfenniger, M. Jonsson, A. Zurbuchen, V. M. Koch, R. Vogel, *Ann. Biomed. Eng.* **2013**, *41*, 2248.
- [298] A. D. Jose, D. Collison, *Cardiovasc. Res.* **1970**, *4*, 160.
- [299] American Heart Association, Understanding Blood Pressure Readings, <https://www.heart.org/en/health-topics/high-blood-pressure/understanding-blood-pressure-readings> (accessed: August 2020).
- [300] J.-D. Lin, Y.-L. Chen, C.-Z. Wu, C.-H. Hsieh, D. Pei, Y.-J. Liang, J.-B. Chang, *Medicine* **2016**, *95*, e3188.
- [301] C. Dagdeviren, B. D. Yang, Y. Su, P. L. Tran, P. Joe, E. Anderson, J. Xia, V. Doraiswamy, B. Dehdashti, X. Feng, B. Lu, R. Poston, Z. Khalpey, R. Ghaffari, Y. Huang, M. J. Slepian, J. A. Rogers, *Proc. Natl. Acad. Sci. USA* **2014**, *111*, 1927.
- [302] M. Safaei, H. A. Sodano, S. R. Anton, *Smart Mater. Struct.* **2019**, *28*, 113001.
- [303] H. Ouyang, Z. Liu, N. Li, B. Shi, Y. Zou, F. Xie, Y. Ma, Z. Li, H. Li, Q. Zheng, X. Qu, Y. Fan, Z. L. Wang, H. Zhang, Z. Li, *Nat. Commun.* **2019**, *10*, 1821.
- [304] P. Ritter, G. Z. Duray, C. Steinwender, K. Soejima, R. Omar, L. Mont, L. V. Boersma, R. E. Knops, L. Chinitz, S. Zhang, C. Narasimhan, J. Hummel, M. Lloyd, T. A. Simmers, A. Voigt, V. Laager, K. Stromberg, M. D. Bonner, T. J. Sheldon, D. Reynolds, *Eur. Heart J.* **2015**, *36*, 2510.
- [305] Q. Zheng, H. Zhang, B. Shi, X. Xue, Z. Liu, Y. Jin, Y. Ma, Y. Zou, X. Wang, Z. An, W. Tang, W. Zhang, F. Yang, Y. Liu, X. Lang, Z. Xu, Z. Li, Z. L. Wang, *ACS Nano* **2016**, *10*, 6510.
- [306] Y. Ma, Q. Zheng, Y. Liu, B. Shi, X. Xue, W. Ji, Z. Liu, Y. Jin, Y. Zou, Z. An, W. Zhang, X. Wang, W. Jiang, Z. Xu, Z. L. Wang, Z. Li, H. Zhang, *Nano Lett.* **2016**, *16*, 6042.
- [307] A. Zurbuchen, A. Pfenniger, A. Stahel, C. T. Stoeck, S. Vandenberghe, V. M. Koch, R. Vogel, *Ann. Biomed. Eng.* **2013**, *41*, 131.
- [308] L. S. Y. Wong, S. Hossain, A. Ta, J. Edvinsson, D. H. Rivas, H. Naas, *IEEE J. Solid-State Circuits* **2004**, *39*, 2446.
- [309] S. H. Kim, C.-H. Yu, K. Ishiyama, *IEEE/ASME Trans. Mechatron.* **2016**, *21*, 122.
- [310] A. Pfenniger, L. N. Wickramaratna, R. Vogel, V. M. Koch, *Med. Eng. Phys.* **2013**, *35*, 1256.
- [311] A. Pfenniger, R. Vogel, V. M. Koch, M. Jonsson, *Artif. Organs* **2014**, *38*, E68.
- [312] M. Jonsson, A. Zurbuchen, A. Haerberlin, A. Pfenniger, R. Vogel, *Exp. Clin. Cardiol.* **2014**, *20*, 2000.
- [313] C. G. Lausted, A. C. Johnson, W. H. Scott, M. M. Johnson, K. M. Coyne, D. C. Tourney, *Biomed. Eng. Online* **2006**, *5*, 29.
- [314] K. Rawlings-Anderson, J. Hunter, *Nurs. Stand.* **2008**, *22*, 41.
- [315] M. A. Cretikos, R. Bellomo, K. Hillman, J. Chen, S. Finfer, A. Flabouris, *Med. J. Aust.* **2008**, *188*, 657.
- [316] K. M. Sanders, S. D. Koh, S. Ro, S. M. Ward, *Nat. Rev. Gastroenterol. Hepatol.* **2012**, *9*, 633.
- [317] V. A. McLin, S. J. Henning, M. Jamrich, *Gastroenterology* **2009**, *136*, 2074.
- [318] S. Moosavi, A. Rezaie, M. Pimentel, N. Pichetshote, *Atlas of High-Resolution Manometry, Impedance, and pH Monitoring*, Springer International Publishing, Switzerland **2020**.
- [319] K. M. Sanders, S. D. Koh, S. M. Ward, *Annu. Rev. Physiol.* **2006**, *68*, 307.
- [320] J. E. Pandolfino, P. J. Kahrilas, *Gastroenterology* **2005**, *128*, 209.
- [321] F. A. M. Herbella, L. R. O. Aprile, M. G. Patti, *Updates Surg.* **2014**, *66*, 177.
- [322] E. Husebye, V. Skar, O. O. Aalen, M. Osnes, *Dig. Dis. Sci.* **1990**, *35*, 1057.
- [323] E. M. M. Quigley, P. H. Deprez, P. Hellstrom, E. Husebye, E. E. Soffer, V. Stanghellini, R. W. Summers, A. Wilmer, D. L. W. Wingate, *Dig. Dis. Sci.* **1997**, *42*, 2395.
- [324] S. S. C. Rao, P. Sadeghi, J. Beaty, R. Kavlock, K. Ackerson, *Am. J. Physiol.: Gastrointest. Liver Physiol.* **2001**, *280*, G629.
- [325] H. P. Parkman, J. L. C. Urbain, L. C. Knight, K. L. Brown, D. M. Trate, M. A. Miller, A. H. Maurer, R. S. Fisher, *Gut* **1998**, *42*, 243.
- [326] W. A. A. Kunze, J. B. Furness, *Annu. Rev. Physiol.* **1999**, *61*, 117.
- [327] A. Bogte, A. J. Bredenoord, J. Oors, P. D. Siersema, A. J. P. M. Smout, *Neurogastroenterol. Motil.* **2013**, *25*, 762.
- [328] S. K. Ghosh, J. E. Pandolfino, Q. Zhang, A. Jarosz, N. Shah, P. J. Kahrilas, *Am. J. Physiol.: Gastrointest. Liver Physiol.* **2006**, *290*, G988.
- [329] J. Desipio, F. K. Friedenber, A. Korimilli, J. E. Richter, H. P. Parkman, R. S. Fisher, *Neurogastroenterol. Motil.* **2007**, *19*, 188.
- [330] J. H. Chen, Y. Yu, Z. Yang, W. Z. Yu, W. L. Chen, H. Yu, M. J. M. Kim, M. Huang, S. Tan, H. Luo, J. Chen, J. D. Z. Chen, J. D. Huizinga, *Sci. Rep.* **2017**, *7*, 41436.
- [331] J. L. Puckett, V. Bhalla, J. Liu, G. Kassab, R. K. Mittal, *Neurogastroenterol. Motil.* **2005**, *17*, 791.
- [332] W. Kou, A. P. S. Bhalla, B. E. Griffith, J. E. Pandolfino, P. J. Kahrilas, N. A. Patankar, *J. Comput. Phys.* **2015**, *298*, 446.
- [333] M. Wegener, R. J. Adamek, B. Wedmann, M. Jergas, P. Altmeyer, *Dig. Dis. Sci.* **1994**, *39*, 2209.
- [334] S. Brandstaeter, S. L. Fuchs, R. C. Aydin, C. J. Cyron, *Ges. Angew. Math. Mech.* **2019**, *42*, e201900001.
- [335] E. Deloose, P. Janssen, I. Depoortere, J. Tack, *Nat. Rev. Gastroenterol. Hepatol.* **2012**, *9*, 271.
- [336] L. K. Cheng, P. Du, G. O'Grady, *Physiology* **2013**, *28*, 310.
- [337] D. Stavitsky, E. O. Macagno, J. Christensen, *J. Biomech.* **1981**, *14*, 183.
- [338] P. Boulby, R. Moore, P. Gowland, R. C. Spiller, *Neurogastroenterol. Motil.* **1999**, *11*, 27.
- [339] M. J. Ferrua, R. P. Singh, *J. Food Sci.* **2010**, *75*, R151.
- [340] J. W. Arkwright, I. D. Underhill, S. A. Maunder, N. Blenman, M. M. Szczesniak, L. Wiklendt, I. J. Cook, D. Z. Lubowski, P. G. Dinning, *Opt. Express* **2009**, *17*, 22423.
- [341] J. D. Hardcastle, C. V. Mann, *Gut* **1968**, *9*, 512.
- [342] M. D. Sinnott, P. W. Cleary, J. W. Arkwright, P. G. Dinning, *Comput. Biol. Med.* **2012**, *42*, 492.
- [343] C. Dagdeviren, F. Javid, P. Joe, T. von Erlach, T. Bense, Z. Wei, S. Saxton, C. Cleveland, L. Booth, S. McDonnell, J. Collins, A. Hayward, R. Langer, G. Traverso, *Nat. Biomed. Eng.* **2017**, *1*, 807.
- [344] M. Hayakawa, *Conges European de Chronometrie*, C, E, C, Sept, 23–24, 1986/1986, 81.
- [345] M. S. Silberberg, *Principles of General Chemistry*, McGraw Hill Education, New York **2010**.
- [346] A. J. Bard, L. R. Faulkner, *Electrochemical Methods: Fundamentals and Applications*, Wiley, Hoboken, NJ **2000**.
- [347] L. Yin, H. Cheng, S. Mao, R. Haasch, Y. Liu, X. Xie, S.-W. Hwang, H. Jain, S.-K. Kang, Y. Su, R. Li, Y. Huang, J. A. Rogers, *Adv. Funct. Mater.* **2014**, *24*, 645.
- [348] O. Z. Roy, R. W. Wehnert, *Med. Biol. Eng.* **1974**, *12*, 50.
- [349] E. Katz, K. MacVittie, *Energy Environ. Sci.* **2013**, *6*, 2791.
- [350] C. Dagdeviren, Z. Li, Z. L. Wang, *Annu. Rev. Biomed. Eng.* **2017**, *19*, 85.

- [351] M. C. Beilke, T. L. Klotzbach, B. L. Treu, D. Sokic-Lazic, J. Wildrick, E. R. Amend, L. M. Gebhart, R. L. Arechederra, M. N. Germain, M. J. Moehlenbrock, Sudhanshu, S. D. Minter, *Micro Fuel Cells* **2009**, 24, 179.
- [352] T. Miyake, K. Haneda, N. Nagai, Y. Yatagawa, H. Onami, S. Yoshino, T. Abe, M. Nishizawa, *Energy Environ. Sci.* **2011**, 4, 5008.
- [353] K. MacVittie, J. Halámek, L. Halámková, M. Southcott, W. D. Jemison, R. Lobel, E. Katz, *Energy Environ. Sci.* **2013**, 6, 81.
- [354] A. Zebda, S. Cosnier, J. P. Alcaraz, M. Holzinger, A. Le Goff, C. Gondran, F. Boucher, F. Giroud, K. Gorgy, H. Lamraoui, P. Cinquin, *Sci. Rep.* **2013**, 3, 1516.
- [355] S. Yoshino, T. Miyake, T. Yamada, K. Hata, M. Nishizawa, *Adv. Energy Mater.* **2013**, 3, 60.
- [356] R. F. Drake, B. K. Kusserow, S. Messinger, S. Matsuda, *Trans.—Am. Soc. Artif. Inter. Organs* **1970**, 16, 199.
- [357] L. Halámková, J. Halámek, V. Bocharova, A. Szczupak, L. Alfonta, E. Katz, *J. Am. Chem. Soc.* **2012**, 134, 5040.
- [358] A. Szczupak, J. Halámek, L. Halámková, V. Bocharova, L. Alfonta, E. Katz, *Energy Environ. Sci.* **2012**, 5, 8891.
- [359] M. Rasmussen, R. E. Ritzmann, I. Lee, A. J. Pollack, D. Scherson, *J. Am. Chem. Soc.* **2012**, 134, 1458.
- [360] J. A. Castorena-Gonzalez, C. Foote, K. MacVittie, J. Halámek, L. Halámková, L. A. Martinez-Lemus, E. Katz, *Electroanalysis* **2013**, 25, 1579.
- [361] S. El Ichi, A. Zebda, J. P. Alcaraz, F. Boucher, J. Boutonnat, P. Cinquin, D. K. Martin, *IECBES 2014, Conference Proceedings—2014 IEEE Conference on Biomedical Engineering and Sciences: “Miri, Where Engineering in Medicine and Biology and Humanity Meet,”* IEEE, Piscataway, NJ **2014**, p. 51.
- [362] S. El Ichi-Ribault, J. P. Alcaraz, F. Boucher, B. Boutaud, R. Dalmolin, J. Boutonnat, P. Cinquin, A. Zebda, D. K. Martin, *Electrochim. Acta* **2018**, 269, 360.
- [363] A. Zebda, J. P. Alcaraz, P. Vadgama, S. Shleev, S. D. Minter, F. Boucher, P. Cinquin, D. K. Martin, *Bioelectrochemistry* **2018**, 124, 57.
- [364] D. H. Wasserman, *Am. J. Physiol.: Endocrinol. Metab.* **2009**, 296, E11.
- [365] P. Malachuk, G. Holleck, F. McGovern, R. Devarakonda, Proceedings of the 7th Intersociety Energy Conversion Engineering Conference, San Diego, California, USA **1972**, pp. 727–732.
- [366] F. C. P. F. Sales, R. M. Iost, M. V. A. Martins, M. C. Almeida, F. N. Crespilho, *Lab Chip* **2013**, 13, 468.
- [367] L. Klinker, S. Lee, J. Work, J. Wright, Y. Ma, L. Ptaszek, R. C. Webb, C. Liu, N. Sheth, M. Mansour, J. A. Rogers, Y. Huang, H. Chen, R. Ghaffari, *Extreme Mech. Lett.* **2015**, 3, 45.
- [368] S. P. Lee, L. E. Klinker, L. Ptaszek, J. Work, C. Liu, F. Quivara, C. Webb, C. Dagdeviren, J. A. Wright, J. N. Ruskin, M. Slepian, Y. Huang, M. Mansour, J. A. Rogers, R. Ghaffari, *Proc. IEEE* **2015**, 103, 682.
- [369] M. L. Kringsbach, N. Jenkinson, S. L. F. Owen, T. Z. Aziz, *Nat. Rev. Neurosci.* **2007**, 8, 623.
- [370] B. I. Rapoport, J. T. Kedzierski, R. Sarpeshkar, *PLoS One* **2012**, 7, e38436.
- [371] V. Andoralov, M. Falk, D. B. Suyatin, M. Granmo, J. Sotres, R. Ludwig, V. O. Popov, J. Schouenborg, Z. Blum, S. Shleev, *Sci. Rep.* **2013**, 3, 3270.
- [372] E. Dassau, E. Renard, J. Place, A. Farret, M. J. Pelletier, J. Lee, L. M. Huyett, A. Chakrabarty, F. J. Doyle, H. C. Zisser, *Diabetes, Obes. Metab.* **2017**, 19, 1698.
- [373] C. J. Witkowski, C. Saudek, *J. Diabetes Sci. Technol.* **2008**, 2, 703.
- [374] J. J. Bonczynski, L. L. Ludwig, L. J. Barton, A. Loar, M. E. Peterson, *Vet. Surg.* **2003**, 32, 161.
- [375] O. RoY, R. Wenhert, *Electronics* **1966**, 39, 105.
- [376] H. Massie, P. Racine, R. Pasker, A. W. Hahn, H. H. Sun, *Med. Biol. Eng.* **1968**, 6, 503.
- [377] V. P. Satinsky, J. Cassel, A. Salkind, *J. Assoc. Adv. Med. Instrum.* **1971**, 5, 3.
- [378] A. C. C. Tseung, W. J. King, B. Y. C. Wan, *Med. Biol. Eng.* **1971**, 9, 175.
- [379] M. Tsang, A. Armutlulu, F. Herrault, R. H. Shafer, S. A. B. Allen, M. G. Allen, *J. Microelectromech. Syst.* **2014**, 23, 1281.
- [380] E. F. Garay, R. Bashirullah, *J. Microelectromech. Syst.* **2015**, 24, 70.
- [381] X. Huang, D. Wang, Z. Yuan, W. Xie, Y. Wu, R. Li, Y. Zhao, D. Luo, L. Cen, B. Chen, H. Wu, H. Xu, X. Sheng, M. Zhang, L. Zhao, L. Yin, *Small* **2018**, 14, 1800994.
- [382] A. J. Bhandodkar, J. Wang, *Electroanalysis* **2016**, 6, 1188.
- [383] Y. Yu, J. Nassar, C. Xu, J. Min, Y. Yang, A. Dai, R. Doshi, A. Huang, Y. Song, R. Gehlhar, A. D. Ames, W. Gao, *Sci. Rob.* **2020**, 5, eaaz7946.
- [384] A. J. Bhandodkar, J.-M. You, N.-H. Kim, Y. Gu, R. Kumar, A. M. V. Mohan, J. Kurniawan, S. Imani, T. Nakagawa, B. Parish, M. Parthasarathy, P. P. Mercier, S. Xu, J. Wang, *Energy Environ. Sci.* **2017**, 10, 1581.
- [385] C. Wang, E. Shim, H.-K. Chang, N. Lee, H. R. Kim, J. Park, *Biosens. Bioelectron.* **2020**, 169, 112652.
- [386] S. O. Garcia, Y. V. Ulyanova, R. Figueroa-Teran, K. H. Bhatt, S. Singhal, P. Atanassov, *ECS J. Solid State Sci. Technol.* **2016**, 5, M3075.
- [387] I. Jeerapan, B. Cui, I. Martin, C. Cristea, R. Sandulescu, J. Wang, *J. Mater. Chem. B* **2018**, 6, 3571.
- [388] K. Dong, B. Jia, C. Yu, W. Dong, F. Du, H. Liu, *Biosens. Bioelectron.* **2013**, 41, 916.
- [389] R. Tutuian, D. O. Castell, *GI Motility online* **2006**.
- [390] K. Kalantar-Zadeh, K. J. Berean, R. E. Burgell, J. G. Muir, P. R. Gibson, *Nat. Rev. Gastroenterol. Hepatol.* **2019**, 16, 733.
- [391] N. Metheny, *Fluid and Electrolyte Balance*, Jones & Bartlett Publishers, Burlington, MA **2011**.
- [392] L. Kalantzi, K. Goumas, V. Kalioras, B. Abrahamsson, J. B. Dressman, C. Reppas, *Pharm. Res.* **2006**, 23, 165.
- [393] C. Pentafragka, M. Symillides, M. McAllister, J. Dressman, M. Vertzoni, C. Reppas, *J. Pharm. Pharmacol.* **2019**, 71, 557.
- [394] M. G. Espey, *Free Radicals Biol. Med.* **2013**, 55, 130.
- [395] A. M. Mowat, W. W. Agace, *Nat. Rev. Immunol.* **2014**, 14, 667.
- [396] A. Lindahl, A.-L. Ungell, L. Knutson, H. Lennernäs, *Pharm. Res.* **1997**, 14, 497.
- [397] P. B. Pedersen, P. Vilmann, D. Bar-Shalom, A. Müllertz, S. Baldursdottir, *Eur. J. Pharm. Biopharm.* **2013**, 85, 958.
- [398] M. Vertzoni, P. Augustijns, M. Grimm, M. Koziulek, G. Lemmens, N. Parrott, C. Pentafragka, C. Reppas, J. Rubbens, J. Van Den Abeele, T. Vanuytsel, W. Weitschies, C. G. Wilson, *Eur. J. Pharm. Sci.* **2019**, 134, 153.
- [399] J. I. S. Bleier, T. Hedrick, *Clin. Colon Rectal Surg.* **2010**, 23, 142.
- [400] J. M. Maurer, R. C. A. Schellekens, H. M. van Rieke, C. Wanke, V. Iordanov, F. Stellaard, K. D. Wutzke, G. Dijkstra, M. van der Zee, H. J. Woerdenbag, H. W. Frijlink, J. G. W. Kosterink, *PLoS One* **2015**, 10, e0129076.
- [401] A. Diakidou, M. Vertzoni, K. Goumas, E. Söderlind, B. Abrahamsson, J. Dressman, C. Reppas, *Pharm. Res.* **2009**, 26, 2141.
- [402] G. Pye, D. F. Evans, S. Ledingham, J. D. Hardcastle, *Gut* **1990**, 31, 1355.
- [403] M. Koziulek, M. Grimm, D. Becker, V. Iordanov, H. Zou, J. Shimizu, C. Wanke, G. Garbacz, W. Weitschies, *J. Pharm. Sci.* **2015**, 104, 2855.
- [404] H. Jimbo, N. Miki, *Sens. Actuators, B* **2008**, 134, 219.
- [405] P. Mostafalu, S. Sonkusale, *Biosens. Bioelectron.* **2014**, 54, 292.
- [406] Y. J. Kim, S.-E. Chun, J. Whitacre, C. J. Bettinger, *J. Mater. Chem. B* **2013**, 1, 3781.
- [407] K. Scott, E. H. Yu, M. M. Ghangrekar, B. Eralp, N. M. Duteanu, *Comprehensive Renewable Energy*, Elsevier, Amsterdam **2012**, pp. 277–300.
- [408] V. Ruiz-Valdepeñas Montiel, J. R. Sempionatto, S. Campuzano, J. M. Pingarrón, B. Esteban Fernández de Ávila, J. Wang, *Anal. Bioanal. Chem.* **2019**, 411, 4597.

- [409] K. Oliphant, E. Allen-Vercoe, *Microbiome* **2019**, *7*, 91.
- [410] S. H. Light, L. Su, R. Rivera-Lugo, J. A. Cornejo, A. Louie, A. T. Iavarone, C. M. Ajo-Franklin, D. A. Portnoy, *Nature* **2018**, *562*, 140.
- [411] M. T. Khan, S. H. Duncan, A. J. M. Stams, J. M. van Dijk, H. J. Flint, H. J. M. Harmsen, *ISME J.* **2012**, *6*, 1578.
- [412] Q. Xu, F. Zhang, L. Xu, P. Leung, C. Yang, H. Li, *Renewable Sustainable Energy Rev.* **2017**, *67*, 574.
- [413] Y. Han, C. Yu, H. Liu, *Biosens. Bioelectron.* **2010**, *25*, 2156.
- [414] G. A. Justin, Yingze Zhang, Mingui Sun, R. Sclabassi, In *The 26th Annu. Int. Conf. of the IEEE Engineering in Medicine and Biology Society*, IEEE, Piscataway, NJ **2004**, pp. 4096–4099.
- [415] R. Arechederra, S. D. Minter, *Electrochim. Acta* **2008**, *53*, 6698.
- [416] D. Bhatnagar, S. Xu, C. Fischer, R. L. Arechederra, S. D. Minter, *Phys. Chem. Chem. Phys.* **2011**, *13*, 86.
- [417] J. Newnham, *Br. Med. J.* **1972**, *1*, 250.
- [418] Acoustical Society Standards.
- [419] Y. Zhu, S. O. R. Moheimani, M. R. Yuce, *IEEE Sens. J.* **2011**, *11*, 155.
- [420] P. R. Stauffer, M. M. Paulides, *Comprehensive Biomedical Physics* (Ed: Brahme, A.), Elsevier, Oxford **2014**, pp. 115–151.
- [421] K. F. Graff, In *Power Ultrasonics* (Eds: Gallego-Juárez, J. A. ; Graff, K. F.), Woodhead Publishing, Oxford **2015**, pp. 127–158.
- [422] M. Fazlyyyakhmatov, *J. Phys.: Conf. Ser.* **2018**, *1038*, 012109.
- [423] I. H. Rivens, R. L. Clarke, G. R. ter Haar, *IEEE Trans. Ultrason., Ferroelectr. Freq. Control* **1996**, *43*, 1023.
- [424] T. Fjield, X. Fan, K. Hynynen, *J. Acoust. Soc. Am.* **1996**, *100*, 1220.
- [425] C. R. Bawiec, W. A. N'Djin, G. Bouchoux, N. Sénégond, N. Guillen, J.-Y. Chapelon, *IRBM* **2018**, *39*, 295.
- [426] A. Carovac, F. Smajlovic, D. Junuzovic, *Acta Inform. Med.* **2011**, *19*, 168.
- [427] F. Mazzilli, P. E. Thoppay, V. Praplan, C. Dehollain, *2012 IEEE Int. Symp. on Circuits and Systems (ISCAS)*, IEEE, Piscataway, NJ **2012**, pp. 2865–2868.
- [428] L. Jiang, Y. Yang, R. Chen, G. Lu, R. Li, J. Xing, K. K. Shung, M. S. Humayun, J. Zhu, Y. Chen, Q. Zhou, *Adv. Funct. Mater.* **2019**, *29*, 1902522.
- [429] M. Donohoe, B. Jennings, J. M. Jornet, S. Balasubramaniam, *IEEE Trans. Nanotechnol.* **2017**, *16*, 919.
- [430] The European Aesthetic Guide Supplement Spring **2010**.
- [431] Q. Shi, T. Wang, C. Lee, *Sci. Rep.* **2016**, *6*, 24946.
- [432] R. Hinchet, H.-J. Yoon, H. Ryu, M.-K. Kim, E.-K. Choi, D.-S. Kim, S.-W. Kim, *Science* **2019**, *365*, 491.
- [433] L. Jiang, Y. Yang, Y. Chen, Q. Zhou, *Nano Energy* **2020**, *77*, 105131.
- [434] Q. Shi, T. Wang, T. Kobayashi, C. Lee, *2016 IEEE 29th International Conference on Micro Electro Mechanical Systems (MEMS)*, IEEE, Piscataway, NJ **2016**, pp. 1256–1259.
- [435] L. Jiang, Y. Yang, R. Chen, G. Lu, R. Li, D. Li, M. S. Humayun, K. K. Shung, J. Zhu, Y. Chen, Q. Zhou, *Nano Energy* **2019**, *56*, 216.
- [436] A. G. Fowler, S. O. R. Moheimani, S. Behrens, *J. Microelectromech. Syst.* **2014**, *23*, 1454.
- [437] R. V. Taalla, Md. S. Arefin, A. Kaynak, A. Z. Kouzani, *IEEE Access* **2019**, *7*, 2092.
- [438] G. ter Haar, *Interface Focus* **2011**, *1*, 686.
- [439] T. Maleki, N. Cao, S. H. Song, C. Kao, S.-C. Ko, B. Ziaie, *IEEE Trans. Biomed. Eng.* **2011**, *58*, 3104.
- [440] L. Radziemski, I. R. S. Makin, *Ultrasonics* **2016**, *64*, 1.
- [441] Center for Devices and Radiological Health in United States Food and Drug Administration, Marketing Clearance of Diagnostic Ultrasound Systems and Transducers, <https://www.fda.gov/regulatory-information/search-fda-guidance-documents/marketing-clearance-diagnostic-ultrasound-systems-and-transducers>, (accessed: August 2020).
- [442] D. Seo, R. M. Neely, K. Shen, U. Singhal, E. Alon, J. M. Rabaey, J. M. Carmena, M. M. Maharbiz, *Neuron* **2016**, *91*, 529.
- [443] Institute of Electrical and Electronics Engineers, IEEE standard for safety levels with respect to human exposure to radio frequency electromagnetic fields, 3 kHz to 300 GHz, Institute of Electrical and Electronics Engineers, New York, **2006**.
- [444] A. Auricchio, P.-P. Delnoy, F. Regoli, M. Seifert, T. Markou, C. Butter, *Europace* **2013**, *15*, 1191.
- [445] H. Kawanabe, T. Katane, H. Saotome, O. Saito, K. Kobayashi, *Jpn. J. Appl. Phys.* **2001**, *40*, 3865.
- [446] V. T. Rathod, *Electronics* **2019**, *8*, 169.
- [447] D. Seo, J. M. Carmena, J. M. Rabaey, E. Alon, M. M. Maharbiz, (preprint) *arXiv*, arXiv:1307.2196, v1, submitted: July **2013**.
- [448] C. A. Rosen, K. A. Fish, H. C. Rothenberg, *US2830274*, **1958**.
- [449] J. Wang, F. Memon, G. Touma, S. Baltasavias, J. H. Jang, C. Chang, M. F. Rasmussen, E. Olcott, R. B. Jeffrey, A. Arababian, B. T. Khuri-Yakub, *2017 IEEE Int. Ultrasonics Symp. (IUS)*, IEEE, Piscataway, NJ **2017**, pp. 1–4.
- [450] J. R. Howell, M. P. Menguc, R. Siegel, *Thermal Radiation Heat Transfer*, 5th ed., CRC Press, Boca Raton, FL **2010**.
- [451] S. Y. R. Hui, W. Zhong, C. K. Lee, *IEEE Trans. Power Electron.* **2014**, *29*, 4500.
- [452] S. Amin, B. Ahmed, M. Amin, M. I. Abbasi, A. Elahi, U. Aftab, *2017 IEEE Asia Pacific Microwave Conference (APMC)*, IEEE, Piscataway, NJ **2017**, pp. 57–60.
- [453] B. J. Houston, B. Nixon, B. V. King, G. N. D. Iulius, R. J. Aitken, *Reproduction* **2016**, *152*, R263.
- [454] A. Triviño-Cabrera, J. M. González-González, J. A. Aguado, In *Wireless Power Transfer for Electric Vehicles: Foundations and Design Approach* (Eds: Triviño-Cabrera, A. ; González-González, J. M. ; Aguado, J. A.), Springer International Publishing, Cham **2020**, pp. 1–18.
- [455] J. S. Ho, S. Kim, A. S. Y. Poon, *Proc. IEEE* **2013**, *101*, 1369.
- [456] J. Edrich, P. C. Hardee, *IEEE Trans. Microwave Theory Tech.* **1976**, *24*, 273.
- [457] S. Curto, P. McEvoy, X. Bao, M. J. Ammann, *IEEE Trans. Antennas Propag.* **2009**, *57*, 2564.
- [458] L. V. Blake, M. W. Long, *Antennas: Fundamentals, Design, Measurement*, Institution of Engineering and Technology, Stevenage, UK **2009**.
- [459] A. Abid, J. M. O'Brien, T. Bensele, C. Cleveland, L. Booth, B. R. Smith, R. Langer, G. Traverso, *Sci. Rep.* **2017**, *7*, 46745.
- [460] A. Yakovlev, S. Kim, A. Poon, *IEEE Commun. Mag.* **2012**, *50*, 152.
- [461] Jaehoon Kim, Y. Rahmat-Samii, *IEEE Trans. Microwave Theory Tech.* **2004**, *52*, 1934.
- [462] F. Merli, B. Fuchs, J. R. Mosig, A. K. Skrivervik, *IEEE Trans. Antennas Propag.* **2011**, *59*, 21.
- [463] W. Xia, K. Saito, M. Takahashi, K. Ito, *IEEE Trans. Antennas Propag.* **2009**, *57*, 894.
- [464] W. X. Zhong, S. Y. R. Hui, *IEEE Trans. Power Electron.* **2015**, *30*, 4025.
- [465] F. Zhang, X. Liu, S. A. Hackworth, R. J. Sclabassi, M. Sun, In *2009 IEEE/NIH Life Science Systems and Applications Workshop*, IEEE, Piscataway, NJ **2009**, pp. 84–87.
- [466] E. Moradi, S. Amendola, T. Björninen, L. Sydänheimo, J. M. Carmena, J. M. Rabaey, L. Ukkonen, *IEEE Trans. Antennas Propag.* **2015**, *63*, 719.
- [467] A. Kiourti, M. Christopoulou, K. S. Nikita, *2011 IEEE International Symposium on Antennas and Propagation (APSURSI)*, IEEE, Piscataway, NJ **2011**, pp. 392–395.
- [468] T. Sun, X. Xie, Z. Wang, *Wireless Power Transfer for Medical Microsystems*, Springer-Verlag, New York, **2013**.
- [469] A. Karalis, J. D. Joannopoulos, M. Soljačić, *Ann. Phys.* **2008**, *323*, 34.
- [470] R. Jegadeesan, S. Nag, K. Agarwal, N. V. Thakor, Y.-X. Guo, *IEEE J. Biomed. Health Inf.* **2015**, *19*, 958.
- [471] M. A. Green, *Phys. E* **2002**, *14*, 11.
- [472] O. Madelung, In *Semiconductors: Data Handbook* (Ed: Madelung, O.), Springer, Berlin **2004**, pp. 7–70.
- [473] T. Markwart, A. McEvoy, L. Castaner, *Practical Handbook of Photovoltaics: Fundamentals and Applications*, Elsevier, Amsterdam **2003**.
- [474] H. Lorach, G. Goetz, R. Smith, X. Lei, Y. Mandel, T. Kamins, K. Mathieson, P. Huie, J. Harris, A. Sher, D. Palanker, *Nat. Med.* **2015**, *21*, 476.

- [475] K. Mathieson, J. Loudin, G. Goetz, P. Huie, L. Wang, T. I. Kamins, L. Galambos, R. Smith, J. S. Harris, A. Sher, D. Palanker, *Nat. Photonics* **2012**, *6*, 391.
- [476] E. Moon, D. Blaauw, J. D. Phillips, *IEEE Trans. Electron Devices* **2017**, *64*, 2432.
- [477] A. Polman, M. Knight, E. C. Garnett, B. Ehrler, W. C. Sinke, *Science* **2016**, *352*, aad4424.
- [478] T. R. Ray, J. Choi, A. J. Bandodkar, S. Krishnan, P. Gutruf, L. Tian, R. Ghaflari, J. A. Rogers, *Chem. Rev.* **2019**, *119*, 5461.
- [479] S. Stolik, J. A. Delgado, A. Pérez, L. Anasagasti, *J. Photochem. Photobiol., B* **2000**, *57*, 90.
- [480] K. Welsher, S. P. Sherlock, H. Dai, *Proc. Natl. Acad. Sci. USA* **2011**, *108*, 8943.
- [481] A. M. Smith, M. C. Mancini, S. Nie, *Nat. Nanotechnol.* **2009**, *4*, 710.
- [482] I. C. on N.-I. R. Protection, *Health Phys.* **2013**, *105*, 74.
- [483] J. C. Goldschmidt, S. Fischer, *Adv. Opt. Mater.* **2015**, *3*, 510.
- [484] C.-Y. Wu, W.-J. Sung, P.-H. Kuo, C.-K. Tzeng, C.-C. Chiao, Y.-C. Tsai, *2015 IEEE Biomedical Circuits and Systems Conference (BioCAS)*, IEEE, Piscataway, NJ **2015**, pp. 1–4.
- [485] S. Ayazian, V. A. Akhavan, E. Soenen, A. Hassibi, *IEEE Trans. Biomed. Circuits Syst.* **2012**, *6*, 336.
- [486] T. Ghomian, O. Kizilkaya, J. W. Choi, *Appl. Energy* **2018**, *230*, 761.
- [487] K. A. Romyantsev, K. K. Turoverov, V. V. Verkhusha, *Sci. Rep.* **2016**, *6*, 36588.
- [488] R. Hulstrom, R. Bird, C. Riordan, *Sol. Cells* **1985**, *15*, 365.
- [489] K. Song, J. H. Han, T. Lim, N. Kim, S. Shin, J. Kim, H. Choo, S. Jeong, Y.-C. Kim, Z. L. Wang, J. Lee, *Adv. Healthcare Mater.* **2016**, *5*, 1572.
- [490] K. Song, J. H. Han, H. C. Yang, K. I. Nam, J. Lee, *Biosens. Bioelectron.* **2017**, *92*, 364.
- [491] L. Lu, Z. Yang, K. Meacham, C. Cvetkovic, E. A. Corbin, A. Vázquez-Guardado, M. Xue, L. Yin, J. Boroumand, G. Pakeltis, T. Sang, K. J. Yu, D. Chanda, R. Bashir, R. W. Gereau, X. Sheng, J. A. Rogers, *Adv. Energy Mater.* **2018**, *8*, 1703035.
- [492] L. Wang, K. Mathieson, T. I. Kamins, J. D. Loudin, L. Galambos, G. Goetz, A. Sher, Y. Mandel, P. Huie, D. Lavinsky, J. S. Harris, D. V. Palanker, *J. Neural Eng.* **2012**, *9*, 046014.
- [493] Y. Mandel, G. Goetz, D. Lavinsky, P. Huie, K. Mathieson, L. Wang, T. Kamins, L. Galambos, R. Manivanh, J. Harris, D. Palanker, *Nat. Commun.* **2013**, *4*, 1.



So-Yoon Yang received her B.S. degree in Electrical Engineering and Computer Science at Seoul National University in 2017 and M.S. degree in Electrical Engineering at California Institute of Technology in 2019. She is pursuing her Ph.D. degree in Electrical Engineering and Computer Science at Massachusetts Institute of Technology. Her research interest focuses on the energy harvesting systems for biomedical electronic devices and their application to ingestible electronics.



Vitor Sencadas is a senior lecturer in the School of Mechanical, Materials, Mechatronic, and Biomedical Engineering at the University of Wollongong, Australia. His current research interest focuses on the development of noninvasive energy harvesting systems, electronic-skins, and wearable devices, for continuous and early detection of abnormal health conditions, facilitating improved diagnosis.



Giovanni Traverso, a gastroenterologist and biomedical engineer, is an assistant professor in the Department of Mechanical Engineering, Massachusetts Institute of Technology, and at Brigham and Women's Hospital, Harvard Medical School. His current research program is focused on developing the next generation of drug delivery systems to enable safe and efficient delivery of therapeutics as well as developing novel ingestible electronic devices for sensing a broad array of physiologic and pathophysiologic parameters.